A Multisystem Physiological Perspective of Human Frailty and Its Modulation by Physical Activity

Taylor, Joseph A; Greenhaff, Paul L; Bartlett, David B; Jackson, Thomas A; Duggal, Niharika A; Lord, Janet M

DOI:
10.1152/physrev.00037.2021

A Multisystem Physiological Perspective of Human Frailty and its Modulation by Physical Activity

Joseph A Taylor[1], Paul L Greenhaff[1,2], David B Bartlett[3,4], Thomas A Jackson[5], Niharika A Duggal[5], Janet M Lord[5,6]

[1]MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, UK

[2]NIHR Nottingham Biomedical Research Centre, The University of Nottingham, Queen's Medical Centre, Nottingham, UK

[3]Department of Medicine, Division of Medical Oncology, Duke University, Durham, NC, USA

[4]Department of Nutritional Sciences, Faculty of Health and Medical Sciences, University of Surrey, UK.

[5]MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, UK.

[6]NIHR Birmingham Biomedical Research Centre, University Hospital Birmingham and University of Birmingham, Birmingham, UK.

Correspondence to: Professor Janet M Lord; email: j.m.lord@bham.ac.uk

Running header: Physiology of Frailty

Abstract

"Frailty" is a term used to refer to a state characterised by enhanced vulnerability to, and impaired recovery from, stressors, when compared to a non-frail state, which is increasingly viewed as a loss of resilience. With increasing life expectancy and the associated rise in years spent with physical frailty, there is a need to understand the clinical and physiological features of frailty and the factors driving it. We describe the clinical definitions of age-related frailty and their limitations in allowing us to understand the pathogenesis of this prevalent condition. Given age-related frailty manifests in the form of functional declines such as poor balance, falls and immobility, as an alternative we view frailty from a physiological viewpoint and describe what is known of the organ-based components of frailty, including adiposity, the brain, and neuromuscular, skeletal muscle, immune and cardiovascular systems, as individual systems and as components in multisystem dysregulation. By doing so we aim to highlight current understanding of the physiological phenotype of frailty and reveal key knowledge gaps and potential mechanistic drivers of the trajectory to frailty. We also review the studies in humans that have intervened with exercise to reduce frailty. We conclude that more longitudinal and interventional clinical studies are required in older adults. Such observational studies should interrogate the progression from a non-frail to a frail state, assessing individual elements of frailty to produce a deep physiological phenotype of the syndrome. The findings will identify mechanistic drivers of frailty and allow targetted interventions to diminish frailty progression.

Clinical Highlights

- Frailty assessment is currently used as a diagnostic score to estimate risk in older people at times of ill health, such as bed-rest, surgery, infections, and bone fractures.
- Clinicians typically use frailty to predict adverse outcomes in older patients, such as risk of dying, good or poor recovery, and moving into a care home.
- Clinicians use multimodal interventions to manage frailty. These have been shown to slow progression of frailty and reverse frailty. As a greater understanding of the underlying physiological dysregulation and biology grows, so should robust trials of new interventions, based on physical activity, nutrition, and pharmacological agents.
- A more detailed physiological systems approach is needed to standardise frailty assessments which will enable clinicians to describe the heterogeneity in health and physical function progression as humans age with greater insight and sensitivity. This will need a multi-disciplinary approach involving geriatricians and physiologists employing longitudinal study designs.

Table of Contents

List of abbreviations

ADL	Activities of daily living
ASL	Arterial Spin Labelling
ATP	Adenosine triphosphate
BAK-1	BCL2 antagonist/killer 1
BIA	Bioelectrical Impedance Analysis
BDNF	Brain-derived neurotrophic factor
CMAP	Compound Muscle Action Potential
CHS	Cardiovascular Health Study
COPD	Chronic Obstructive Pulmonary Disease
CRP	C Reactive Protein
CSA	Cross-Sectional Area
CSVD	Cerebral Small Vessel Disease
CT	Computerised Tomography
CXCL13	C-X-C motif chemokine ligand 13
DEXA	Dual Energy X-ray Absorptiometry
DHEAS	Dehydroepiandrosterone sulfate
DIG	Delayed intervention group
DNA	Deoxyribonucleic acid
DTI	Diffusion tensor imaging
EF	Ejection fraction
EMRA	Effector Memory expressing RA
FOXM1	Forkhead box M1
FSR	Fractional Synthetic Rate
iEMG	intramuscular ElectroMyoGraphy
IFNγ	Interferon gamma
IGF-1	Insulin-like growth factor 1
IGFPB3	Insulin-Like Growth Factor Binding Protein 3
IMAT	Intra Muscular Adipose Tissue
IL	Interleukin
LCFA	Long Chain Fatty Acids

MFGM	milk fat globule membrane complex powder
MD	Mean diffusivity
MRI	Magnetic Resonance Imaging
fMRI	Functional MRI
MRS	Magnetic resonance spectroscopy
mTOR	Mammalian target of rapamycin
mt DNA	mitochondria DNA
MU	Motor Unit
MUP	Motor Unit potential
NF-Kb	Nuclear Factor kappa B
OGTT	Oral glucose tolerance test
PCr	Phosphocreatine
PST	Problem solving therapy
PUMA	p53-Upregulated Modulator of Apoptosis
RASM	Relative appendicular skeletal muscle mass
RNA	Ribonucelic acid
SASP	Senescence associated secretory phenotype
SMA	Supplementary motor areas
SNP	Single nucleotide polymorphism
STAT	Signal transducer and activator of transcription
TNFα	Tumor Necrosis Factor-alpha
WMH	White Matter Hyperintensities

1.0 Introduction

As a result of advances in medicine and public health policy over the last 150 years, life expectancy has doubled and continues to increase globally. In the UK, 1 in 4 adults are predicted to be aged over 65 by the year 2050 and 20% of boys and 26% of girls born in 2019 are expected to reach their 100^{th} birthday (1). However, although we are living longer we are spending more years in ill health, as healthy life expectancy (the length of time we can expect to live in a healthy, disease free state) has not kept pace with the extension in lifespan. In the period from 2009-2011 to 2016-2018, life expectancy in the UK increased by 0.8 years and 0.6 years for males and females, respectively. In contrast, healthy life expectancy for males increased by 0.4 years and for females it actually decreased by 0.2 years in the same period (2). As a result of the failure of healthy life expectancy to keep pace with lifespan extension over decades, older males now spend an average of 16.5 years in ill health and for women this is 19.8 years, with multimorbidity and frailty major components of poor health in old age.

Frailty is a largely age-related clinical syndrome characterised by the physiological decline in several body systems, resulting in an increased vulnerability to poor health outcomes and death (3). A systematic review of data from 62 countries, covering over 1.7 million individuals, revealed a global prevalence for frailty of between 12% and 24% dependent upon the specific method for frailty assessment used (4). The transition from health to frailty is a critical factor in the loss of independence in old age. Indeed the impact on health and social care services of an ageing population has led the UK government to set a target of adults spending 5 more years in independent living by 2035. Understanding the factors influencing the progression to frailty and developing practical approaches to prevent this progression, will be key to achieving this target.

In this review, we describe the clinical and physiological features of frailty from an organ/systems based perspective and the evidence that increased systemic inflammation, increased physical inactivity and sedentary behaviour, with consequent increased adiposity, play roles in frailty development. We review the evidence for the ability of exercise and physical activity to reduce frailty in older adults. We conclude with our perspective on the major knowledge gaps regarding our understanding of the physiology of frailty and priorities for future research.

2.0 The clinical phenotype of frailty

2.1. Current definitions of frailty

Initial descriptions of frailty tended to describe a static physiological phenotype (5), which was first challenged in the 1990s by Rockwood and colleagues who instead suggested a description of frailty as a dynamic model that balances assets and deficits (6). This ultimately provided a mathematical framework to describe the heterogeneity of ageing, estimating frailty as the difference between biological and chronological age (7). As such, an exercise to describe a typical person with frailty may seem counterintuitive. However, it provides an initial structure for our review from which to explore the physiological phenotype of frailty.

A consensus group has defined frailty as "a medical syndrome with multiple causes and contributors that is characterised by diminished strength, endurance and reduced physiologic function that increases an individual's vulnerability for developing increased dependency and/or death" (3) (**Figure 1**). Importantly, frailty is conceptually different, but distinctly related, to ageing, comorbidity and disability (8, 9). For example, in a large cross-sectional study of frail individuals, 29.1% of people had an activities of daily living (ADL) disability, and 81.8% had one or more comorbidities (9). These findings underpin the difficulties in producing an exact frailty definition, by showing that frailty can present alongside, and potentially be a consequence of, disability and comorbidity, but may also occur in the absence of these conditions. The absence of detailed physiological insight pertaining to the condition undoubtedly contributes to the current lack of understanding of frailty aetiology and progression.

Despite this lack of understanding, frailty is strongly associated with an increased risk of adverse events, including falls, hospitalisation and mortality (10, 11). Furthermore, some signs and symptoms appear essential for describing the frailty state. The most important of which may be the deterioration of physical function. Specifically, decreased performance in measures such as skeletal muscle strength, mobility and ADL, which is highly predictive of frailty presence (12). Conceptually, frailty development involves decreases in functional capacity following a stressor event (e.g. a minor acute illness or fall), with this capacity then remaining at a lower level than baseline following recovery from the event (13) (**Figure 1**). In short, a lack of resilience to return to prior functional capacity. Progressively decreasing functional capacity instigates a cascade of functional decline resulting in frailty, whereby an individual loses independence and becomes at significantly increased risk of disability, morbidity and mortality (14, 15).

2.2 Frailty assessment

Although usually present, functional decline is not the only clear presentation of a frail individual. Instead, frailty is typically defined by multiple measures of functional decline. Fried and colleagues have operationalised this as the concurrent presence of three or more of the following criteria: low grip strength, slow walking speed, exhaustion, low physical activity levels or unintentional weight loss (16). Termed the physical frailty phenotype, these authors also defined a state of pre-frailty, when one or two criteria are present, identifying individuals at increased risk of becoming frail (16). The physical frailty phenotype is currently the recommended international standard for frailty identification and assessment (13). Rockwood and colleagues have used deficit accumulation to determine the presence of frailty by employing a frailty index, which is calculated by considering a number (usually 40 or more) of potential deficits (e.g. age-related symptoms, signs and diseases) (17). The physical frailty phenotype and frailty index are the two most cited frailty assessment tools within the literature (18), having both been validated as predictive of clinically important outcomes (e.g., hospitalisation, mortality) (19).

Due to our lack of knowledge of the underlying pathophysiology of frailty, frailty is currently operationalised by measured outcome, rather than underlying physiological or biological drivers of these outcomes. This lack of consensus of pathophysiology hinders the development of interventions to combat the syndrome's progression. Therefore, a clear goal for emerging frailty research has been to elucidate the syndrome's physiological characteristics, enhance knowledge, and improve subsequent treatment options for frail individuals.

2.3 Clinical manifestations of frailty

Investigations of frailty in human populations commonly describe the proportion of people with frailty within a said population. For example, in a representative survey of 2740 people aged 65 to 102 from the Canadian Study of Health and Aging, 23% of participants were described as frail using the frailty index definition (17, 20). In a prospective cohort study (the Cardiovascular Health Study (CHS)) which included 5317 people aged over 65 years, but excluded those with dementia, 7% were deemed to be frail using the physical frailty phenotype definition (16). Age was consistently associated with frailty, and frailty, therefore, identified in groups of people with age-related diseases, such as 19% of people with COPD, and 40% of people with heart failure (21, 22).

Thus, it is also important to consider how a typical person with frailty presents clinically and how frailty affects that person's individual risks. There are several important risk factors and clinical characteristics identified in longitudinal studies that increase the risk of someone developing frailty over time: People who develop frailty are more likely to be female, of non-white ethnicity, have a lower level of education, and of lower socio-economic backgrounds (23). Clinical risk factors include obesity, depressive symptoms, and smoking. Protective associative factors include eating a Mediterranean diet and maintaining physical activity (23, 24) (**Figure 2**). Therefore, our final clinical description of people with frailty identifies common conditions and outcomes associated with ageing, and reports how commonly people with frailty have them. Frail adults are at higher risk of adverse outcomes, and this is the most important clinical utility of identifying frailty currently. People with frailty are more likely to be hospitalised, fall and fracture bones, and develop a disability, both in physical function and ADL. In addition, people with frailty have high rates of heart failure, cerebrovascular disease, hypertension, COPD, anaemia and diabetes (**Figure 3**). They are also more likely to have multimorbidity (the co-occurrence of two or more diseases), polypharmacy, and sarcopenia (**Table 1**). As such, compared to individuals without frailty, people with frailty have a greater risk of death (25).

Some diseases are difficult to diagnose in people with frailty if functional impairments from frailty affect the disease itself. Dementia is a clear example, where it is likely that in moderate to severe dementia, frailty may well be ubiquitous due to functional and physical impairment caused by dementia. There are positive associations with dementia (26) and worse cognitive impairment in people as the degree of frailty worsens (27). Therefore, dementia highlights how treating frailty as a binary condition, simply present or absent, has limitations. Consideration of the severity of frailty states may begin to lead to more explicit phenotypic definitions of frailty as well as mechanistic understanding of its pathogenesis.

3.0 The physiological phenotype of frailty

The term 'phenotype' is defined as "the observable traits of the organism", covering various characteristics such as morphology, physiology and behaviour (28). The physiological phenotype of the human can be influenced and altered by disease and degenerative syndromes, resulting in measurable distinctions between healthy and disordered states. For example, the condition of sarcopenia, defined as the loss of skeletal muscle mass, quality and function with age (29), can negatively influence the physiological phenotype of a person through various mechanisms of

skeletal muscle deterioration, which leads to observable presentations such as functional decline. Determining exactly how states of health and disorder differ will help identify biological targets for interventions and treatments to combat medical conditions and provide greater insight into the aetiology and pathophysiology of complex conditions such as frailty. For example, detailed molecular analyses at the transcriptome level in frailty are now beginning to emerge, including from blood cells and relevant tissues such as skeletal muscle. Zhang *et al.,* analysed blood cell transcriptomic data for nonagenarians from the Vitality 90+ longitudinal study of ageing, comparing non-frail and frail participants. They identified 3 genes associated with the emergence of frailty, *TSIX, BEST1* and *ADAMTSL4* suggestive of key roles for inflammation and regulation of cellular metabolism in frailty, discussed further in section 3.2.1 (30). Analysis of the same dataset for transcriptomic signatures associated with mortality revealed NFκB signalling as a key node, reinforcing inflammation as a potential pathophysiological mechanism in frailty (31). Another study has examined the transcriptome of skeletal muscle from healthy young, non-frail and a mixed pre-frail and frail group of older adults. Whilst the differences in gene expression were less marked than between the young and old groups, significant differences were seen between the non-frail and (pre-)frail elders, including for genes regulating muscle function (MYLK4) and metabolism (NNMT) (32). Importantly, whether these relatively small differences in MYLK4 and NNMT are a driver or consequence of emerging frailty is unknown, but needs to be resolved. Whilst such transcriptomic analyses may help in mechanistic understanding of the drivers of frailty and aid drug development, perhaps more pertinent, given that people with frailty are invariably at increased risk of adverse events, identifying a distinct physiological phenotype differentiating frail from non-frail states would be a key priority. Comprehensively characterising the frailty phenotype would undoubtedly aid in developing strategically targeted interventions against the condition by highlighting typical locations and features of dysregulation.

3.1 The physiological phenotype of frailty: the resting state condition

Determining the physiological phenotype of human frailty is a challenging prospect. In this way, phenotyping requires intuitive methods to encapsulate complex physiological variables and investigations into how different physiological processes interact and affect each other. In the ideal scenario, the most robust science would require integrative modelling of individual component parts to predict the overall collective response, i.e., the physiological phenotype.

However, whilst the research focus on frailty has increased in recent years, this level of insight is far from being achieved. The majority of studies have involved assessing the physiological characteristics of individual organs under resting-state conditions, which in itself is somewhat incongruous given that frailty seems to be best characterised by a decline in physical functioning and adverse response to stressors. Here we review six systems that contribute in different ways to the frail physiological phenotype, namely: skeletal muscle, the neuromuscular junction and motor unit, the brain, immune and cardiovascular systems, and adiposity (**Figure 4**), and then consider multisystem dysregulation.

3.1.1 Skeletal muscle: Ageing is accompanied by a loss of skeletal muscle mass (33), which often culminates in sarcopenia (29, 34). Sarcopenia reduces insulin sensitivity (35) and is accompanied by deconditioning and the associated loss of mitochondrial mass (36). These observations point to age-related changes in lifestyle factors (e.g., physical inactivity) inducing these muscle level changes, particularly as prescribed, supervised exercise intervention can at least partly restore muscle mass and function (37) and mitochondrial mass (38), even in frail very old people (39).

Sarcopenia influences functional deficits associated with frailty, including a loss of mobility, decreased strength and an increased risk of bone fractures (40-42). Therefore, attenuation of skeletal muscle mass and quality likely contributes to frailty development. Frailty and sarcopenia are linked, but distinct correlates of musculoskeletal ageing. This is evidenced by overlap, but incomplete concurrence, in frailty and sarcopenia prevalence (43). Nonetheless, the interrelated nature of frailty and sarcopenia makes it essential to consider skeletal muscle characteristics as contributing factors towards the frailty phenotype (**Figure 4**).

Whole-body lean mass: Dual energy X-ray absorptiometry (DEXA) is an X-ray scanning modality allowing the quantification of lean tissue mass (a composite of non-fat and non-bone tissue) and fat mass at a whole body level or regionally. Similarly, bioelectrical impedance analysis (BIA) assesses lean and fat masses based on the notion that lipid-rich adipose tissue is more resistant to the passage of an electrical current compared to tissues rich in water (e.g., muscle tissue). Although DEXA and BIA do not provide direct measures of muscle mass, they are routinely employed in studies of ageing, with lean tissue mass observed to decrease with advancing age (so-called sarcopenia) (44). Further, lean mass reductions with age are associated with decreased physical function and quality of life (29, 45), and can be used as a predictor of

mortality (46), justifying the use of this parameter as a valid physiological variable. Of published longitudinal studies, Koster *et al*., (47) reported the loss of leg lean muscle mass occurred at a rate of 0.7-0.8% per annum during a 7 year follow up of individuals in their 70s. In agreement, Frontera *et al*., (48) demonstrated a 1% per annum decline in thigh muscle mass volume over the course of a 12 year longitudinal study, and concluded this was a major contributor to the decrease in muscle strength seen over this time. Furthermore, in a cross-sectional study of 18-88 year old men and women, muscle mass loss was reported to be greater in the lower body, being twice as high as the upper body (33).

In studies defining frailty using the Fried physical frailty phenotype (16), estimates of lean mass by DEXA revealed a lower whole-body lean mass in pre-frail and frail people compared to non-frail people. Furthermore, significant differences were apparent when comparing frail versus pre-frail individuals (49). In a study of 1,839 older Taiwanese adults, frail participants had significantly lower total lean body and appendicular lean mass, when compared with pre-frail and non-frail adults (50). Similarly, whole-body lean mass determined by BIA in 220 older adults was significantly less in frail and pre-frail compared to non-frail older males and females (51). However, others have contradicted these findings, reporting no differences in appendicular lean mass across non-frail, pre-frail and frail subgroups of 250 older women (52).

As outlined above, DEXA and BIA do not quantify muscle mass *per se* which adds to the variance in study outcomes focused on muscle mass. To address this issue, advances in mass spectrometry technology have enabled machine sensitivity to be increased, such that orally administered stable-isotope tracers can now be applied to quantify muscle mass directly in community dwelling people, e.g., the deuterated creatine (D_3-creatine) dilution method (53-55). This method is based on the assumption that approximately 98% of the total body creatine pool is present in skeletal muscle, and is turned over in muscle in a non-enzymatic reaction that degrades creatine to creatinine at a constant rate of about 2g/day. The additional assumption is that oral consumption of a trace amount of D_3-creatine has 100% bioavailablity and once absorbed is sequestered by muscle. The urinary excretion of creatine, creatinine and enrichment with D_3-creatine allows the muscle enrichment of D_3-creatine to be calculated, allowing the determination of the dilution of the tracer in the muscle creatine pool. Of note, the measurement does not require invasive procedures, but simply collection of urine and saliva so could be readily employed in large population studies. This method of assessing of skeletal muscle mass in longitudinal large-scale cohort studies may reveal sarcopenia as a powerful biomarker of frailty progression. For example, D_3-creatine estimation of muscle mass was associated

with functional capacity and risk of injurious falls and disability, while assessments of lean body mass or appendicular lean mass by DXA were only weakly or not associated with these outcomes (54).

Skeletal muscle volume and cross-sectional area: Quantity of skeletal muscle can also be determined with measures of muscle volume and cross sectional area (CSA). Magnetic resonance imaging (MRI) and computed tomography (CT) are imaging methods considered as the gold standard for muscle volume and CSA measurement, due to their excellent accuracy when compared to cadaver analysis (r = 0.99) (56), with these methods utilised to demonstrate muscle volume and CSA reductions in older compared to younger adults (57, 58).

There are few studies utilising these imaging methods to quantify muscle volume, with CSA used in most studies of muscle quantity in frailty. A study of 26 older adults reported 6.4% lower thigh muscle CSA in frail compared to non-frail males and females when quantified using MRI (59). Similarly, MRI-derived average quadriceps muscle CSA of frail hemodialysis patients was lower than non-frail counterparts (60). Comparisons across these studies is hindered by the adoption of different frailty classification criteria. Muscle CSA estimates derived from CT scanning also point to lower skeletal muscle quantity in frailty. In a study of 923 participants, frail adults had significantly lower muscle calf areas compared to those without frailty, albeit numerically small absolute differences (61). A reduced thigh muscle CSA in frail compared to non-frail nonagenarians has been reported using CT scanning, providing one of few absolute measures of muscle CSA in frail nonagenarians (62). It should be noted however that lower skeletal muscle CSA is not always reported in frail versus non-frail individuals. For example, one study assessing thigh muscle CSA by MRI observed similar values when comparing non-frail (n=12) and frail (n=11) individuals (63). The smaller number of frail individuals studied alongside the mixed-gender sample adopted, may explain the difference in findings between this study and others. Nonetheless, these discrepancies clearly demonstrate the need for further research to delineate differences in skeletal muscle mass between frailty states. In addition, data derived from imaging methods is needed to definitively illustrate skeletal muscle characteristics evident during frailty, so that key mediators can be targeted with future interventions (e.g., exercise training). For example, if regional differences in muscle volume are apparent during frailty, areas more prone to mass and quality attenuation would be prime targets for interventions.

Skeletal muscle quality: It is worth noting that skeletal muscle quantity (i.e., CSA or volume) may not be the only important variable related to muscle within the context of frailty. Recent evidence from multicomponent exercise trials highlight an improvement in functional capacity in older adults, but these gains were not mediated by changes in lower extremity muscle CSA (64). The enhancement of functional capacity evidenced in this study may be attributable to increases in cardiorespiratory function (aerobic capacity) and improved muscle quality, e.g., increased mitochondrial mass, which is consistent with the physiological impact of endurance exercise training intervention in older people (38, 65).

Muscle quality can be assessed from its structural and functional properties, such as muscle aerobic capacity, muscle fibre orientation, myosteatosis and fibrosis. Muscle quality diminishes with age and is associated with reduced muscle function and mobility (for review see: (40)) and frailty (66).

MRI is a non-invasive and accurate method for assessing skeletal muscle quality, but data in frail individuals are scarce. Melville *et al.,* used MR spectroscopy to highlight greater mean intramuscular adipose tissue (IMAT) content in the vastus lateralis and medialis of pre-frail and frail individuals, when compared to non-frail counterparts (67). Whilst the clustering of pre-frail and frail participants into a single group for analysis potentially reduced contrast between groups in this study (67), increased IMAT in the frail has also been reported by others using MRI methods. Addison *et al.,* reported significantly greater IMAT in the thigh muscles of frail compared to non-frail males and females (59). Similar findings were also observed in a study utilising T2 weighted MR imaging, in which frail individuals had a greater intramuscular fat fraction compared to non-frail subjects (63). Overall, the limited number of studies assessing IMAT support an apparent lipid infiltration of skeletal muscle during frailty. However, generalisation of these findings may be hindered by a lack of study power and stratification between genders (59, 63), given the reported differences in IMAT between older males and females (68).

Potential drivers and mechanisms of skeletal muscle deterioration in frailty

Several interconnected and age-related mechanisms potentially contribute to the reported lower skeletal muscle mass, quality and function in frailty (for reviews see (69-71)). Sarcopenia is considered by many as a core component of frailty (72), with this notion supported by reports of

overlap in the presence of sarcopenia and frailty (43). However, definitive longitudinal data in humans are missing.

Anabolic resistance: One mechanism proposed to influence the loss of muscle mass in old age is anabolic resistance, the inability of feeding and/or exercise to stimulate muscle protein synthesis or inhibit muscle protein breakdown to the same extent as that seen in young individuals. Seminal research in this area employed stable isotope tracer infusion methods to determine protein turnover in healthy young and older men in response to essential amino acid infusion, thereby avoiding any age-related impact on gut amino acid absorption (73). The authors reported a blunting of muscle protein synthesis in response to essential amino acids in older compared with young participants. Furthermore, the increase in the phosphorylation status of anabolic signalling proteins thought to regulate muscle protein translation initiation, such as mammalian target of rapamycin (mTOR), was also reduced in the older volunteers in response to essential amino acid infusion, indicating impaired muscle nutrient sensing rather than nutrient availability was underpinning the reduced muscle protein synthetic response. Similarly, a diminished muscle protein synthetic response was observed following a bout of resistance exercise in older compared to young men, which was accompanied by a blunting of the exercise induced increase in phosphorylation of anabolic signalling molecules (74). Notably, in a study that quantified muscle protein synthesis over the course of a 6 week resistance exercise intervention, it was observed that chronic muscle protein synthesis was diminished in healthy older compared with young volunteers (75). Furthermore, this was accompanied by a blunted muscle hypertrophic response to the training intervention in the older volunteers, which appeared to reflect blunted ribosomal biogenesis and translational efficiency and lower blood anabolic hormone concentrations (75). It is not known whether the extent of anabolic resistance is greater in older frail adults when compared to non-frail older adults or whether anabolic resistance is a feature of ageing *per se* and/or occurs secondary to factors that accompany ageing such as decreased physical activity levels. Nevertheless, the consensus is that deficits in muscle protein synthesis, rather than increases in muscle protein breakdown is the primary driver of anabolic resistance in older people (76).

Inflammation: The vastus lateralis muscle of non-obese frail individuals has been reported to have increased interleukin (IL)-6 mRNA and protein content compared with non-frail individuals, purportedly due to the release of pro-inflammatory cytokines from elevated

intramuscular adipose tissue in the frail individuals (59). The authors concluded this intramuscular adipose tissue-inflammatory axis provided a potential link between intramuscular adiposity and decreased muscle mass and mobility function in frailty, but did not see any parallel associations involving muscle TNF-α. Nevertheless, potential processes underlying inflammation-mediated muscle loss include exacerbation of anabolic resistance by downregulated muscle anabolic signalling. For example, IL-6 infusion into rodent skeletal muscle at levels consistent with chronic inflammation, induces muscle atrophy (77). Atrophy was accompanied by a 60% reduction in the phosphorylation of ribosomal S6 kinase, 33% reduction of pSTAT5 and a 2-fold increase in pSTAT3 (77). This effect is likely mediated through reduced IGF-1 as transgenic overexpression of IL-6 in mice results in reduced serum IGF-1 levels, possibly due to increased proteolysis of the IGF-1 binding protein 3 or increased IGF-1 clearance (78). Accordingly, lower serum IGF-1 concentrations have been observed in frail individuals with low relative appendicular skeletal muscle mass (RASM) compared to frail persons with normal RASM (79).

Other emerging evidence suggests that inflammation contributes to sarcopenia by inducing apoptosis in skeletal muscle fibres, with Chen and colleagues reporting the downregulation of miR-532-3p in muscle from sarcopenic adults. This miRNA targets the proapoptotic gene BAK1 (BCL2 antagonist/killer 1) and the authors showed that this downregulation was inflammation dependent with NFKB1, a subunit of the transcription factor NF-kappa B, able to bind to the promoter region of miR-532-3p and repress its expression (80). A separate study examined the role of long chain fatty acids (LCFA) showing that pentadecanoic acid accumulated in human skeletal muscle in sarcopenia (81), with in vitro studies revealing that this LCFA induced the expression of the transcription factor FOXM1 (Forkhead box M1) and several pro-apoptotic genes including PUMA (p53-upregulated modulator of apoptosis) and Bax (B cell/lymphoma 2 associated x).

A third underlying mechanism is the increasing levels of TNF-α in the circulation with advancing age. This cytokine induces upregulation of 11-βHSD1 in skeletal muscle, increasing local generation of the catabolic steroid cortisol. Importantly, expression of 11-βHSD1 in muscle increases with age in women and is negatively correlated with hand grip strength (82). Taken together, these findings present possible mechanisms by which inflammation may induce muscle mass loss during frailty, by impairing muscle regeneration and anabolic processes. However, it is

493 unknown whether these muscle level characteristics are drivers of muscle deterioration in frailty
494 or a consequence of it.

495 *Physical inactivity:* As evidenced by reduced step counts and increased sedentary behavior in
496 frail people (83-85), physical inactivity is likely to be another important driver of muscle atrophy
497 and impaired muscle quality, possibly by increased muscle anabolic resistance (86). As people
498 age, physical activity levels tend to decline (87), but studies investigating muscle mass and
499 functional decline with age have rarely controlled for differences in physical activity levels
500 across age groupings in cross-sectional studies. Here, data from studies of episodic periods of
501 increased bed-rest are informative and will likely induce a greater physiological burden than
502 reduced step count (88). Ten days of bedrest has been shown to induce ~1 kg lean mass loss
503 from the lower extremities and a 16% decline in knee extensor strength in older individuals (89),
504 which was attributed to a 30% reduction in muscle protein synthesis (89). A metanalysis of
505 transcriptomic data from studies of disuse or bedrest (≥ 7days) revealed significant increases in
506 transcripts involved in protein ubiquitination, immune signaling and apoptosis and
507 downregulation of genes involved in mitcohondrial organisation and metabolic function (90),
508 some of the pathways also seen in transcriptomics data from studies of frail elders (30). Other
509 research also highlights bed-rest induced reductions in skeletal muscle protein synthesis with
510 may underpin muscle atrophy and functional losses (91, 92). Moreover, the increased burden of
511 bed rest and illness likely explains why hospitalisation will transition an older person from the
512 non-frail to frail state (11, 93). Whether bed-rest induces increased muscle mass loss and
513 functional decline in an already frail person is currently unknown but warrants consideration.

514 ***3.1.2 The neuromuscular junction and motor unit***

515 The size and function of the motor unit (MU; the motor neuron and all fibres it innervates) have
516 become a recent focus of ageing research, and it has been postulated that muscle fibre atrophy
517 and loss promotes age-related sarcopenia (94). Human MU characteristics can be quantified
518 using the intramuscular electromyography (iEMG) technique. Motor unit potentials (MUPs) (i.e.,
519 the sum of action potentials produced by muscle fibres of a motor unit during voluntary
520 contraction) are assessed using this approach, with the size of an MUP proportional to the
521 number of fibres contributing to it (95). Thus, as outlined in **Figure 5**, MUP size is indicative of
522 MU size. Further, a measure of electrical activity termed compound muscle action potential
523 (CMAP) represents a summation of the single-fibre action potentials from all muscle fibres

contributing to the signal (96). Dividing the CMAP by the size of an average MUP provides an estimate of the number of MUs within the whole muscle (97).

With advancing age, reorganisation of MU fibres is observed (for a comprehensive review of ageing effects on the MU and neuromuscular junction (NMJ) see (98)), which precedes the grouping of fibre types and localised atrophy (99-101). Reorganisation includes an increase in MU size with age (102, 103), which is thought to result from branching of nearby motor neurons to reinnervate recently denervated fibres (104, 105). Furthermore, research involving elite master athletes suggests they have a greater capacity to reinnervate muscle fibres (106). Morphological changes also occur at the site of the NMJ, with findings from electron and light microscopy techniques revealing an expansion of the junction perimeter along fibres, and more complex branching of the nerve terminal with the synaptic site (107, 108). These morphological changes may occur as an attempt to compensate for a gradual loss of motoneurons during ageing, as a result of denervation. Indeed, an age-related decline in myelinated neurons has been shown in human peripheral nerves (109, 110), suggesting ageing promotes denervation (**Figure 5**). In conjunction with morphological changes, age-associated neuromuscular deterioration has also been inferred from the lower MU firing rate observed using iEMG in the vastus lateralis of older compared to younger men (103). Furthermore, based on iEMG and muscle cross-sectional area measurements, this study estimated 50-60% fewer MUs in the older participants (103). As well as a reduction in MU number with age (103), it has been proposed that sarcopenic individuals have smaller MUPs during voluntary muscle contractions compared to non-sarcopenic older adults, suggesting reinnervation of denervated fibres occurs to expand the MU size in the muscle of non-sarcopenic individuals, but not during sarcopenia (94). Thus, it is becoming clear that distinct neuromuscular remodelling occurs during ageing, alongside sarcopenia, resulting in a reduction in MU number and size.

Building on these findings, increased frailty severity is associated with a smaller size of vastus lateralis MUPs during voluntary contractions and smaller CMAPs generated during electrical stimulation; independent of age and BMI (111). These results suggest frailty exacerbates MU number and size loss compared to ageing without frailty. Given the links between smaller MUs and reduced functional performance (e.g., strength and power) with age (112), the reductions in MU size and number during frailty, evidenced by Swiecicka *et al*., may contribute to the impaired functional performance of the frailty syndrome (66). Accordingly, the same authors

subsequently revealed negative relationships between CMAP and MUP and performance in the timed up and go test in frail individuals (113).

Potential mechanisms for neuromuscular junction and motor unit deterioration during frailty

As thoroughly reviewed by Larsson and colleagues (98), the mechanisms underlying NMJ and MU deterioration with age are complex and remain poorly understood. DNA damage and modification in old age have been implicated in NMJ functional deterioration and motoneuron loss during ageing producing the aged neuromuscular phenotype (114). Spinal motoneurons exhibit apoptotic cell death following treatment with neurotoxic intermediates of glycation, suggesting by-products of glycation may also contribute to motoneuron degeneration (115). Furthermore, the absence of several molecules involved in NMJ formation and maintenance appear to produce pre- and post-synaptic alterations in aged muscle. Genetic deletion of the molecule agrin (a molecule involved in the formation of synapses between neurons) (116, 117), or its muscle receptor Lrp4 (118, 119), results in degeneration of motor axon terminals and partial or complete denervation of endplates, suggesting effects on these molecules may contribute to NMJ deterioration (**Figure 5**).

From the perspective of human frailty, the relationship between MU characteristics and plasma concentrations of anabolic hormones has been explored, with free testosterone and dehydroepiandrosterone sulfate (DHEAS) found to be significantly associated with CMAP in frail individuals (113). With the earlier reports of attenuated CMAP in frail men (111), this finding suggests diminished androgen availability may accelerate MU decline into frailty. Mechanistic insight from a rodent model of spinal cord injury demonstrated that atrophy of motor unit dendrites and muscle fibres was prevented by four weeks of sub-cutaneous testosterone administration that maintained normal physiological concentrations (120). Similarly, testosterone administration mitigated motor neuron atrophy following the castration of male adult rats (121, 122). Thus, hypogonadism during frailty may contribute to a decline in MU size and number.

3.1.3 The Brain

Ageing is associated with various physiological changes in the brain, such as alterations in brain size, vasculature and cognition (123, 124). Incidence of brain related diseases such as Alzheimer's and other dementias also increases with age (125), suggesting advancing age has profound physiological effects on the brain. Frailty is associated with an increased risk of

cognitive decline and dementia (126-128), suggesting neurodegenerative and neurovascular changes contribute to the physiological phenotype of frailty. Consequently, reported MRI correlates of frailty include lower global or regional brain volume, an increased number of cerebral microbleeds and a higher number of white matter hyperintensities (WMHs) (126, 129-131). Collectively, these findings provide strong indications of brain structure deterioration during frailty (**Figure 4**) and warrant further investigation of the brain within non-frail, pre-frail and frail older adults. **Figure 6** outlines MRI methods currently being employed to study brain architecture and function.

Brain volume: Brain volume refers to the mass of nervous tissue within the skull (i.e., the total size of the brain), and can be further partitioned into regional volumes of white matter, grey matter and cerebrospinal fluid. Measures of total brain volume are strongly correlated with cognitive ability level throughout adulthood (132, 133). During ageing, brain volume declines, which is associated with cognitive decline (134, 135), and impairments in physical function (136). Considering the links between frailty, cognitive decline (126, 127) and functional impairments (66), this evidence warrants investigation of brain volumes as key physiological variables during ageing and frailty.

Early studies reported global cortical atrophy and reduced grey matter in the brains of frail adults (129, 131). Low recruitment of frail individuals in one of these studies resulted in combining pre-frail and frail participants into a single group, possibly reducing the contrast between this group and non-frail adults during analysis (129). Other studies adopting the physical frailty phenotype assessment have provided more detailed findings. Kant *et al.,* reported significantly lower total brain volume and grey matter volume in frail compared to non-frail older adults. Further, the frail group exhibited lower total brain and grey matter volumes than pre-frail participants. No differences were observed between pre-frail and non-frail states (137). Adopting a similar MRI scan sequence, another study also observed total brain volume as significantly reduced in frail versus non-frail subjects (138). These findings indicate the presence of regional and global brain atrophy during the more severe stages of frailty (**Figure 6**), but again whether associations are causative or a consequence of frailty is not known.

In contrast to these observations, voxel-based analyses of regional grey matter volumes revealed no significant associations between any particular brain region and frailty (139). However, the weakness and slowness criteria of the physical frailty phenotype were associated with reduced

grey matter volumes in regions including the hippocampus and the amygdala. Discrepancies with previous research may be attributable to the use of a voxel-based morphometry (VBM) approach, as opposed to previous region of interest (ROI) based methods. VBM involves measurement of tissue volume within each image voxel (or within a specified region), whereas ROI based methods provide an average estimate of multiple voxels with a large region. This may potentially lead to methodological differences in subsequent image analysis. Nonetheless, these differential findings warrant further research to determine if frailty *per se*, or rather elements of the syndrome's component criteria, are associated with lower brain volumes and in specific brain regions.

Cortical thickness, defined as the distance between the outer cortical surface and the grey-white matter boundary (140), is another structural marker of grey matter volume quantified by MRI (**Figure 6**). Thinning of the cortex in specific brain regions has been shown during normal ageing (140-142) and during Alzheimer's disease (143) has been proposed as a biomarker of neurodegeneration (144). As far as we are aware, only two studies have assessed the relationship between cortical thickness and frailty. One study reported lower global cortical thickness in frail compared to pre-frail and non-frail participants. However, these authors did not report any statistical evidence for this finding (137). A more recent cross-sectional analysis found that older adults with greater global cortical thickness were less likely to be pre-frail and frail (145). These studies indicate cortical thinning may present during frailty, but further studies are required to confirm these findings.

White matter hyperintensities: Lesions within brain white matter, termed white matter hyperintensities (WMHs), are common features of the ageing brain, with an increase in WMH volume observed with advanced age (146). WMHs are also considered MRI markers of cerebral small vessel disease (cSVD) (147). WMHs are associated with adverse outcomes linked to frailty, such as cognitive impairment (148), slow gait (149) and functional decline (150), indicating these lesions, in addition to cSVD, may present within the pathophysiology of frailty. Recent studies have attempted to clarify the relationship between WMHs and frailty, when defined by the physical frailty phenotype (16). Significantly greater mean WMH volume has been observed in frail and pre-frail groups when compared to non-frail participants (138, 151). Unfortunately, analysis of WMH volume between pre-frail and frail individuals was lacking in these studies, limiting insight between these two states and the progression to frailty. The

association of increased WMH volume during frailty has been corroborated in several studies adopting the accumulated deficits frailty index assessment (17), with larger WMH volume shown to be related to higher frailty index scores (152, 153). Further, higher frailty index score has been significantly associated with the presence of mild, moderate and severe deep WMH and severe periventricular WMH burden (154). Interestingly, using WMH segmentation techniques, it has also been reported that pre-frail, but not frail, individuals had a more complex shape of periventricular (situated around ventricles in the brain) and confluent (lesions that extend from a ventricle to > 10mm into deep white matter) WMHs than non-frail subjects (151). These early reports present an interesting area for further research regarding frailty progression, highlighting WMHs as key markers of brain deterioration during frailty.

Microstructural integrity: Diffusion tensor imaging (DTI) is an MRI technique enabling assessment of the microstructural integrity of white and grey matter tissue by mapping the directionality of water molecule diffusion (155) (**Figure 6**). Common measures of diffusion assessed during DTI include, fractional anisotropy (FA) and mean diffusivity (MD). DTI has been utilised to demonstrate deterioration in brain microstructural integrity during ageing, such as an increase in MD (156, 157), warranting investigation as a physiological feature of the frailty state.

Frail individuals have been observed to have higher MD (indicating degeneration of the tissue that prevents undirected water diffusion) and lower FA in white matter tissue, when compared to non-frail counterparts (158), with similar findings also reported in the grey matter tissue of another cohort of frail and non-frail individuals (138). Further, baseline white matter diffusivity estimates have been significantly associated with worsening frailty over a 5 year follow up (159). Common findings of reduced FA and increased MD indicate that frailty is accompanied by degeneration in structural brain tissue through a loss of organised structure.

Some additional findings from these DTI based studies are noteworthy. Firstly, during region-specific analyses of MD, the medial frontal and anterior cingulate cortexes were strongly associated with frailty (138). The medial frontal cortex is a brain region important for motor function and lower extremity performance, whilst the anterior cingulate is associated with locomotion and gait performance (160-162). These findings suggest that microstructural deterioration in these brain regions may present a physiological cause of functional decline experienced by frail individuals. Secondly, in frail subjects, a larger global WMH volume was

associated with decreased FA and increased values in all diffusivity estimates (158). This finding suggests that different features of brain deterioration are linked and negatively influence each other, thereby increasing the risk of frailty development.

Cerebral perfusion and oxygenation: The brain oxygen requirement in the adult human accounts for about 15% of the resting cardiac output (**Figure 7**), for a relative body size of only 2%. Cerebral perfusion is therefore a high flow, low pressure system, which can be quantified using imaging techniques (e.g., MRI and CT). Arterial spin labeling (ASL) is an MRI technique enabling quantification of cerebral perfusion by applying magnetism to 'label' arterial blood before flowing into the brain, then subsequently imaging the contrast between labelled blood and brain tissue. Similar to ASL, MRI techniques quantifying cerebral oxygenation can magnetically label venous blood, and the rate at which the magnetic signal is lost is indicative of blood oxygen levels. Cerebral oxygenation can also be quantified using near-infrared spectroscopy (NIRS) and is based on the differential light absorbance of oxyhemoglobin and deoxyhemoglobin, as these 'chromophores' absorb different wavelengths of light. Both cerebral perfusion and oxygenation are observed to decline with age (163, 164) and this decline is associated with Alzheimer's disease and other dementias (165, 166), suggesting these variables are key physiological markers of neurodegeneration. One study has assessed global grey matter perfusion using ASL, evidencing no association between global grey matter perfusion and frailty (151). This lack of relationship may have been due to the reduced sample size adopted when performing the ASL scanning procedures, which the authors acknowledged compromised the statistical power of their analyses (151). Cerebral oxygenation was previously measured in frail hospital patients during aneasthesia using NIRS (167). These authors found increased cerebral desaturation in the frail compared to the non-frail group, suggesting oxygenation of the brain is impaired during the frailty state.

Potential mechanisms of brain deterioration in frailty

Although current research into brain deterioration during frailty is mainly observational, some insight into potential interrelated mechanisms of brain degeneration can be inferred. One possible mechanism is based on the finding of reduced cerebral perfusion within WMHs (168). Considering this finding, and the higher WMH burden evident during frailty (151, 152), cerebral perfusion may be attenuated. Accordingly, in healthy and cognitively impaired participants, relationships between reduced cerebral blood flow and brain atrophy have been observed (169,

170). Further, in a study of middle-aged adults, lower cerebral blood flow has been associated with increased brain atrophy, but only in patients with moderate to severe WMH volume burden (171). Taken together, this evidence suggests WMH-mediated attenuations in cerebral perfusion may contribute to brain deterioration during frailty. However, mechanistic insight cannot be inferred given the evidence presented in these human studies is only associative. Experimental evidence for the role of reduced cerebral blood flow in the pathogenesis of brain atrophy is provided by animal models (172). However, only one underpowered estimation of cerebral perfusion exists within the human frailty literature (151), leaving this notion speculative at present.

Physical inactivity and increased sedentary behaviour have also been conveyed as factors contributing to altered brain structure during ageing (173, 174). For example, a recent study demonstrated that a five-year decrease in white matter volume was associated with increased amounts of sedentary behaviour and reduced physical activity levels, when measured by accelerometry methods in non-frail older adults (175). A previous review outlines evidence to suggest that sedentary behaviour and reduced physical activity may cause detrimental effects in the brain through mechanisms such as reduced neurogenesis, synaptic plasticity and angiogenesis, and by increased inflammation (176). Collectively, these findings indicate that physical activity levels and sedentary behaviour may mediate the mechanisms leading to reduced total brain volumes (137) and increased WMH volumes (151) in frail individuals.

Neuroinflammation is a common feature of ageing (177, 178) and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Multiple Sclerosis (179). Considering frailty is an age-related syndrome associated with neurodegenerative disease (180), it seems logical that neuroinflammation may contribute to brain deterioration in frail individuals. However, neuroinflammation has not been explored extensively within the context of frailty. Nevertheless, research combining cerebrospinal fluid sampling and brain MRI indicates reduced cognitive function is associated with increased levels of the neuroinflammatory marker YKL-40 in older adults (181), with a second two year longitudinal study reporting increased cerebrospinal fluid YKL-40 concentrations associated with loss of microstructural integrity and brain atrophy of older individuals (182). These markers of structural decline are also evident in frailty (138), suggesting neuroinflammation may contribute to brain deterioration during the syndrome, which warrants further investigation.

Mechanisms of cerebral degeneration are difficult to uncover in human research due to the invasiveness of accessing and sampling brain tissue. However, insight into causal mechanisms may benefit from region-specific analyses when studying the brain in human imaging studies. In the context of frailty, these analyses are helpful as they may provide specific targets for further research aiming to uncover underlying mechanisms of brain deterioration. For example, during frailty, attenuation in brain volume (129, 183) and microstructural integrity (138) has been found within regions of the brain related to physical function, such as the medial frontal and anterior cingulate cortexes. This information could be used in animal models of frailty (e.g., the IL-10 knock out mouse model of frailty (184)) to inform on the mechanistic links between brain deterioration and functional decline during frailty. Alternatively, to provide further insight into human frailty, future studies should adopt similar protocols to Tian *et al*., where multiple features of brain structure, including brain volumes, WMHs and DTI parameters, are investigated simultaneously (138). Although this application of multiparametric MRI is not a new approach in human studies, and may even be considered standard practice in Alzheimer's and dementia research (185, 186), we stress the importance of employing this approach in future frailty work to aid in understanding how different features of brain deterioration interact and potentially exacerbate frailty development.

3.1.4 The cardiovascular system

The prevalence of cardiovascular disease increases with age (187, 188) and encompasses complex pathophysiology in numerous interrelated organs and tissues. A meta-analysis of 6000 non-frail, 7000 pre-frail and 1500 frail individuals revealed frail (odds ratio = 3.4) and pre-frail (odds ratio = 1.5) persons are at increased risk of cardiovascular disease compared to non-frail counterparts (189). This provides associative evidence for the role of cardiovascular dysfunction in the development of frailty. However, the specific alterations in cardiovascular structure and function that might contribute to frailty remain unclear. A summary of cardiac and vascular characteristics present during frailty is shown in **Figure 4**.

Cardiac parameters: Ageing is associated with various physiological changes in heart structure and function, such as an increase in left ventricular (LV) wall thickness, atrial fibrillation, and a decrease in LV ejection fraction (190). Impairments in cardiac structure and function, assessed by echocardiography, are associated with physical function decline in older individuals (191, 192), suggesting cardiac dysregulation may contribute to frailty. Some common findings are

772 evident across studies assessing cardiac parameters during frailty. In the Cardiovascular Health
773 Study, increased LV mass was observed in frail versus non-frail participants (193), with several
774 other studies since reporting an increased LV mass index as well as increased left atrial volume
775 index within frail individuals (194-196). Despite some common findings, inconsistencies have
776 been reported for several other cardiac parameters during frailty. For example, LV ejection
777 fraction (EF) has been observed as significantly attenuated in frail versus non-frail groups in
778 some studies (195, 196), but not others (197, 198). These differential findings may be due to the
779 mean age of participants in some studies being higher (195) and the adoption of differing
780 echocardiographic protocols. It would be worthwhile to build on these echocardiography derived
781 findings by employing the less patient and investigator dependent cardiac MRI methodology
782 (199-201). Furthermore, cardiac MRI enables the assessment of myocardial scarring and diffuse
783 fibrosis (202), which may be a cause of the increased LV mass observed in frail individuals. As
784 such, it appears there are currently no MRI based measures of cardiac parameters within the
785 literature associated directly with frailty *per se*, reinforcing the need to apply this modality to
786 enhance understanding in this area.
787 In a large sample of frail individuals, increased LV hypertrophy, along with impaired LV systolic
788 and diastolic function, has been found in the frail compared to the non-frail (196). Interestingly,
789 this study reported greater prevalence of abnormal cardiac measures in the frail even after
790 impairments in the pulmonary, renal, hematologic and adipose systems had been accounted for
791 in the analysis. Further, cardiac abnormalities, such as LV hypertrophy, showed the greatest
792 association with frailty of all the organ systems studied (196). Collectively these findings suggest
793 that heart dysfunction significantly contributes to the physiological frailty phenotype (**Figure 4**).
794 *Vascular parameters*: Alterations in the physiological characteristics of the human vasculature
795 are also observed with advancing age, such as increased arterial stiffness (203), wall thickness
796 (204) and endothelial dysfunction (e.g., reduced vasodilatory response and nitric oxide
797 bioavailability) (205, 206). Further, vascular dysfunction is associated with sarcopenia,
798 potentially through decreased muscle micro-perfusion (207) and sedentariness (208), indicating
799 pathophysiology within the vasculature may contribute to the phenotype of frailty.
800 However, only a limited number of studies have assessed parameters of vascular structure and
801 function during frailty. Assessing carotid-femoral pulse wave velocity, two large sample studies,
802 including the Framingham Heart Study, reported an increase in arterial stiffness during frailty

(196, 209). Markers of endothelial dysfunction, such as abnormal ankle-brachial index, pulse wave velocity and low levels of flow-mediated dilatation, have also been associated with frailty (210). Further, frailty has been linked to a greater blood concentration of dimethylarginine (211), which is elevated in endothelial dysfunction and is an independent risk factor for major adverse cardiovascular events, and reduced flow-mediated dilation (212, 213). This small number of studies collectively provide some indications of vascular deterioration during frailty.

Hypertension: Hypertension is a well-known cardiovascular risk factor associated with ageing (214) with blood pressure, particularly systolic pressure, increasing with age (215). Hypertension may contribute to cardiovascular decline through exacerbating endothelial dysfunction (216) and promoting an increase in LV mass (217). Furthermore, traits related with frailty, such as physical function decline and cognitive impairment are associated with hypertension (218-220), implying blood pressure is an important parameter to assess in the context of frailty. However, a systematic review and meta-analysis revealed an inconclusive relationship between frailty and hypertension, with cross-sectional and longitudinal studies reporting mixed results (221). Discrepancies may be due in part to the different frailty assessment criteria adopted across cross-sectional studies, which may partially explain why the meta-analysis failed to show any significant associations. The mixed results from longitudinal analyses (221) are in line with the findings of a randomised control trial (RCT) that was unable to show any impact of treatment of hypertension on the onset of frailty (222). However, a possible explanation for this RCT data may be that individuals developing frailty might be more likely to be lost before follow-up, with this selective drop out making it difficult to draw firm conclusions regarding the effect of the treatment on frailty-related outcomes (223). Nonetheless, these mixed results warrant further investigation of the relationship between frailty and hypertension, ideally with large sample size longitudinal studies.

Potential mechanisms of cardiovascular dysfunction in frailty

Inflammation: Higher serum inflammatory markers in older individuals are related to features of cardiac dysregulation, such as increased LV hypertrophy and diastolic dysfunction (224). Given that these cardiac abnormalities are also evident during frailty (196), increased inflammation in frail individuals may contribute to cardiac deterioration. Inflammatory cytokines have been proposed as regulators of cardiac dysregulation through several mechanisms. Overexpression of TNF-α in cardiac tissues in mice leads to proteasome dysfunction and accumulation of

834 ubiquitinated proteins in the left ventricle (225), which may be a mechanism contributing to
835 increased LV mass during frailty (193). Similarly, chronic TNF-α overexpression restricted to
836 cardiac tissues reduces the activity of collagenolytic enzymes, resulting in an attenuation of LV
837 dilation (226). These processes may underpin cardiac dysfunction during frailty, mediated by a
838 chronically heightened inflammatory state in the heart.
839 *Physical inactivity:* Reduced physical activity levels may also contribute to cardiovascular
840 dysfunction during frailty (83). For example, lower LV EF, which has been noted during frailty
841 (195, 196), is associated with reduced physical activity levels in middle-aged adults (227). This
842 may be explained by physical inactivity induced promotion of cardiac atrophy (228), which in
843 turn attenuates LV function via less contractile tissue being available for contraction. This is
844 supported by findings of marked reductions in the synthesis of cardiac proteins and significant
845 cardiac tissue loss following limb unloading (229). Increased arterial stiffness in frail individuals
846 may also be contributed to by reduced physical activity, given that higher arterial stiffness is
847 observed in older individuals with increased amounts of sedentary time (230). Arterial stiffening
848 may also be influenced by low vascular blood flow during sedentary time, leading to lower
849 endothelial shear stress and impairments in endothelial function (231). For example, low
850 endothelial shear stress is associated with low nitric oxide synthase expression (232), and
851 blocking nitric oxide synthesis increases arterial stiffness *in vivo* (233).
852 **3.1.5** ***The Immune system***
853 As with the four organ systems described above**,** the immune system is significantly altered with
854 age (**Figure 4**), termed immunesenescence, resulting in a decline in the ability to mount a robust
855 immune response to infection or vaccines and increased risk of autoimmune and chronic
856 inflammatory diseases (234, 235). These age-related changes are also a key factor in the increase
857 in systemic inflammation seen with advancing age, *inflammaging* (**Figure 8**), which is associated
858 with an increased risk of a broad range of age-related diseases (236). Importantly, the immune
859 system by the very nature of its function in defending against pathogens, has access to all parts of
860 the body. A compromised immune system thus has the potential to influence functional decline
861 throughout the body and contribute to multi-system dysregulation in frailty. That an aged
862 immune system may have broad influences on organ function and thereby frailty has recently
863 been suggested by studies in mice in which only the T cell compartment was modified.
864 Specifically mitochondrial function was compromised by the knockdown of mitochondrial

transcription factor A (TFAM), resulting in accelerated T cell senescence. The TFAM deficient mice showed an aged phenotype including multimorbidity, reduced physical function and premature death, a phenotype that was rescued by blocking of TNFα signalling or restoration of mitochondrial function with nucleoside riboside (237).

As the hallmarks of immunesenescence have been reviewed extensively (238) we will focus on those elements that may support the increased inflammatory status seen in old age and the development of frailty.

Immunesenescence

The innate immune system is the first line of defence against pathogens and includes cells such as macrophages. These are tissue-resident sentinel cells that rapidly alert the rest of the immune system to infection by producing inflammatory cytokines. During early life, the innate immune system is able to return to a quiescent state post-antigen exposure. However, with advancing age, these cells are in a state of low-level constitutive activation resulting in the secretion of pro-inflammatory cytokines in the absence of infection, contributing to inflammaging (239, 240). The adaptive immune system is also altered with age, driven primarily by the atrophy of the thymus in early adulthood. This results in a reduced production of naïve T cells and a consequent expansion of memory T cells to maintain the lymphocyte pool (**Figure 8**). With repeat stimulation across the lifecourse these memory T cells experience telomere attrition and enter a state of terminal differentiation as EMRA (Effector Memory expressing RA) cells marked by loss of CD28 and CD27 and expression of CD57 and CD45RA (238). These cells have poor proliferative capacity and are highly pro-inflammatory, adding to the inflammatory burden (241, 242). Other hallmarks of immunesenescence that contribute to inflammaging include an increased propensity of T cells to differentiate towards the pro-inflammatory Th1 and Th17 phenotypes (243). Single cell RNA sequencing has recently identified a subset of age-associated granzyme K expressing CD8 T cells that amplify the inflammatory phenotype and contribute to inflammaging (244). Further, the immune system has a variety of mechanisms to prevent persistence of an inflammatory state but these also decline with age. For example, cells including macrophages and regulatory T and B lymphocytes have an anti-inflammatory role secreting cytokines such as IL-10, but with age, their function declines (238, 245) reducing the homeostatic resolution of inflammation. In addition, the immune system plays a key role in removing senescent cells, which are pro-inflammatory (see below), with Natural Killer cells and

CD8 T cells recognising these cells via the NKG2D receptor (246). As their cytototoxic ability declines with age this will contribute to the accumulation of senescent cells (247).

That immunesenescence plays a role in frailty in humans is unclear as few studies have assessed indicators of immune ageing in frail and non-frail individuals and the majority simply compare healthy young and old subjects. However, the Singapore Longitudinal Ageing Study assessed markers of T cell ageing in 421 older adults who were non-frail, pre-frail and frail, showing that loss of CD28 on CD4 and CD8 T cells were positively associated with frailty and CD28 negative CD8 T cells were predictive of a pre-frail state (248). A recent two year longitudinal study assessed the neutrophil to lymphocyte ratio (NLR) and systemic inflammation index (SII), as indicators of immunesenescence, in 1822 older adults for their association with incident frailty using the physical frailty phenotype. Both log NLR and log SII were positively associated with incident frailty, the association remained when adjusted for multimorbidities (249). In contrast, a five year longitudinal study in 657 over 85 year olds, found no association of T cell senescence with loss of muscle function or prevalent or incident sarcopenia (250). Although this study did not report data for frailty, it does support the need for further longitudinal studies and a broad assessment of immunesenescence to identify specific elements that may be contributing to frailty and could be targeted in future interventional studies with compounds such as nucleoside riboside.

Inflammaging

Physiological ageing is characterised by a chronic state of elevated sub-clinical levels of pro-inflammatory cytokines (e.g., TNFα, IL-6, CRP) termed inflammaging (251). Although the majority of studies of inflammaging do not include measurements of anti-inflammatory cytokines such as IL-10, levels of this cytokine have been reported to decline with age in longitudinal studies (252). It should be noted that other studies have reported a rise in IL-10 with age, suggesting a compensatory mechanism to counterbalance inflammaging (253, 254) (**Figure 8**). This dynamic progression to a pro-inflammatory state has been recognised as a biomarker of biological ageing associated with an increased risk of a broad range of age-related diseases (255). For example, inflammaging has been associated with increased cognitive impairment (256), cardiac dysregulation (224), sarcopenia (257), cancer (258) and Alzheimer's disease (259). In contrast, studies in centenarians (260) and naturally long-lived mice (261) show a cytokine profile similar to younger people/mice with no inflammaging. Furthermore, even in

those who are not among the exceptionally long lived, inflammaging is not an inevitable consequence of advancing age, for example several studies have shown that maintaining high levels of physical activity in to old age will prevent inflammaging (262). Inflammaging is therefore not inevitable and may well be an index of adiposity (see section 3.1.6), or an early indicator of biological ageing and decline towards frailty.

The majority of studies in humans investigating associations between inflammation and frailty are cross-sectional in nature, with fewer longitudinal studies or clinical trials using anti-inflammatory drugs to test for causality. Nevertheless, indirect support for a causative role of inflammation in frailty can be deduced from the IL-10 deficient mouse which develops a frail phenotype with many similarities to humans (263) and the IKK2 knockout mouse, which has compromised NFkB activation, and shows preservation of muscle mass (264).

Cross-sectional studies: Evidence from multiple cross-sectional studies supports a positive relationship between increased systemic inflammation with age and frailty, some directly assessing frailty but others providing indirect evidence by focussing on elements of sarcopenia (for reviews see (265-267)). Elevated circulating levels of pro-inflammatory cytokines (e.g., TNFα, IL-6, CRP) have been associated with loss of muscle mass and strength (268), poor physical performance (269), loss of aerobic fitness (270) and disability (271). Interestingly, studies examining sex-specific differences have observed a stronger association between markers for inflammation and frailty in women than in men, potentially driven by sex differences in body fat quantity and distribution (272). Fried's multiparameter analysis of systems affected in frail older adults also showed that older women with three or more divergent systems, including inflammation, were more likely to be frail (273).

A systematic review of 50 studies has revealed that several elements of an increased inflammatory status, i.e., raised IL-6, TNFα, CRP, neopterin, fibrinogen, neutrophil and monocyte counts, are present in frail adults (274). A 2016 systematic review and meta-analysis of 32 cross-sectional studies also showed that the pre-frail and frail states were associated with higher levels of CRP, IL-6, fibrinogen and leukocyte counts (257). Furthermore, a recent analysis of the plasma proteome to determine biomarkers of frailty in 752 older adults from the InCHIANTI study, found four proteins (creatine kinase M-type, B-type CKB, C-X-C motif chemokine ligand 13 (CXCL13), and thrombospondin 2) were associated with frailty (275). In addition to associations with circulating levels of cytokines, a strong linkage between several

single nucleotide polymorphisms (SNPs) in the *CRP* gene (rs3093059, rs2794520, rs1205) and reduced handgrip strength in older adults have been identified (276). Another study reported that frail individuals carry a CRP (1846G>A) gene polymorphism, an underpinning factor contributing towards elevated frailty (277). Additionally, an inverse correlation has also been observed between the production of pro-inflammatory cytokines (such as TNFα) and handgrip strength in older adults (278).

Longitudinal studies: Longitudinal studies, though less numerous than cross-sectional, have been performed to assess associations between increased blood inflammation status and frailty. A longitudinal study in 901 healthy older adults assessing physical functioning in the participants nine years apart reported a significant increase in IL-6 levels and a 21% decline in grip strength and gait speed over the study period (279). Similar longitudinal relationships between higher CRP and lower grip strength have been reported in large scale birth cohort studies (280). In the Inchianti cohort study mentioned above, two proteins, cyclin-dependent kinase 5 and IL-1α, were associated with worsening of frailty in a longitudinal analysis (275) supporting a role of inflammation. A smaller longitudinal study sampled 144 adults from middle age every 5 years up to 65-75 years of age. The data revealed elevated levels of IL-6 pathway markers, namely CRP and sIL-6R, were associated with more frailty and reduced physical strength. Other associations were detected in women, notably increasing sCD14 levels and frailty, an indicator of monocyte over activation (281). In contrast, in a recent longitudinal study of a large birth cohort (n=1091), the physical frailty phenotype and frailty index were both used to assess frailty in participants 12 years apart. They found higher CRP associated with increased frailty at follow up assessed by the frailty index, but not by the physical frailty phenotype (282). Some of the discrepancies in findings may therefore reflect differences in the frailty assessment used.

Evidence from anti-inflammatory interventions: There are few interventional studies using anti-inflammatory drugs in humans with frailty as an endpoint, with most assessing different aspects of sarcopenia. A systematic review considered 28 studies assessing the impact of anti-inflammatory drugs on inflammation and skeletal muscle. Not all of the studies were in older adults but those that were found that celecoxib and piroxicam, two non-steroidal anti-inflammatory drugs, could reduce inflammation and improve physical performance in older adults with raised systemic inflammation. They also found that ibuprofen increased exercise-induced muscle hypertrophy and muscle strength and in general, concluded that the effects on

muscle were achieved most consistently when combined with exercise (283). Pharmacological blockade of IL-6 by Tocilizumab and inhibition of Jak/STAT3 pathway by Ruxolitinib have been shown to suppress muscle atrophy by downregulating the expression of the atrophy genes MuRF1 and MAFbx *in vitro* and in an animal atrophy model (284). In addition, senolytic drugs, which remove pro-inflammatory senescent cells reduce frailty in mice (285) and improve physical function in humans (286). It is important to point out that the beneficial effects of blocking inflammation for muscle adaptation to exercise may not extend to older adults not exhibiting raised systemic inflammation (287). Whilst the effect of NSAIDS on muscle protein synthesis have shown mixed results, they have been suggested to compromise satellite cell activity (288).

Taken together, these studies suggest that the emergence of inflammaging is coincident with elevated frailty in humans with age, but further evidence, especially from longitudinal and interventional studies that include the transition from the non-frail to frail state, are required to support any causal relationship in humans.

Potential mechanisms contributing to inflammaging

In addition to the contribution made by immunesenescence, inflammaging is a multifactorial process with a range of genetic (289) and environmental factors identified that contribute towards its development (290) (**Figure 8**).

Cell senescence: Cell senescence is a state of irreversible cell cycle arrest induced by various stressors, including DNA damage, telomere shortening, and protein aggregation. Cell senescence has been identified as one of the nine Hallmarks of Ageing that underlie the development of the aged phenotype (291). Removal of these cells, either genetically (292) or pharmacologically through the use of senolytic drugs (293), has been shown to extend lifespan and healthspan in mice. Trials are now underway in humans with senolytic drugs, the first of which (Dasatinib and Quercetin) reported improved physical function in patients with idiopathic pulmonary fibrosis (286). Importantly, although senescent cells are proliferatively quiescent, they are highly metabolically active. In particular, they produce a secretome, the senescence-associated secretory phenotype (SASP), containing a broad range of pro-inflammatory cytokines and chemokines as well as proteases and growth factors. These cells accumulate in the body with age and therefore contribute to inflammaging through their SASP (294).

Microbial dysbiosis: Gut microbial composition changes dramatically with advancing age, including a reduced abundance of anti-inflammatory bacterial species (e.g., *Bifidobacterium spp.,* and *F. prausnitzii*) and an expansion of pro-inflammatory pathogenic microbes (e.g. *Streptococcus spp.,* and *Staphylococcus spp*.), termed microbial dysbiosis (295). Additionally, the intestinal barrier deteriorates with age resulting in increased mucosal barrier permeability, allowing translocation of microbes and toxins into the circulation (296), with an associated increase in systemic immune cell activation and inflammation (297, 298). Studies in mice have revealed that co-housing aged mice with young germ free mice increase systemic inflammation and immunesenescence in the young mice as they ingest faeces of the aged mice and acquire their gut microbiome (299). These data together suggest that age-related dysbiosis contributes to immunesenescence and inflammaging, though these findings need to be confirmed in humans.

Physical inactivity: A wealth of observational studies have confirmed that regular physical activity is associated with lower levels of circulating pro-inflammatory cytokines, such as CRP and IL-6 (300, 301). In a recent meta-analysis, data from eight exercise intervention studies (resistance, aerobic and combined) showed a positive effect of exercise in reducing the inflammatory profile in older adults (302). The potential mechanisms by which physical activity exerts an anti-inflammaging effect include reduction in fat mass, we discuss the potential role of adiposity in inflammaging and frailty further in section 3.4. Part of the pro-inflammatory nature of adipose tissue is based upon the infiltration of monocytes/macrophages and senescent cells, which then produce pro-inflammatory cytokines (303). Studies in mice have shown that enforced physical inactivity (withdrawal of a running wheel) led to an increased senescent cell load in adipose tissue which was prevented by exercise (304). Importantly, exercising muscle is anti-inflammatory. When released from exercising muscle, IL-6 is termed a myokine and, in this context, produces systemic anti-inflammatory effects (305) via a variety of actions including increased levels of anti-inflammatory cytokines IL-10 and IL-1RA as well as cortisol (306). IL-6 is thus a dual functioning cytokine with its actions very much context-dependent; when produced by immune cells and at a high circulating level, such as during infection, it is pro-inflammatory, but when produced at lower levels, such as during exercise, it acts on macrophages to switch them to an M2 phenotype producing anti-inflammatory cytokines (307).

3.1.6 Adipose tissue

Ageing is associated with increased adiposity, such as an increased whole body and abdominal fat deposition (308-311). This age-related increase in abdominal adiposity is reportedly mainly attributable to increased visceral, as opposed to subcutaneous, fat deposition (312, 313). The health implications of increased adiposity with age are complex and still poorly understood, with adiposity in overweight and obese older people being positively associated with mortality in some studies (314, 315), but not others (316). Being overweight and obese has even been associated with better outcomes in various medical conditions (316-318) and a reduced risk of clinical events in frail individuals (319). Nonetheless, the links between adiposity and physical function deterioration and disability (320, 321), in conjunction with the presence of weight loss as a component criterion of the physical frailty phenotype (16), warrants the investigation of adipose tissue within the context of frailty.

Crude indices of obesity (e.g., BMI $\geq$ 30 kg/m^2 and waist circumference) have been adopted as indirect assessments of adiposity within studies of frailty, producing conflicting results. A systematic review of 6 longitudinal studies revealed a direct association between obesity and the incidence of frailty (23). For example, a longitudinal study among 28,181 older women reported an almost four-fold increased risk of developing frailty in obese individuals compared to those with a normal BMI, after a 3-year follow-up (322). This finding has been confirmed in another large sample study, showing an increased risk of frailty with each additional year of obesity (323). Cross sectional data also highlights that obesity is associated with a higher risk of pre-frailty and frailty in women aged 70-79 years (324). Whether this is a direct causative relationship is unknown, but the association remained statistically significant after adjustment for multiple conditions (diabetes mellitus, heart failure etc.) and inflammation status (324).

In contrast to the above findings, longitudinal studies illustrate that low BMI (<18.5 kg/m^2) is associated with the risk of frailty, when compared with normal BMI (18.5-24.9 kg/m^2) (322). This observation is corroborated by cross-sectional data highlighting a significantly lower BMI in frail versus non-frail individuals (325). Accordingly, a U-shaped relationship between frailty and adiposity may be evident, with low and high (as opposed to normal) levels of adipose tissue contributing to increased risk of frailty, which would be consistent with BMI data (322). However, the adoption of crude and indirect assessments of adiposity (i.e., body mass and waist circumference) in these studies limits insight into the relationship between frailty and adiposity.

Studies quantifying adiposity with imaging techniques during frailty are rare. Idaote *et al*., (62) highlighted greater pericardial and visceral adipose tissue in the lumbar region of non-frail compared to frail older participants following CT scanning, providing support for the longitudinal data highlighting associations between low BMI and frailty (322). Reduced adiposity may therefore underpin the typical non-intentional weight loss trait exhibited by frail persons (16). However, a large sample study adopting CT scanning observed similar lower leg adipose tissue CSA in non-frail and frail individuals (61). Direct comparison of the results of this study to those of Idaote *et al*., (62) is difficult due to differences in quantification of adipose tissue stores in different body regions. Consequently, research in this area would benefit from utilising imaging techniques to directly quantify whole body and regional adiposity with longitudinal study designs, in order to better understand the complex relationship between frailty and adipose tissue.

DEXA estimates of fat mass also reveal mixed findings regarding the link between frailty and adiposity, with one study reporting a greater body fat percentage (i.e., total fat mass in relation to total body mass) in frail compared to non-frail participants (49). However, when expressed as an absolute estimate (measured in grams) the difference in total body fat mass was non-significant. DEXA estimates of total fat mass have also been highlighted as similar between non-frail, pre-frail and frail individuals in a large Taiwanese sample (50) and a smaller cohort from the Women's Health and Aging study (52). Thus, these conflicting results underscore poor understanding of the relationship between frailty and adiposity, reinforcing the requirement for uniform measurement approaches and large sample longitudinal studies to progress this area.

Potential mechanisms of altered adiposity during frailty

Physical inactivity and high levels of sedentary behaviour contribute to increased fat mass (326, 327). Considering these behaviours are associated with frailty (83, 328), and low physical activity is a component criterion of the physical frailty phenotype (16), inactivity may contribute to increased fat mass during the syndrome. Mechanisms mediating physical inactivity induced elevations in adiposity may include a reduction in skeletal muscle insulin sensitivity, leading to the accumulation of central and visceral adipose tissue (329, 330). For example, bed rest models of inactivity highlight a reduction in insulin sensitivity and dysregulated lipid and glucose oxidation in tandem with increased adiposity and IMAT accumulation (331), particularly under conditions of positive energy balance (332, 333). These findings are reinforced by reports of

greater rates of hepatic free fatty acid uptake in individuals with low physical activity levels (334), whereas habitual endurance training is associated with a reduced hepatic free fatty acid uptake (335). Although these findings are not specific to frailty, they present potential mechanisms by which inactivity contributes to increased adiposity in frail individuals.

Increased adiposity may be contributing to the enhanced inflammatory state evident in frail individuals (336, 337). Higher levels of circulating IL-6 have been attributed to increased fat mass and obesity (338), with previous work demonstrating that up to 30% of circulating levels of IL-6 may be released from subcutaneous adipose tissue in obese subjects (339). Proinflammatory cytokines may in turn negatively influence other physiological systems, such as muscle mass and function (268). IMAT is also a proposed site of inflammatory cytokine release. Accordingly, increased IMAT and IL-6 protein content in the vastus lateralis has been observed during frailty (59), perhaps suggesting larger IMAT stores may further contribute to an enhanced inflammatory environment and facilitate skeletal muscle atrophy in frail individuals. Indeed, obese older men, who presented with heightened systemic inflammation and far greater adiposity compared their non-obese age-matched counterparts, also experienced a blunting of the acute muscle protein synthetic response to increased nutrient delivery (340). However, these same individuals presented with greater lean tissue mass and had no impairment of muscle strength or work done during repeated knee extensor contractions. Analysis of muscle mRNA expression in these obese older men, showed reduced levels of transcripts for cytochrome c, peroxisome proliferator–activated receptor-α, peroxisome proliferator–activated receptor-γ coactivator 1-α, and TFAM which are associated with mitochondrial biogenesis or oxidative phosphorylation, whereas expression of myostatin, a negative regulator of muscle growth, was greater in obese skeletal muscle (340). Whether these observations in non-frail men are representative of frail people is unknown, but the mRNA pattern was consistent with muscle deconditioning being a driver of metabolic dysregulation (340), which is pertinent to frailty. Importantly, it is unknown whether any of these muscle level characteristics are drivers of muscle deterioration in obesity or a consequence of it.

3.1.7 Multisystem dysregulation

Research on ageing and frailty biomarkers, including most studies cited above, has traditionally focused on individual biomarkers. However, investigations into single mechanism explanations of ageing, such as inflammation and oxidative stress, have produced multi-factorial explanations,

in which multiple physiological processes interact (341, 342). This has led to the proposal of nine Hallmarks of Ageing, comprising a sequence of processes that lead to the aged phenotype in various organ systems. The sequence is initiated by the accumulation of damage within cells, producing responses such as mitochondrial dysfunction and cell senescence, with endpoints of inflammation and reduced stem cell turnover effecting biological ageing (291). This understanding has led to a change in how ageing, and in turn frailty, mechanisms are perceived, with many researchers now acknowledging multisystem physiological dysregulation as a key biological underpinning of health decline during ageing.

The rationale for considering frailty as a state of several disordered systems is provided by the links between frailty and different syndromes such as sarcopenia (343), vascular dementia (128) and heart failure (193) (**Figure 4**). Further, results from the Cardiovascular Health Study cohort revealed associations between frailty and dysregulation in the cardiac, vascular and cerebral systems (193). Although, in this study, these systems were not evaluated together regarding their contribution to frailty presence. Nonetheless, collectively these findings point to dysregulation in multiple physiological systems during frailty, which has instigated a focus of research in this area.

Multisystem dysregulation was first investigated by analysing 12 biomarkers in eight different physiological systems (anaemia, inflammation, IGF-1, DHEAS, haemoglobin A1c, micronutrients, adiposity and fine motor speed) of frail and non-frail older women (273). It was demonstrated that an increasing number of abnormal physiological systems were related to an increased likelihood of being frail, with abnormality in three or more systems deemed a significant predictor of frailty (273). Notably, the cumulative number of dysregulated systems, as opposed to any specific system, was the dominating factor predicting frailty severity. The relationship between accelerating frailty and an increasing number of abnormal systems was non-linear (273), suggesting there may be a threshold beyond which an adverse downward spiral of frailty progression is evident. This would be consistent with the concept of ‘majority rules’ in systems biology (344, 345), whereby the aggregate of impaired systems may adversely affect the function of other unimpaired systems driving the whole system to a more dysregulated state.

Frailty at a multi-system level has also been investigated using a statistical approach that estimates physiological dysregulation during ageing by assessing the difference between a discrete biomarker value and the average value for a population mean (341). Using data from

nearly 33,000 individuals, and analysis of 37 biomarkers grouped into six physiological systems (lipids, immune, oxygen transport, liver function, vitamins and electrolytes), Li *et al*., revealed dysregulation in several systems, and proposed the establishment of a global dysregulation score (collated estimates on all biomarkers) that predicts the magnitude of frailty presence (346). Interestingly, no individual system was markedly better at predicting frailty than another (346). Using this statistical approach, and similar physiological system groupings for biomarkers, a study of 1754 volunteers also reported multisystem dysregulation during frailty (347) and also concluded no individual systems were more important than others. This is particularly relevant given the study assessed a different group of physiological systems to that used by Fried *et al*., (273). However, some noteworthy discrepancies can be seen between these two studies. Firstly, the nonlinearity effect of enhanced frailty risk with an increasing number of dysregulated systems, reported by Fried *et al*., (273), was not corroborated and was attributed to the limited sample size of frail individuals (347). Secondly, this study did not confirm that the number of systems dysregulated was predictive of frailty presence. This inconsistency may be partially explained by the different definitions of frailty criteria adopted across studies, which has been shown to affect the agreement and predictive ability of the physical frailty phenotype (348). Further, the sample in Fried *et al.,* (273) was comprised of all female participants whereas the cohorts studied by Ghacem *et al.,* (347) included men and women. The widely reported greater prevalence of frailty in females (349) suggests there may be a gender difference in the physiological characteristics of frailty, which may contribute to differential findings across these studies.

Multisystem dysregulation has also been reported by other research groups. Using previously established cutoff points, against which measured values for different systems were compared, the prevalence of frailty was found to be directly related to the number of abnormal organ systems (when considering cardiac, vascular, pulmonary, renal, haematological and adipose systems) (196). Additionally, this study found that cardiac abnormalities showed the strongest association with frailty compared to the other organ systems measured, supporting the premise outlined earlier that the heart is a key organ contributing to frailty development.

The observations of multisystem dysregulation support the concept of frailty as a condition of numerous abnormalities in a complex system (i.e., the human body). However, current findings from studies comparing physiological characteristics across systems and organs may be

compromised by less precise and inaccurate assessment methodologies. For example, whole body adiposity has been measured using skinfold thickness (273) and BIA methods (196), which are less robust than DEXA and MRI but were likely adopted due to their feasibility of application in studies involving large participant numbers. Furthermore, the physiological systems assessed in many studies are distinguished based on circulating biomarkers, which are by their very nature likely to be less representative of the associated organ and tissue functions. Thus, to further understand the contribution of different physiological systems to the frailty phenotype and to more accurately model and predict frailty progression, future studies should strive to gather more direct measures of key organ structure and function to expand on initial circulating biomarker-based reports.

3.2 *The physiological phenotype of frailty: using a stress stimulus paradigm*

The literature described thus far has identified numerous physiological traits associated with frailty. Despite this, the distinct physiological characteristics of frailty remain poorly understood. This lack of clarity may be because many studies are performed under resting-state conditions, thus failing to capture the dysregulation of dynamic homeostasis that is central to the definition of frailty (350). In short, in the absence of acute infection, illness and injury, without the presence of external stressors such as physical activity, the dysregulation of physiological homeostasis in frailty may be subtle or undetectable, particularly in the absence of robust and sensitive measurement techniques to quantify physiological resilience. Thus, the phenotypic traits of frailty would likely manifest more overtly than in the resting state if individuals were studied during a physiological stress challenge, such as exercise (**Figure 7**), particularly if using state-of-the-art dynamic measurement approaches to quantify physiological responses. Indeed, frailty is considered as a state during which an individual's ability to cope with and combat stressors is reduced (13), i.e., reduced resilience. Accordingly, the measurement of dynamic responsiveness to physiological stressors has been identified as a fundamental next step in frailty research (351). Despite this, understanding of the physiological responses to stressors during frailty remains limited, with much less available data relative to measures made in the resting state (outlined above). Nonetheless, a recent review by Fried and colleagues (352) discussed various physiological responses to stressors during frailty, which, promisingly, indicates that this area of research is gaining attention. The following section will attempt to summarise the current evidence and understanding of the physiological responses to stressors during frailty.

A highly effective method of inducing physiological stress *in vivo* is acute exercise. A bout of exercise will induce rapid and marked changes in physiological function involving multiple organs (for review see (353)). For example, **Figure 7** illustrates the change in cardiac output and its distribution transitioning from rest to vigorous exercise across multiple organ systems.

3.2.1 Skeletal muscle energy metabolism

Exercise necessitates a rapid and sustained increase in muscle ATP turnover, from circa 0.07 mol ATP/min at rest to > 2 mol ATP/min in heavy exercise (354). When the rate of ATP demand exceeds that of mitochondrial ATP production, energy is derived from non-mitochondrial routes, namely anaerobic glycolysis and phosphocreatine (PCr) hydrolysis (**Figure 9**). Muscle lactate accumulation and PCr hydrolysis during exercise are robust markers of muscle myopathy (355, 356) and mitochondrial dysfunction (357). Furthermore, muscle deconditioning and mitochondrial loss in ageing and chronic disease are associated with increased non-mitochondrial muscle ATP production during exercise stress (38, 358). Finally, as muscle PCr resynthesis following exercise is entirely mitochondrial-dependent, the slowing of PCr resynthesis kinetics during recovery from exercise can be viewed as a robust index of mitochondrial function and/or mass (359, 360). Changes in muscle energy metabolism during exercise and recovery are therefore likely to provide valuable insight into muscle metabolic and functional decline during frailty.

^{31}Phosphorous magnetic resonance spectroscopy (MRS) represents a robust, non-invasive *in vivo* approach to quantify muscle PCr and pH changes during exercise and recovery, making it well suited to study age and frailty related decline. A recent study employed this approach in age matched non-frail and frail older individuals, who performed graded multi-stage plantar flexion exercise within the bore of a 3 Tesla magnet using ^{31}P MRS focussed on the gastrocnemius and soleus muscles of the calf (63). During exercise, muscle PCr hydrolysis was four-fold greater in the frail participants (and ten-fold greater than middle-aged controls), when normalised to the work of activity performed. Further, this increased rate of PCr hydrolysis was strongly inversely associated with performance in a six-minute walk test and peak oxygen uptake (63). These results help illuminate potential physiological mechanisms underpinning the reduced physical function and subjective sense of fatigue in frailty (16). Of interest, this study also reported no difference in MRI derived calf muscle CSA when comparing frail and non-frail individuals. Instead, the muscle CSA fat fraction (expressed as a proportion of total muscle area) of frail

individuals was greater than their non-frail counterparts (63). Furthermore, the fat fraction was positively associated with PCr hydrolysis, suggesting differences in muscle metabolic quality, rather than mass, can differentiate the frail phenotype. It also begs the question as to whether increased habitual physical activity intervention in frail people could improve muscle metabolic resilience and thereby functionality in everyday living.

Considering exercise recovery, Andreux and colleagues compared calf muscle PCr recovery following plantar flexion exercise in pre-frail and non-frail older individuals using ^{31}P MRS at 7 Tesla (361). Pre-frail individuals exhibited longer PCr recovery times than physically active non-frail counterparts, suggesting reduced mitochondrial respiration/content is a feature of the pre-frail state. However, this study did not report the muscle PCr concentration immediately post-exercise, making it difficult to interpret the findings, i.e., was the slower recovery a consequence of differences in the rate of ATP turnover, and thereby PCr degradation, during exercise? Given that cellular ADP concentration is a primary driver of post-exercise mitochondrial resynthesis, this is a pivotal question to resolve.

A noteworthy limitation of the work described above concerns the lack of efforts to normalise PCr recovery kinetics to total mitochondrial content across the muscle of interest. Without this normalisation, mitochondrial dysfunction cannot be assumed because a lower mitochondrial content would also slow PCr recovery kinetics. Indeed, the available data indicate that dysfunction in mitochondrial respiration that is apparent in ageing (38) and chronic disease (e.g. COPD (362); diabetes (363)) fails to persist when mitochondrial respiration is corrected for muscle mitochondrial content. Accordingly, ‘mitochondrial dysfunction’ in older people was reversed by exercise training increasing mitochondrial content (38). Assessing succinate dehydrogenase as a marker, lower mitochondrial content has been observed in pre-frail compared to non-frail men in all fibre types of the vastus lateralis (364). A lower vastus lateralis muscle mitochondrial content has also been demonstrated in pre-frail and frail women, when compared to young inactive participants (365). Additionally, large cohort studies have revealed inverse associations between mitochondrial DNA (mtDNA) copy number (an index of mitochondrial number) and polymorphisms in mtDNA with frailty (366, 367). Furthermore, lower abundance and maximal activity of mitochondrial respiratory complexes has been reported in muscle of frail and pre-frail compared to non-frail individuals (361, 368).

Collectively, these findings point to greater research being needed to differentiate between the relative contribution of mitochondrial dysfunction vs decline in mitochondrial content to the loss of metabolic resilience in frailty. However, irrespective of this point, emerging evidence indicates altered muscle energy metabolism is a key underlying feature of generalised physiological decline and fatigue in frailty (**Figure 9**). Furthermore, as the change in tissue energy metabolism is seemingly associated with dysregulation across numerous different organ systems, this may be a common biological feature of frailty related decline.

3.2.2 Responses to feeding

Alternative to exercise stress, a substantial physiological response can also be elicited by feeding. Following ingestion of carbohydrates, plasma glucose concentrations increase, stimulating pancreatic insulin secretion. Insulin facilitates skeletal muscle and hepatic glucose uptake for storage and/or use; thus, insulin secretion and action are key responses mediating glucose tolerance. Ageing is associated with changes in the response to feeding, with older adults demonstrating decreased insulin sensitivity and elevated blood glucose levels after an oral glucose challenge (369, 370). Whilst many studies have demonstrated insulin resistance in healthy older participants, fewer studies have controlled for typical physiological characteristics of ageing that may influence the interpretation of results, such as muscle mass, a decline in habitual physical activity, changes in liver size and delays in gut carbohydrate absorption. These limitations make it difficult to infer if impaired glucose tolerance is a feature of normal ageing *per se* or a consequence of age-related changes in lifestyle factors that vary in presence and magnitude between individuals.

An oral glucose tolerance test (OGTT) has been used to elicit a physiological response across different frailty states. Kalyani and colleagues reported no differences in fasted blood glucose and insulin concentrations between frailty states. However, following an oral glucose challenge, frail females exhibited exaggerated increases in blood glucose and insulin concentrations over 180 min compared to pre-frail and non-frail women, demonstrating impaired glucose tolerance (371). These findings are consistent with the observation that plasma glucose concentration was elevated 2 hours post oral glucose ingestion in frail volunteers compared to non-frail individuals, but not in the baseline fasted state (372). Similarly, following a standardised 700 kcal liquid mixed-meal test, the area under the curve values for five hours post-consumption for glucose and insulin were elevated in frail compared to non-frail women (373). Whilst these findings may

reinforce an apparent reduction in glucose tolerance in frail individuals, frailty in this study was defined using only the slow gait speed and low physical activity criteria of the physical frailty phenotype (16), and thus may be deemed an inappropriate evaluation of frailty ascertainment. That said, there is evidence these two frailty criteria are the most predictive components of the frailty phenotype assessment (374), potentially supporting the assessment of frailty in this way.

The studies outlined above suggest glucose tolerance is impaired during frailty. However, nutrient absorption in the gastrointestinal tract often deteriorates with age (375) and therefore will influence glucose absorption following an OGTT or meal test. Furthermore, body size will influence the blood glucose response when a fixed dose of carbohydrate is administered, e.g., in the OGTT. For this reason, researchers may employ an intravenous glucose tolerance test or the euglycaemic insulin clamp technique to control for the effects of gut absorption and body size/lean mass on blood glucose disposal (and insulin action in the case of the insulin clamp technique). When this has been done, the rate of glucose disposal normalised to body surface area (and across a range of steady-state insulin infusion rates) was less in healthy, non-obese older volunteers compared to younger volunteers (376). The same is true when comparing older lean and obese individuals at the level of whole body and leg glucose uptake (340). Although equivalent data in frail volunteers are missing, these lower rates of normalised whole-body and leg glucose disposal in older vs young people demonstrates insulin resistance with age is a real phenomenon, and likely to be multi-factorial. It appears that methods such as the Quantitative Insulin Sensitivity Check Index and homeostasis model assessment scores have been most frequently adopted to assess insulin sensitivity in frailty (377-379). However, these approaches are estimates based on fasting blood glucose and insulin concentration and therefore do not reflect the dynamic gluco-regulatory response to feeding. Accordingly, in the Baltimore Longitudinal Study of Aging, glucose level at two hours post-OGTT was a better predictor of mortality risk than fasting glucose alone (370, 380), with similar findings evident in the Cardiovascular Health Study concerning incident cardiovascular events (381). Although not specific to frailty, these findings reinforce the importance and efficacy of studying physiological characteristics under conditions of stress in order to effectively interpret results.

4.0 Exercise interventions in frailty prevention

In the last 10-years there has been a noticeable increase in exercise-based interventions to limit, reverse or prevent frailty in older adults (**Table 2**). This is because it is becoming increasingly

recognised that regular exercise induces positive adaptation in most, if not all, organ/physiological systems. As described above, muscle weakness, low physical activity and slowness are the most discriminant physical components of frailty, suggesting they are important modifiable targets for interventions (382-384). As such, multifactorial interventions (e.g., nutrition, psychosocial and balance) that include increased exposure to exercise are strong candidates for targeting components of frailty (385). Several meta-analyses have examined the strength and outcomes of exercise trials that aim to change frailty status or reduce frailty prevalence (386-391) (**Table 2**). Although there is heterogeneity among trials, those that include exercise interventions generally favour better outcomes over non-exercise based interventions (389). Reasons for such variance are the heterogeneity of study design and study populations. In general, the study populations are also multimorbid, with many participants having 10 or more chronic diseases (389). Additionally, although several studies have assessed the impact of exercise interventions on individual components of frailty in non-frail older adults (e.g., walk speed and grip strength) and observed positive effects, results require careful interpretation (389, 390). Specifically, as frailty is a complex construct, focusing effects on one dimension of frailty may not adequately address an individual's underlying drivers of frailty. In the following section, we review the findings of exercise interventions that have determined changes specifically on frailty, in pre-frail or frail older adults (**Table 2**). We will discuss the components of frailty that were changed by exercise interventions and attempt to link findings to pathophysiological drivers of frailty.

4.1 Reversing Frailty in Frail Adults

Prior to the Fried physical frailty phenotype, one of the most impressive interventions showing positive results in long-term nursing home men and women was the Boston FICSIT study (37, 39). Although frailty was less well defined, the majority of participants were likely frail due to low mobility, strength and nutritional intake measurements. In the first of these studies, 8-weeks of high-intensity (around 80% of 1 repetition maximum) supervised progressive lower-body resistance training resulted in significant muscle strength, mass, and function gains (39). In the randomised control follow-up study, 10-weeks of the same exercise programme with or without a dietary supplement also increased muscle strength, mass, and function (37). Together, the Boston FICSIT suggested that high-intensity supervised resistance training could improve physical function in predominantly frail or dysfunctional very old adults.

Given there were few adverse events, and the intervention was feasible, the results of the below trials using predominantly moderate-intensity exercise, highlights a continuing debate. Can a frail person perform, and should we expect them to perform exercise at the necessary intensity and duration to induce frailty improvements? To the best of our knowledge, only three adequately powered and randomised control studies (392-394) and one randomized sub-study (395) have been conducted specifically in frail adults with the aim of reversing frailty. Using the Fried frailty phenotype, frailty reversal was considered if status changed from frail (score ≥ 3) to either pre-frail (score = 1 – 2) or non-frail (score = 0) at post-intervention and/or follow-up.

Kim *et al*., assessed 131 women randomized to one of four 3 month interventions followed by a 4-month post-intervention follow-up (393). Groups consisted of combinations of either a milk-based nutritional supplement (MFGM) or placebo and twice-weekly 60-minute moderate-intensity instructor-led exercise classes that included 30-minutes of strengthening exercises and 20-minutes of balance and gait training. At the three-month time point, between 28.1% and 57.6% of participants were reclassified as not frail, with the exercise and nutritional supplement observing the largest changes in frailty scores. At the four-month follow-up, both exercise groups continued to have significantly more reclassified participants than the placebo group suggesting a positive longevity effect of exercise. Although weight loss, exhaustion, low physical activity, and slow walk speed were improved by exercise, muscle strength and mass were unchanged. Even though the strengthening exercises included arm, leg, and upper body exercises, it is unclear whether these lack of changes resulted from inadequate amounts or intensity of exercise. The Boston FICSIT study clearly shows that increases in muscle mass and strength can be achieved in poorly functioning older adults if the right exercise intervention is used and in healthy community-dwelling older adults, exercise training can increase muscle mass and strength in interventions as short as 3-months (396).

In an attempt to understand the physiological mechanisms responsible for the improvements seen, Kim *et al.,* measured blood biomarkers associated with general muscle health and brain function. BDNF increased in all groups indicating that frailty improvements are associated partially with improved neurocognitive capabilities and other studies have shown that exercise can increase BDNF and neurocognitive functions in healthy older adults (397). Additionally, only the exercise + MFGM group observed reduced myostatin and ratio of IGFBP3 post intervention. Although this would indicate improved muscle health that perhaps contributes to

the reduction in frailty, the lack of strength and lean mass changes do not support this. As the IGFBP3/IGF-1 is presented as a ratio, understanding these directional changes is more complex, as it would be expected that lower myostatin and higher IGF-1 would increase muscle mass (398). Myostatin is a negative regulator, while IGF-1 is a positive regulator of muscle mass and levels of these blood biomarkers are associated with frailty (79). However, inconsistent group findings for myostatin and IGFBP3/IGF-1 in this study make it challenging to determine the relevance of the results.

Although these results provide evidence that exercise training can reverse frailty in some frail adults, it is unclear why the effects were not observed in all participants. One possible explanation is the exercise program was not specific for each physical dysfunction that contributed to frailty. To address issue, Cameron *et al.,* assessed 216 men and women randomized to either 12-months of usual care or a frailty criteria specific multifactorial intervention (392). The intervention focused on each participant's deficit in individual components of frailty. For example, if the weight-loss criteria was identified, participants were referred to the study dietician for appropriate nutritional recommendations. The exercise component was prescribed if participants met weakness, slowness, and/or low energy expenditure requirements. The exercise program consisted of 10 home-based physiotherapist sessions and an individualised home-based program which focuses on balance, strengthening, and aerobic exercises using progressive moderate-intensities (399).

There were significantly more participants in the exercise group following the intervention than controls that were no longer frail, though the proportion with reversal of frailty was lower than seen by Kim *et al.,* Similar to Kim *et al.,* there were no differences in muscle strength. Cameron *et al.,* also measured the short physical performance battery and observed improved balance, chair stand and walk scores at 12-months suggesting that muscle health was improving. In most other settings, supervised exercise training is superior to home-based training for positive changes in outcomes and may be so in frail adults. Furthermore, only 44% of participants completed the intervention with more than 50% adherence (400), with greater adherence associated with better frailty outcomes, suggesting that the amount of exercise needed to see meaningful effects is critical.

In a third study, Tarazona-Santabalbina *et al.,* assessed 100 men and women randomised to either 6-months of usual care or a multicomponent exercise program (MEP) (394). The MEP

consisted of 5 x 65-minute group sessions per week, combining short periods of proprioception and balance, low-to-moderate intensities of aerobic exercise and muscle strengthening exercises. More MEP participants were no longer classified as frail following the intervention, while all control participants remained frail. However, it is unclear from the study which frailty criteria were reduced. Instead, improvements were observed for functional measures, including walk speed and physical performance test, and also cognitive function as measured by the mini-mental state exam (MMSE). Again no changes were observed for lean mass, although lean mass was reported as a percentage and not absolute values, limiting our interpretation of the intervention.

Finally, Cesari *et al.,* conducted exploratory analyses from the Lifestyle Interventions and Independence for Elders pilot (LIFE-P) study (395, 401). Here, 424 community-dwelling men and women were randomised to either 12-months of successful ageing education (controls) or a progressive physical activity intervention consisting of supervised and home-based activities. At 12-months, the intervention group was over twice less likely to be frail than controls. Furthermore, in this paper, no indications of physiological measures were given limiting our ability to relate the study to others, other than a reduction in the incidence of frailty. However, the LIFE-P study was not designed to prevent or reduce frailty, and not all the participants were frail. Therefore, it is likely that this study design was inappropriate for targeting frailty. It is important to note that it is a limitation of such large scale intervention studies that they rarely include well controlled exercise protocols, for practical reasons, and moreover the end point measures do not give mechanistic insight.

4.2 Lowering the progression to frailty in pre-frail adults

Specifically targeting pre-frail adults has the potential to slow down or prevent progression to frailty and adverse frailty outcomes. We are aware of only two large, randomised control studies that assessed the prevalence of frailty specifically in adults who were pre-frail at baseline (402, 403) (**Table 2**). Serra-Prat *et al.,* assessed 172 men and women classified as pre-frail and randomised to either 12-months of usual care or a nutritional and exercise intervention (403). Only those at risk of malnutrition were referred to clinical nutritional care, while everyone was assigned the exercise program. At 12-months, the intervention group had fewer participants who had progressed to becoming frail, compared to the control group. No measures of lean mass were performed, and BMI was similar between groups at 12-months.

More recently, Chen *et al.,* assessed 70 men and women who were randomised to either 8-weeks of usual care or an exercise intervention consisting of three weekly-supervised sessions of 45 – 60 minutes/session of elastic band strengthening exercises (402). After 8-weeks, the intervention group had more participants who were no longer pre-frail, compared to the control group. No measures of lean mass were performed. Interestingly, the intervention group improved absolute grip strength, walking speed and physical activity levels. Unlike the aforementioned studies the increased grip strength was unique and suggests that muscle health can be targeted and improved.

That said, Chen *et al*., like Serra-Prat *et al*., targeted grip strength and improved it, suggesting that in pre-frail adults, targeting one major frailty criteria is enough to reduce the progression of frailty.

These and the frailty only studies would suggest that exercise training can slow frailty development in pre-frail, while reversing frailty in frail adults and that an intensive supervised group program rather than unsupervised home-based exercise is associated with better improvements in frailty status in pre-frail adults.

4.3 Interventions in mixed frailty populations

The previous studies suggest differential responses to exercise depending on the program's duration and intensity, supervision and the severity of the frailty classification (i.e., pre-frail v frail). To date, most randomised studies have assessed the effects of an intervention in a mixed group of frail and pre-frail older adults. As a result the findings are inconsistent because of the heterogeneity of people within the study and the type and duration of interventions.

One of the most comprehensive interventions observed significant reductions in frailty scores and reclassification of frailty status across each intervention group (404). Reclassification was considered if participants changed from frail to pre-frail, frail to non-frail or pre-frail to non-frail. Ng *et al*., assessed 246 mostly pre-frail and frail men and women randomised to one of five 6-month interventions and a 6-month follow-up. Interventions were: 1) usual care with a placebo supplement; 2) a nutritional supplement; 3) cognitive training; 4) exercise training; or 5) a combination of the nutritional supplement, cognitive and exercise training. At 6 months, frailty composite scores were lower in both exercise training groups compared to controls. At 12-months, frailty was significantly reclassified in all the groups except the control group, with both exercise groups having the most likelihood of changing their frailty status.

Unlike the studies that used grip strength, compared to controls, the frailty criteria of strength improved for the exercise and combined groups. Although Ng *et al*., used leg strength as a muscle weakness indicator, which may have biased frailty outcomes, it reinforces our suggestion that specificity in measurements limits our ability to interpret physiological changes. Although lean mass was not measured and BMI remained unchanged, all other frailty criteria improved across certain interventions. This study provides evidence that a period of intensive supervised training at the beginning of the intervention provides the best chance of long-term frailty outcomes.

In a second study, Chan *et al*., randomised 117 adults who were mostly pre-frail or frail to 3-months of either an exercise and nutrition intervention, a problem-solving therapy (PST) intervention or one of 2 controls of each intervention (405). At the end of the study only the exercise group had significantly more participants who had frailty reclassified to a lower status, with 32% of pre-frail participants improved to non-frail and 40% and 20% of frail participants improved to pre-frail and non-frail, respectively. These data suggest that exercise may equally improve frailty status across differing frailty definitions. However, in terms of the physiological responses, fat-free mass decreased, leg strength increased, but no neurocognitive functions were changed in any of the groups. The frailty criteria used was a modified Fried phenotype with a classification status based on comorbidities. The actual number of co-morbidities was relatively low across the groups (average of 3.5 each) and as such, the participants were a relatively 'healthy' cohort of frail and pre-frail participants.

Similarly, Seino *et al*., used a frailty index designed and validated by themselves and recruited 77 men and women in a randomised 3-month immediate start or delayed start crossover design (406). The Check-List 15 (CL15) criteria (407, 408) identified 56 participants as pre-frail and 21 as frail. Similar to Ng *et al*., (404), the intervention consisted of exercise, nutritional and psychosocial guidance. For all participants, regardless of when the intervention started, it reduced frailty scores, 18.4% (immediate) and 12.8% (delayed) of frail participants improved to pre-frail or non-frail, respectively. Similar to Kim *et al*., (393), there was a legacy effect at the 6-month follow-up. In terms of physiological responses, although lean mass was not assessed, the intervention increased weight and BMI and improved timed-up-and go (TUG). At the same time, grip strength was ambiguous and cognitive function remained unchanged. As such, it is difficult to determine which physiological improvements were driving lowered frailty scores and

increased reclassification in frailty. Taken together, the three studies above suggest that exercise training may equally lower frailty scores and status in frail and pre-frail older adults, with frail adults more likely to improve status.

We identified three trials with no effects compared to controls. Nagai *et al*., assessed whether the addition of aerobic exercises to a resistance training program would improve frailty (409). With both groups receiving resistance training, the 24-week study in 41 frail and pre-frail men and women observed reduced frailty scores in those with the addition of aerobic training. However, this did not translate to significant differences between groups for frailty classification. The combined group improved the frailty criteria for weight loss and grip strength, while the exhaustion criteria worsened in the control group. In terms of physiological changes, the combined group increased leg strength and power, time spent in low-intensity physical activity, and cognitive behaviour changed more than the controls. Both groups equally improved their walking speed and TUG times. These effects suggest that resistance plus aerobic training for 24 weeks can improve muscle strength, components of cardiovascular fitness and cognitive function more than resistance, while physical performance is equally improved with resistance training.

Chan *et al*., completed the follow-up to their 2012 pilot study (reviewed earlier in this section) and utilized similar intervention components, except combined into one intervention with two groups (410). Here, they assessed 289, mainly pre-frail and frail men and women randomized to 6-months of either a predominantly home-based DVD or an intensive supervised exercise and problem-solving sessions, and the home DVD. At 6-months, with around 40% of all participants changing frailty status, both groups observed similar effects between home-based and supervised interventions. Using the modified frailty index that reflected the Taiwanese population, at most time points there were frailty criteria improvements observed for exhaustion, energy expenditure, 5-meter walking time and grip strength. Although these modified frailty scores were improved, only the TUG and one-leg-stand time improved, while lean mass remained unchanged for the Fried Frailty Phenotype. As such, both an intensive and less intensive intervention may improve frailty criteria.

Finally, Luger *et al*., assessed 80 mostly pre-frail and frail men and women randomized to 12-weeks of either social support (controls) or a whole-body resistance-based exercise and nutrition intervention (411). After 12-weeks, both groups combined significantly reduced the prevalence of frailty, but no differences between groups were observed. This study focussed on nutritional

health, and as such no measures of individual frailty criteria or muscle mass were completed, limiting our ability to determine physiological responses.

4.4 Longevity of the impact of interventions

A final aspect of interventions is the longevity, or legacy, of the observed effect. Few studies have considered this element, but recently Oh *et al.,* reported on a non-randomised multicomponent intervention in 383 socioeconomically vulnerable older Korean men and women (412). One hundred and eighty-seven participants chose the 6-month intervention consisting of supervised group exercise sessions. In addition, participants received a daily nutritional supplement, medication assessment to reduce polypharmacy, therapy for depression if this was diagnosed, and home environment assessment to minimise trip hazards. Frailty was assessed by the Fried frailty phenotype and the deficit-accumulation frailty index at baseline (6 months before the start of the intervention) and at the end of the intervention, plus 6 months after the intervention completion and again 12 months later. The baseline scores for frailty phenotype and frailty index suggest the groups were largely pre-frail. The intervention group were frailer, suggesting that less frail individuals are less likely to desire an intervention. At the end of the 6-month intervention, the intervention group had a lower frailty index and phenotype scores than controls. However, when participants were reassessed 6 and 18 months after the intervention, the differences between groups were non-significant. Nevertheless, at the end of the intervention, the intervention group had significantly higher physical performance scores (SPPB) and these scores remained higher than controls until the completion of the study 18 months later. As such, these findings are in line with other studies in pre-frail adults but critically suggest that interventions must be maintained for the benefit to persist, which is to be expected.

4.5 Summary exercise interventions in frailty prevention

Taken together, when exercise is included as part of a frailty prevention or reduction program, positive effects compared to usual care control groups are generally observed. Specifically, if exercise is part of a multimodal approach that also targets other components of frailty, including nutritional deficits, psychosocial education or cognitive function, effects are larger and appear more robust over time. Frailty scores and frailty status appear to be improved more when the program is designed for frailty, rather than other conditions such as poor mobility. Additionally, adherence is often low and may explain, in part, the heterogeneity of responses. Increasing adherence, either through simplifying the program or conducting it in a supervised environment

will likely improve outcomes. However, not all supervised interventions improved frailty status. We noticed that the majority of studies prescribe exercise using non-specific often-qualitative physiological measures, including RPE or predicted maximum heart rate. Although this approach is more generalisable, it often over-, or under-estimates exercise intensity making it challenging to compare results and determine possible underlying physiological mechanisms. For example, we observed there is mostly a lack of effect of exercise on individual frailty criteria, muscle mass and muscle strength. Non-frail older adults typically respond more positively to exercise training studies prescribed from exact fitness measures. However, from the current literature, it is unclear if the lack of effects on muscle results from too low exercise intensities caused by non-specific prescription, or an effect from the underlying pathophysiological causes of an individual's frailty. The work from Boston FICSIT Study would suggest that it may be too low exercise intensities.

5. Knowledge gaps and recommendations for future research

Frailty is currently defined by clinical criteria based either on the physical phenotype or the accumulation of deficits, with little assessment of the physiological changes that drive the criteria. We suggest that this is limiting our ability to adequately stratify pre-frail and frail older adults and design targeted interventions to reduce or prevent frailty developing. Importantly from a physiological standpoint, the majority of studies have involved assessment of the characteristics of individual organs and have been carried out under resting-state conditions. This is not optimal for understanding frailty, which is a complex multi-organ condition whose definition is based upon a decline in robustness or resilience to stressors.

***Recommendation 1*:** We suggest that going forward, we require integrative modelling of individual physiological components at rest and under challenge, including through exercise, to define the physiological phenotype of frailty. In addition to this overarching change in approach to frailty we suggest there are distinct gaps in our understanding or approach to frailty research that should be addressed in future research studies:

Clinical: Clinical studies should focus on reporting the phenotypic differences between non-frail and frail older individuals so it is clear moving forward what we define as normal, or healthy ageing – a chronological process that does not affect function - as opposed to unhealthy ageing, a pathological process that leads to reduction in function (of a person, physiological system, or

organ system). These clinical studies need deliberate matching to concurrent study of the underlying physiology we discuss below.

Brain: Several aspects of age-related changes to brain anatomy and physiology are under-researched in relation to their contribution to frailty, for example, is frailty *per se*, or elements of the syndrome's component criteria underpinned by reduced brain volumes in specific brain regions? Using a range of brain imaging methods will be important to determine how brain alterations lead to physical presentations. For example, decreased cerebral oxygenation may explain the apparent attenuations in neuromuscular function during frailty (111). Reduced cerebral blood flow and cerebrovascular reactivity have been reported during normal ageing (413) and may also present as a feature of the frailty state, potentially contributing to brain structure deterioration during frailty (414).

Skeletal muscle: There are clear associations between skeletal muscle deficits and frailty, with studies to date suggesting muscle quality and mass are drivers of poor physical function and weakness seen in frail adults. Further studies are needed to define, for example, the roles of anabolic resistance, increased fat infiltration, insulin resistance, compromised satellite cell function and reduced NMJ number and function. In relation to mitochondrial function and metabolic resilience in frailty, more research is needed to differentiate between the relative contribution of mitochondrial dysfunction and the decline in mitochondrial content seen in the muscle of frail adults. Whatever the outcome of this research, the current literature indicates altered muscle metabolism is a key underlying feature of physiological decline and fatigue in frailty.

Study design: Frailty research to date has mainly involved a single cross-sectional assessment of frailty(415). Some studies have assessed the longitudinal associations between frailty and brain architecture variables, such as WMH volume, microstructural integrity and macroinfarcts (159, 416, 417). However, interpretation of findings from these studies is restricted by factors such as an inadequate number of frail individuals recruited and prospective study designs incorporating only a single assessment of physiological parameters. Similarly, a small number of studies have attempted to investigate associations between alterations in body composition characteristics and frailty over time. However, this literature is confounded by indirect measures of body composition and skeletal muscle mass (418). These limitations underpin a poor understanding of the temporal relationships between frailty development and underlying physiological changes.

Recommendation 2: To try and understand the factors influencing the trajectory from a non-frail state to frailty, large and robust longitudinal studies assessing temporal relationships between a broad range of physiological parameters and frailty in the same individuals should be prioritised.

Recommendation 3: Key to elucidating mechanisms of frailty development will be the design and implementation of intervention studies, with for example well controlled exercise protocols and end point measures, in longitudinal study designs with associated mechanistic analyses. If specific pathophysiological characteristics and frailty status are improved in tandem by intervention, these physiological processes may be deemed contributing factors to frailty progression. One example in this area is a study using 6 months of a resistance exercise training programme in non-frail and pre-frail older adults and showing improved leg strength in both groups. Transcriptomic analysis of muscle biopsies revealed the improvement in strength was associated with the protocadherin gamma gene cluster which may be related to muscle denervation and re-innervation (32).

Recommendation 4: Whilst inflammation increases with age and is associated with increased risk of frailty in large population-level studies and meta-analyses (257), it is still not clear that there is a causative role of inflammation in the development of frailty. Direct interventional studies in humans assessing the impact on frailty as an endpoint are required and must progress beyond the current literature which is largely focussed on sarcopenia. We recognise that such studies will not be straightforward as many frail older adults are already prescribed drugs that will modify their inflammatory status. Furthermore, given the multi-tissue compromise seen in frailty (e.g. muscle, brain, heart), future studies should consider both local and systemic inflammatory profiles and take a systems modelling approach to understanding the range of influences on frailty at the individual level.

Conclusion: In summary, frailty is a complex multi-organ condition that is currently described in clinical rather than physiological terms. To better understand and treat frailty, we suggest that a multi-organ approach is required, harnessing state-of-art technologies to quantify organ structure and function. Inflammation is associated with frailty development, but proof of causation is lacking. Studies to address this issue may be confounded by the multimorbid, multi-medicated nature of many frail adults. On a positive note, there is evidence that interventions that include exercise can reduce and reverse frailty. However, the most successful are delivered in person rather than via remote home-based programmes.

Acknowledgements

Joseph Taylor is supported by a PhD scholarship funded by the MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research. Janet Lord is supported by the NIHR Birmingham Biomedical Research Centre and Paul Greenhaff by the NIHR Nottingham Biomedical Research Centre. The views expressed here are those of the authors and not necessarily those of the NHS, the NIHR or the Department for Health and Social Care.

Legends to Figures

Figure 1. Key stages in the development of frailty. The cascade of functional decline in older adults from an independent (resilient) non-frail state through to frailty and disability (in the absence of intervention). Figure adapted from Dent et al., (13) with permission under the Creative Commons license: https://creativecommons.org/licenses/by/4.0/.

Figure 2. Risk factors for the development of Frailty. There are several important risk factors that increase the risk of a person developing frailty. These include sex (female), non-white ethnicity, level of education, socio-economic status, obesity, and smoking. Protective factors include eating a Mediterranean diet and maintaining physical activity in to old age.

Figure 3. The clinical manifestations of Frailty. People with frailty have high rates of heart failure, hypertension, COPD and anaemia**.** They are also more likely to have multimorbidity (the co-occurrence of two or more diseases), polypharmacy, and sarcopenia. CI; confidence interval, COPD; chronic obstructive pulmonary disease

Figure 4. Summary of the typical physiological characteristics of a frail person based on a systems physiology approach. BMI, body mass index; CSA, cross sectional area; IL10, interleukin 10; IMAT, intramuscular adipose tissue; LAVI, left atrial volume index; LV, left ventricular; MU, motor unit; SkM, skeletal muscle; WMH, white matter hyperintensity.

Figure 5. Neuromuscular function in frailty. Schematic overview of the measurement of motor unit potential (MUP) using intramuscular electromyography. Compared to the non-frail condition, frailty is associated with a smaller MUP thought to arise from smaller motor units. NMJ, neuromuscular junction.

Figure 6. Overview of magnetic resonance imaging (MRI) techniques routinely used to quantify brain architecture in frailty. DTI, diffusion tensor imaging; WMH, white matter hyperintensity.

Figure 7. Schematic representation of increased cardiac output and the redistribution of blood flow across organs during exercise, when compared to rest.

Figure 8. Factors contributing to the age-related increase in systemic inflammation (inflammaging). Increased systemic inflammation with age, inflammaging, is multifactorial in origin. Key contributors include: an increase in senescent cells which have a pro-inflammatory secretome, the Senescence associated secretory phenotype (SASP); reduced physical activity which contributes to increased adiposity, with adipose tissue being a source of inflammatory mediators such as adipokines; gut dysbiosis and reduced intestinal integrity lead to leaking of microbes in to the circulation which then induces an inflammatory immune response. The degree of inflammaging is associated with increased risk of moving from a non-frail to a frail state.

Figure 9. Schematic illustration of the effect of frailty on substrates and pathways involved in skeletal muscle energy turnover. When the rate of ATP demand during muscle contraction exceeds that of mitochondrial ATP production, ATP turnover is maintained from non-mitochondrial routes, namely glycolysis and phosphocreatine (PCr) hydrolysis. ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP, adenosine monophosphate; Ca^{2+}, calcium; *CK*, creatine kinase; *CPT1*, carnitine palmitoyltransferase I; Cr, creatine; H^+, hydrogen ion; H_2O, water; IMP, inosine monophosphate; NADH, reduced nicotinamide adenine dinucleotide; NAD^+, oxidised nicotinamide adenine dinucleotide; *PDC*, pyruvate dehydrogenase complex; PCr, phosphocreatine; Pi, inorganic phosphate; *TCA cycle*, tricarboxylic acid cycle.

Table 1: Summary of systematic reviews and studies examining the prevalence of age related conditions in people with frailty.

	Condition	Study characteristics	OR of frailty in people with condition (95% CI)	OR of condition, in people with frailty (95% CI)	% of patients with frailty who have condition (95% CI)
			-	-	
Systematic reviews					
Marengoni et al 2020 (419)	Heart failure	20 studies in meta-analysis	3.44 (0.75–15.7)	-	31% (17-45)
Palmer et al 2019 (420)	Cerebrovascular disease*	18 studies	2.32 (2.11-2.55)	-	10% (6-13)
Palmer et al 2019 (421)	Polypharmacy	18 studies in meta-analysis	1.59 (0.90-2.83)	2.62 (1.81–3.79)	59% (42-76)
Vetrano et al 2018 (221)	Hypertension	27 studies	1.33 (0.94-1.89)	-	72% (66-79)
Palmer et al 2018 (422)	Anaemia	12 studies in meta-analysis	2.24 (1.53-3.30)	-	36% (24-48)
Marengoni et al 2018 (21)	COPD	6 studies in meta-analysis	1.97 (1.53-2.53)	-	22% (15-28)
Vetrano et al 2019 (423)	Multimorbidity	25 studies in meta-analysis	2.27 (1.97–2.62)	-	72% (63-81%)

Individual studies

Davies et al 2018 (424)	Sarcopenia EWGSOP criteria[ł]	Toledo Study of Healthy Aging community based, Spain, >65 yrs N=1611	1.67 (0.95-2.96)	-	40.1%
	Sarcopenia FNIH criteria[ǂ]		10.61 (5.8-19.4)	-	72.2%
Avila-Funes et al 2009 (425)	Cognitive impairment (Lowest Quintile)	Community based, Spain >65 yrs N=6030,	-	1.14 (0.58–2.21)	21.9%
Armstrong et al 2010 (426)	Dementia	23,952 home care recipients, Canada	-	-	40.0%

*All studies included stroke only. ł European Working Group on Sarcopenia in Older People (EWGSOP) algorithm . ǂ Foundation for the National Institutes of Health Biomarkers Consortium Sarcopenia Project. Systematic reviews included here were selected using search terms for frailty and each condition run together and those that reported a prevalence of each condition in people with frailty with estimated confidence intervals were selected. The most recent review was selected if there were more than one.

Table 2. Large cohort exercise intervention studies to reduce frailty.

Population	N (% Female) Age (mean ± SD)	Frailty		Intervention				Effects on Frailty	
		Measure	Baseline Prevalance	Study Groups	Exercise Prescription	Duration + Follow-Up	Aligned with Activity Guidelines[c]		
Frail Only									
Kim et al. 2015 (RCT) (393)	131 (100%) 80.9 ± 2.9	Fried Frailty	Frail (100%). Mean Score = 3.7 ± 0.7	1. Control (dietary placebo) 2. Dietary supplement (MFGM) 3. MFGM + exercise training 4. Placebo + exercise training.	2 x week 60-min/session Moderate-Intensity Strengthening, balance, gait Supervised	3 months + 4 month follow-up	No (No specified aerobic)	Frailty re-classified (3 months) 1. 30.3% 2. 28.1% 3. 57.6%* 4. 51.5% Frailty re-classified (Follow-Up) 1. 15.2% 2. 25.0% 3. 45.5%* 4. 39.4%*	MFGM + Ex > Placebo & MFGM alone MFGM + Ex & Placebo + Ex > Placebo
Tarazona-Santabalbina et al. 2016 (RCT) (394)	100 (54%) 80.0 ± 3.7	Fried Frailty	Frail (100%). Mean Score = 3.7 ± 0.7	1. Exercise 2. Control	5 x week 65-min/session Proprioception & balance Aerobic & strength Stretching	24 weeks	Yes	Frailty re-classified 1. 31.4%* 2. 0	Ex > Control
Cameron et al. 2013 (RCT) (392)	216 (68%) 83.3 ± 5.9	Fried Frailty	Frail (100%). Mean Score = 3.4 ± 0.7	1. Multifactorial and frailty specific 2. Control	10 x supervised sessions and WEBB[a] recommendations (balance, strength, aerobic).	12 months	No (No specified aerobic)	Frailty re-classified 1. 38%* 2. 24%	Intervention > Control
Cesari et al. 2015 (RCT) (395)	424 (68.9%) 76.8 ± 4.2	Fried Frailty	Unclear but assumed to be between 20 & 25% considered frail at baseline	1. Physical Activity 2. Health Education (Control)	3 x supervised week (wk 1-8) 2 x supervised week (wks 9-24) + 3 x home based Home based after week 25 Walking, flexibility, strength	12 months	Yes	Prevalance of Frailty 1. 10%* 2. 19.1%	Intervention < Controls

Pre-Frail Only									
Serra-Prat et al. 2017 (RCT) (403)	172 (56.4%) 78.3 ± 4.9	Fried Frailty	Pre-Frail (100%). Mean Score = 1.45 ± 0.5	1. Intervention 2. Control	<u>Aerobic Exercise</u> 4 x week 30-45 min/session Walking Home-based <u>Strength & Balance</u> 4 x week 20-25 min/session Progressive Home-based	12 months	Yes	<u>Frail v Non-Frail</u> 1. 4.9%* 2. 15.3% <u>Robust v Non-Robust</u> 1. 15.3% 2. 21.3%	Intervention < Control
Chen et al. 2019 (RCT) (402)	70 (65%) 76.1 ± 5.6	Fried Frailty	Pre-Frail (100%).	1. Exercise 2. Control	3 x week 45-60 min/session Elastic Band resistance	8 weeks	No (No specified aerobic)	<u>Frailty re-classified</u> 1. 81.8%* 2. 9.1% + 1 person becoming frail	Intervention > Control
Mixed Frailty									
Ng et al. 2015 (RCT) (404)	246 (61.4%) 70.0 ± 4.7	Fried Frailty	Pre-Frail (72%) and Frail (28%). Mean Score = 2.0 ± 0.8	1. Usual Care Controls 2. Cognitive Training 3. Nutritional Supplements 4. Physical Training 5. Combination Treatment	2 x week 90-min/session Moderate-Intensity Strengthening & balance. Supervised (1st 3-months) Home-based (2nd 3-months)	6 months + 6 months follow-up	Yes	<u>Frailty re-classified (12 Months)</u> 1. 15.2% 2. 35.6%* 3. 35.6%* 4. 41.3%* 5. 47.8%*	Each intervention > Control
Chan et al. 2012 (Pilot RCT) (405)	117 (59%) 71.4 ± 3.7	Fried Frailty	Pre-Frail (87%) and Frail (13%).	1. Exercise + nutrition 2. Problem Solving Therapy 3. Control of 1 4. Control of 2	3 x week 60-min/session Brisk walking, stretching, strengthening, balance Supervised	3 months + 6, 9, 12 month follow-up	Yes	<u>Frailty re-classified (3 Months)</u> 1. 45%* 2. 44% 3. 27% 4. 28%	Ex + nutrition > Control 1
Seino et al. 2017 (RCT – CO) (406)	77 (31.2%) 74.6 ± 5.5	Completed the HCS + CL15 frailty score ≥ 2	Pre-Frail (72.7%) and Frail (27.3%). Mean Score = 3 ± 1.4	Exercise + Nutritional + Psychosocial 1. Immediate 2. Delayed (3 months)	2 x week 60-min/session Resistance Program	3 months + 3 month control	No (No specified aerobic)	Intervention reduced CL15 scores that continued during 3-month post intervention	Intervention > Controls

								control. Intervention reclassified fralty to pre-frailty in 45%-58% of frail participants.	
Nagai et al. 2018 (RCT) (409)	41 (90.5%) 81.5 ± 7.2	Fried Frailty	Pre-Frail (41.5%) and Frail (58.5%)	1. Exercise 2. Exercise + Guidance	2 x week Resistance Training	24 weeks	Similar (focused on resistance and gave guidance for physical activity)	<u>Frailty re-classified</u> 1. 15% 2. 28.6%	No difference
Chan et al. 2017 (RCT) (410)	289 (53%) 71.6 ± 4.3	Fried Frailty	Pre-Frail (79%) and Frail (21%).	1. Control (education) 2. Intervention (exerecise + problem solving)	48 sessions 60 min/session Brisk walking, stretching, resistance, balance.	6 months + 3 and 12 month follow-up	Yes	<u>Frailty re-classified (6-months)</u> 1. 39% 2. 42% <u>Frailty re-classified (12-months)</u> 1. 36% 2. 42%	No difference
Luger et al. 2016 (RCT) (411)	80 (84%) 82.8 ± 8.0	Fried Frailty	Robust (1%), Pre-Frail (35%), Frail (64%)	1. Exercise + Nutrition 2. Social Support	2 x week 60 min/session Muscle Strengthening	12 weeks	No (No specified aerobic)	<u>Frailty re-classified</u> 1. 17% 2. 16%	No difference
Oh et al. 2021 (non-randomised control) (412)	383 (72%) 234 (75%)[b] 76.3 ± 5.7[b]	Fried Frailty Phenotype and Deficit Accumulation Index	Unclear 2.2 ± 1.2 phenotype[b] 0.26 ± 0.11 index[b]	1. Multicomponent 3. Comparison	2 x week 60 min/session Resistance (20 min) Balance (20 min) Aerobic (20 min)	24 weeks + 6, 18 month follow up	Similar (similar strengthening but less aerobic)	The intervention reduced frailty index and phenotype scores post-intervention. Differences were not maintained at future assessments	Intervention > Controls

(RCT) Randomized Control Trial; (RCT-CO) RCT-Crossover; (HCS) Hatoyama Cohort Study; (CL15) Check-List 15;. [a]Weight-bearing for better balance program (WEBB) (399). [b]after propensity matching.[c]alignment with physical activity guidelines for older adults. *p<0.05 significantly different than control group.

References

1. **Office for National Statistics**. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/pastandprojecteddatafromtheperiodandcohortlifetables/1981to2018.

2. **House of Lords Science and Technology Committee**. Ageing: Science, Technology and Healthy Living. *https://committeesparliamentuk/work/1/ageing-science-technology-and-healthy-living/publications/* 2021.

3. **Morley JE, Vellas B, Van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea W, Doehner W, Evans J**. Frailty consensus: a call to action. *J Am Med Dir Assoc* 14: 392-397, 2013.
DOI:10.1016/j.jamda.2013.03.022

4. **O'Caoimh R, Galluzzo L, Rodríguez-Laso Á, Van der Heyden J, Ranhoff AH, Lamprini-Koula M, Ciutan M, Samaniego LL, Carcaillon-Bentata L, Kennelly S**. Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis. *Ann Ist Super Sanita* 54: 226-239, 2018.
DOI:10.4415/ANN_18_03_10

5. **Woodhouse KW, Wynne H, Baillie S, James OF, Rawlins MD**. Who are the frail elderly? *Q J Med* 68: 505-506, 1988.
DOI:https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.619.907&rep=rep1&type=pdf

6. **Rockwood K, Fox RA, Stolee P, Robertson D, Beattie BL**. Frailty in elderly people: an evolving concept. *CMAJ* 150: 489-495, 1994.
DOI:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1486322/?page=1

7. **Mitnitski AB, Graham JE, Mogilner AJ, Rockwood K**. Frailty, fitness and late-life mortality in relation to chronological and biological age. *BMC Geriatr* 2: 1-8, 2002.
DOI:10.1186/1471-2318-2-1

8. **Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G**. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. *J Gerontol A Biol Sci Med Sci* 59: M255-M263, 2004.
DOI:10.1093/gerona/59.3.m255

9. **Wong CH, Weiss D, Sourial N, Karunananthan S, Quail JM, Wolfson C, Bergman H**. Frailty and its association with disability and comorbidity in a community-dwelling sample of seniors in Montreal: a cross-sectional study. *Aging Clin Exp Res* 22: 54-62, 2010.
DOI:10.1007/BF03324816

10. **Fang X, Shi J, Song X, Mitnitski A, Tang Z, Wang C, Yu P, Rockwood K**. And mortality in older Chinese adults: Results from the Beijing longitudinal study of aging. *J Nutr Health Aging* 16: 903-907, 2012.
DOI:10.1007/s12603-012-0368-6

11. **Gill TM, Gahbauer EA, Han L, Allore HG**. The relationship between intervening hospitalizations and transitions between frailty states. *J Gerontol A Biol Sci Med Sci* 66: 1238-1243, 2011.
DOI:10.1093/gerona/glr142

12. **Lee L, Patel T, Costa A, Bryce E, Hillier LM, Slonim K, Hunter SW, Heckman G, Molnar F**. Screening for frailty in primary care: Accuracy of gait speed and hand-grip strength. *Can Fam Physician* 63: e51-e57, 2017.
DOI:https://pubmed.ncbi.nlm.nih.gov/28115460/
13. **Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodriguez-Manas L, Fried LP, Woo J, Aprahamian I, Sanford A, Lundy J, Landi F, Beilby J, Martin FC, Bauer JM, Ferrucci L, Merchant RA, Dong B, Arai H, Hoogendijk EO, Won CW, Abbatecola A, Cederholm T, Strandberg T, Gutierrez Robledo LM, Flicker L, Bhasin S, Aubertin-Leheudre M, Bischoff-Ferrari HA, Guralnik JM, Muscedere J, Pahor M, Ruiz J, Negm AM, Reginster JY, Waters DL, Vellas B**. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. *J Nutr Health Aging* 23: 771-787, 2019.
DOI:10.1007/s12603-019-1273-z
14. **Dapp U, Minder CE, Anders J, Golgert S, von Renteln-Kruse W**. Long-term prediction of changes in health status, frailty, nursing care and mortality in community-dwelling senior citizens-results from the longitudinal urban cohort ageing study (LUCAS). *BMC Geriatr* 14: 141, 2014.
DOI:10.1186/1471-2318-14-141
15. **Hoogendijk EO, Romero L, Sánchez-Jurado PM, Ruano TF, Viña J, Rodríguez-Mañas L, Abizanda P**. A new functional classification based on frailty and disability stratifies the risk for mortality among older adults: The FRADEA Study. *J Am Med Dir Assoc* 20: 1105-1110, 2019.
DOI:10.1016/j.jamda.2019.01.129
16. **Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G**. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 56: M146-M157, 2001.
DOI:10.1093/gerona/56.3.m146
17. **Mitnitski AB, Mogilner AJ and Rockwood K**. Accumulation of deficits as a proxy measure of aging. *Sci World J* 1: 323-336, 2001.
DOI:10.1100/tsw.2001.58
18. **Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue Q-L, Bandeen-Roche K, Varadhan R**. Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. *Ageing Res Rev* 26: 53-61, 2016.
DOI:10.1016/j.arr.2015.12.003
19. **Bouillon K, Kivimaki M, Hamer M, Sabia S, Fransson EI, Singh-Manoux A, Gale CR, Batty GD**. Measures of frailty in population-based studies: an overview. *BMC Geriatr* 13: 64, 2013.
DOI:10.1186/1471-2318-13-64
20. **Song X, Mitnitski A and Rockwood K**. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. *J Am Geriatr Soc* 58: 681-687, 2010.
DOI:10.1111/j.1532-5415.2010.02764.x
21. **Marengoni A, Vetrano DL, Manes-Gravina E, Bernabei R, Onder G, Palmer K**. The relationship between COPD and frailty: a systematic review and meta-analysis of observational studies. *Chest* 154: 21-40, 2018.
DOI:10.1016/j.chest.2018.02.014
22. **Marengoni A, Zucchelli A, Vetrano DL, Aloisi G, Brandi V, Ciutan M, Panait CL, Bernabei R, Onder G, Palmer K**. Heart failure, frailty, and pre-frailty: A

systematic review and meta-analysis of observational studies. *Int J Cardiol* 316: 161-171, 2020.
DOI:10.1016/j.ijcard.2020.04.043
23. **Feng Z, Lugtenberg M, Franse C, Fang X, Hu S, Jin C, Raat H**. Risk factors and protective factors associated with incident or increase of frailty among community-dwelling older adults: A systematic review of longitudinal studies. *PLoS One* 12: e0178383, 2017.
DOI:10.1371/journal.pone.0178383
24. **Myers V, Drory Y, Goldbourt U, Gerber Y**. Multilevel socioeconomic status and incidence of frailty post myocardial infarction. *Int J Cardiol* 170: 338-343, 2014.
DOI:10.1016/j.ijcard.2013.11.009
25. **Vermeiren S, Vella-Azzopardi R, Beckwee D, Habbig AK, Scafoglieri A, Jansen B, Bautmans I**. Frailty and the Prediction of Negative Health Outcomes: A Meta-Analysis. *J Am Med Dir Assoc* 17: 1163.e1161-1163.e1117, 2016.
DOI:10.1016/j.jamda.2016.09.010
26. **Waite SJ, Maitland S, Thomas A, Yarnall AJ**. Sarcopenia and frailty in individuals with dementia: A systematic review. *Arch Gerontol Geriatr* 92: 104268, 2021.
DOI:10.1016/j.archger.2020.104268
27. **Robertson DA, Savva GM, Coen RF, Kenny RA**. Cognitive function in the prefrailty and frailty syndrome. *J Am Geriatr Soc* 62: 2118-2124, 2014.
DOI:10.1111/jgs.13111
28. **Nachtomy O, Shavit A and Yakhini Z**. Gene expression and the concept of the phenotype. *Stud Hist Philos Sci C Stud Hist Philos Biol Biomed Sci* 38: 238-254, 2007.
DOI:10.1016/j.shpsc.2006.12.014
29. **Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, van Kan GA, Andrieu S, Bauer J, Breuille D**. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. *J Am Med Dir Assoc* 12: 249-256, 2011.
DOI:10.1016/j.jamda.2011.01.003
30. **Zhang Y, Chatzistamou I and Kiaris H**. Identification of frailty-associated genes by coordination analysis of gene expression. *Aging (Albany N Y)* 12: 4222-4229, 2020.
DOI:10.18632/aging.102875
31. **Jylhävä J, Raitanen J, Marttila S, Hervonen A, Jylhä M, Hurme M**. Identification of a prognostic signature for old-age mortality by integrating genome-wide transcriptomic data with the conventional predictors: the Vitality 90+ Study. *BMC Med Genomics* 7: 54, 2014.
DOI:10.1186/1755-8794-7-54
32. **Hangelbroek RW, Fazelzadeh P, Tieland M, Boekschoten MV, Hooiveld GJ, van Duynhoven JP, Timmons JA, Verdijk LB, de Groot LC, van Loon LJ, Müller M**. Expression of protocadherin gamma in skeletal muscle tissue is associated with age and muscle weakness. *J Cachexia Sarcopenia Muscle* 7: 604-614, 2016.
DOI:10.1002/jcsm.12099
33. **Janssen I, Heymsfield SB, Wang Z, Ross R**. Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. *Journal of applied physiology* 2000.
DOI:https://doi.org/10.1152/jappl.2000.89.1.81

34. **Berger MJ and Doherty TJ**. Sarcopenia: prevalence, mechanisms, and functional consequences. *Body composition and aging* 37: 94-114, 2010.
DOI:https://doi.org/10.1159/000319997
35. **Shou J, Chen P-J and Xiao W-H**. Mechanism of increased risk of insulin resistance in aging skeletal muscle. *Diabetol Metab Syndr* 12: 1-10, 2020.
DOI:https://doi.org/10.1186/s13098-020-0523-x
36. **Marzetti E, Calvani R, Cesari M, Buford TW, Lorenzi M, Behnke BJ, Leeuwenburgh C**. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. *The international journal of biochemistry & cell biology* 45: 2288-2301, 2013.
DOI:https://doi.org/10.1016/j.biocel.2013.06.024
37. **Fiatarone MA, O'Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, Roberts SB, Kehayias JJ, Lipsitz LA, Evans WJ**. Exercise training and nutritional supplementation for physical frailty in very elderly people. *New England Journal of Medicine* 330: 1769-1775, 1994.
DOI:10.1056/NEJM199406233302501
38. **Broskey NT, Greggio C, Boss A, Boutant M, Dwyer A, Schlueter L, Hans D, Gremion G, Kreis R, Boesch C**. Skeletal muscle mitochondria in the elderly: effects of physical fitness and exercise training. *J Clin Endocrinol Metab* 99: 1852-1861, 2014.
DOI:10.1210/jc.2013-3983
39. **Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ**. High-intensity strength training in nonagenarians: effects on skeletal muscle. *JAMA* 263: 3029-3034, 1990.
DOI:2342214/
40. **McGregor RA, Cameron-Smith D and Poppitt SD**. It is not just muscle mass: a review of muscle quality, composition and metabolism during ageing as determinants of muscle function and mobility in later life. *Longev healthspan* 3: 9, 2014.
DOI:10.1186/2046-2395-3-9
41. **Zhang Y, Guo J, Duanmu Y, Zhang C, Zhao W, Wang L, Cheng X, Veronese N, Cafarelli FP, Guglielmi G**. Quantitative analysis of modified functional muscle–bone unit and back muscle density in patients with lumbar vertebral fracture in Chinese elderly men: a case–control study. *Aging Clin Exp Res* 31: 637-644, 2019.
DOI:10.1007/s40520-018-1024-8
42. **Newman AB, Haggerty CL, Goodpaster B, Harris T, Kritchevsky S, Nevitt M, Miles TP, Visser M**. Strength and muscle quality in a well-functioning cohort of older adults: the Health, Aging and Body Composition Study. *J Am Geriatr Soc* 51: 323-330, 2003.
DOI:https://doi.org/10.1046/j.1532-5415.2003.51105.x
43. **Gingrich A, Volkert D, Kiesswetter E, Thomanek M, Bach S, Sieber CC, Zopf Y**. Prevalence and overlap of sarcopenia, frailty, cachexia and malnutrition in older medical inpatients. *BMC Geriatr* 19: 1-10, 2019.
DOI:10.1186/s12877-019-1115-1
44. **Kim S-K, Kwon Y-H, Cho JH, Park SE, Oh H-G, Park C-Y, Lee W-Y, Oh K-W, Park S-W, Rhee E-J**. Changes in body composition according to age and sex among young non-diabetic Korean adults: the Kangbuk Samsung Health Study. *Endocrinology and Metabolism* 32: 442-450, 2017.
DOI:https://doi.org/10.3803/EnM.2017.32.4.442

45. **Rizzoli R, Reginster JY, Arnal JF, Bautmans I, Beaudart C, Bischoff-Ferrari H, Biver E, Boonen S, Brandi ML, Chines A, Cooper C, Epstein S, Fielding RA, Goodpaster B, Kanis JA, Kaufman JM, Laslop A, Malafarina V, Mañas LR, Mitlak BH, Oreffo RO, Petermans J, Reid K, Rolland Y, Sayer AA, Tsouderos Y, Visser M, Bruyère O**. Quality of life in sarcopenia and frailty. *Calcif Tissue Int* 93: 101-120, 2013.
DOI:10.1007/s00223-013-9758-y
46. **Han SS, Kim KW, Kim KI, Na KY, Chae DW, Kim S, Chin HJ**. Lean mass index: a better predictor of mortality than body mass index in elderly Asians. *J Am Geriatr Soc* 58: 312-317, 2010.
DOI:https://doi.org/10.1111/j.1532-5415.2009.02672.x
47. **Koster A, Ding J, Stenholm S, Caserotti P, Houston DK, Nicklas BJ, You T, Lee JS, Visser M, Newman AB**. Does the amount of fat mass predict age-related loss of lean mass, muscle strength, and muscle quality in older adults? *J Gerontol A Biol Sci Med Sci* 66: 888-895, 2011.
DOI:https://doi.org/10.1093/gerona/glr070
48. **Frontera WR, Hughes VA, Fielding RA, Fiatarone MA, Evans WJ, Roubenoff R**. Aging of skeletal muscle: a 12-yr longitudinal study. *Journal of applied physiology* 88: 1321-1326, 2000.
DOI:https://doi.org/10.1152/jappl.2000.88.4.1321
49. **Falsarella GR, Gasparotto LPR, Barcelos CC, Coimbra IB, Moretto MC, Pascoa MA, Ferreira TCR, Coimbra AMV**. Body composition as a frailty marker for the elderly community. *Clin Interv Aging* 10: 1661, 2015.
DOI:10.2147/Cia.S84632
50. **Liu LK, Lee WJ, Chen LY, Hwang AC, Lin MH, Peng LN, Chen LK**. Association between Frailty, Osteoporosis, Falls and Hip Fractures among Community-Dwelling People Aged 50 Years and Older in Taiwan: Results from I-Lan Longitudinal Aging Study. *PLoS One* 10: e0136968, 2015.
DOI:10.1371/journal.pone.0136968
51. **Sao Romao Preto L, Dias Conceicao MDC, Figueiredo TM, Pereira Mata MA, Barreira Preto PM, Mateo Aguilar E**. Frailty, body composition and nutritional status in non-institutionalised elderly. *Enferm Clin* 27: 339-345, 2017.
DOI:10.1016/j.enfcli.2017.06.004
52. **Frisoli Jr A, Chaves PH, Ingham SJM, Fried LP**. Severe osteopenia and osteoporosis, sarcopenia, and frailty status in community-dwelling older women: results from the Women's Health and Aging Study (WHAS) II. *Bone* 48: 952-957, 2011.
DOI:10.1016/j.bone.2010.12.025
53. **Clark RV, Walker AC, O'Connor-Semmes RL, Leonard MS, Miller RR, Stimpson SA, Turner SM, Ravussin E, Cefalu WT, Hellerstein MK, Evans WJ**. Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans. *J Appl Physiol (1985)* 116: 1605-1613, 2014.
DOI:10.1152/japplphysiol.00045.2014
54. **Evans WJ, Hellerstein M, Orwoll E, Cummings S, Cawthon PM**. D(3) - Creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. *J Cachexia Sarcopenia Muscle* 10: 14-21, 2019.
DOI:10.1002/jcsm.12390
55. **Cegielski J, Brook MS, Phillips BE, Boereboom C, Gates A, Gladman JFR, Smith K, Wilkinson DJ, Atherton PJ**. The Combined Oral Stable Isotope Assessment of Muscle (COSIAM) reveals D-3 creatine derived muscle mass as a

standout cross-sectional biomarker of muscle physiology vitality in older age. *Geroscience* 2022.
DOI:10.1007/s11357-022-00541-3
56. **Mitsiopoulos N, Baumgartner R, Heymsfield S, Lyons W, Gallagher D, Ross R**. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. *Journal of applied physiology* 85: 115-122, 1998.
DOI:https://doi.org/10.1152/jappl.1998.85.1.115
57. **Farrow M, Biglands J, Tanner SF, Clegg A, Brown L, Hensor EMA, O'Connor P, Emery P, Tan AL**. The effect of ageing on skeletal muscle as assessed by quantitative MR imaging: an association with frailty and muscle strength. *Aging Clin Exp Res* 33: 291-301, 2020.
DOI:10.1007/s40520-020-01530-2
58. **Ogawa M, Yasuda T and Abe T**. Component characteristics of thigh muscle volume in young and older healthy men. *Clinical physiology and functional imaging* 32: 89-93, 2012.
DOI:https://doi.org/10.1111/j.1475-097X.2011.01057.x
59. **Addison O, Drummond M, LaStayo P, Dibble L, Wende A, McClain D, Marcus R**. Intramuscular fat and inflammation differ in older adults: the impact of frailty and inactivity. *J Nutr Health Aging* 18: 532-538, 2014.
DOI:10.1007/s12603-014-0019-1
60. **Delgado C, Doyle JW and Johansen KL**. Association of frailty with body composition among patients on hemodialysis. *J Ren Nutr* 23: 356-362, 2013.
DOI:10.1053/j.jrn.2013.02.010
61. **Cesari M, Leeuwenburgh C, Lauretani F, Onder G, Bandinelli S, Maraldi C, Guralnik JM, Pahor M, Ferrucci L**. Frailty syndrome and skeletal muscle: results from the Invecchiare in Chianti study. *Am J Clin Nutr* 83: 1142-1148, 2006.
DOI:10.1093/ajcn/83.5.1142
62. **Idoate F, Cadore EL, Casas-Herrero A, Zambom-Ferraresi F, Marcellán T, de Gordoa AR, Rodriguez-Mañas L, Bastarrika G, Marques MC, Martínez-Velilla N**. Adipose tissue compartments, muscle mass, muscle fat infiltration, and coronary calcium in institutionalized frail nonagenarians. *Eur Radiol* 25: 2163-2175, 2015.
DOI:10.1007/s00330-014-3555-5
63. **Lewsey SC, Weiss K, Schär M, Zhang Y, Bottomley PA, Samuel TJ, Xue Q-L, Steinberg A, Walston JD, Gerstenblith G**. Exercise intolerance and rapid skeletal muscle energetic decline in human age-associated frailty. *JCI insight* 5: 2020.
DOI:10.1172/jci.insight.141246
64. **Skoglund E, Lundberg TR, Rullman E, Fielding RA, Kirn DR, Englund DA, von Berens Å, Koochek A, Cederholm T, Berg HE**. Functional improvements to 6 months of physical activity are not related to changes in size or density of multiple lower-extremity muscles in mobility-limited older individuals. *Exp Gerontol* 157: 111631, 2022.
DOI:10.1016/j.exger.2021.111631
65. **Latimer LE, Constantin-Teodosiu D, Popat B, Constantin D, Houchen-Wolloff L, Bolton CE, Steiner MC, Greenhaff PL**. Whole-body & muscle responses to aerobic exercise training and withdrawal in ageing & COPD. *Eur Respir J* 2021.
DOI:10.1183/13993003.01507-2021
66. **Buckinx F, Reginster J-Y, Petermans J, Croisier J-L, Beaudart C, Brunois T, Bruyère O**. Relationship between frailty, physical performance and

quality of life among nursing home residents: the SENIOR cohort. *Aging Clin Exp Res* 28: 1149-1157, 2016.
DOI:10.1007/s40520-016-0616-4
67. **Melville DM, Mohler J, Fain M, Muchna AE, Krupinski E, Sharma P, Taljanovic MS**. Multi-parametric MR imaging of quadriceps musculature in the setting of clinical frailty syndrome. *Skeletal Radiol* 45: 583-589, 2016.
DOI:10.1007/s00256-015-2313-3
68. **Beasley LE, Koster A, Newman AB, Javaid MK, Ferrucci L, Kritchevsky SB, Kuller LH, Pahor M, Schaap LA, Visser M**. Inflammation and race and gender differences in computerized tomography-measured adipose depots. *Obesity* 17: 1062-1069, 2009.
DOI:10.1038/oby.2008.627
69. **Csete ME**. Basic Science of Frailty-Biological Mechanisms of Age-Related Sarcopenia. *Anesth Analg* 132: 293-304, 2021.
DOI:10.1213/ane.0000000000005096
70. **Ng TP, Lu Y, Choo RWM, Tan CTY, Nyunt MSZ, Gao Q, Mok EWH, Larbi A**. Dysregulated homeostatic pathways in sarcopenia among frail older adults. *Aging Cell* 17: e12842, 2018.
DOI:10.1111/acel.12842
71. **Nishikawa H, Fukunishi S, Asai A, Yokohama K, Nishiguchi S, Higuchi K**. Pathophysiology and mechanisms of primary sarcopenia (Review). *Int J Mol Med* 48: 2021.
DOI:10.3892/ijmm.2021.4989
72. **Morley JE, Anker SD and Von Haehling S**. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology—update 2014. *J Cachexia Sarcopenia Muscle* 5: 253-259, 2014.
DOI:10.1007/s13539-014-0161-y
73. **Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, Wackerhage H, Taylor PM, Rennie MJ**. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. *The FASEB Journal* 19: 1-22, 2005.
DOI:10.1096/fj.04-2640fje
74. **Kumar V, Selby A, Rankin D, Patel R, Atherton P, Hildebrandt W, Williams J, Smith K, Seynnes O, Hiscock N**. Age-related differences in the dose–response relationship of muscle protein synthesis to resistance exercise in young and old men. *J Physiol* 587: 211-217, 2009.
DOI:https://doi.org/10.1113/jphysiol.2008.164483
75. **Brook MS, Wilkinson DJ, Mitchell WK, Lund JN, Phillips BE, Szewczyk NJ, Greenhaff PL, Smith K, Atherton PJ**. Synchronous deficits in cumulative muscle protein synthesis and ribosomal biogenesis underlie age-related anabolic resistance to exercise in humans. *J Physiol* 594: 7399-7417, 2016.
DOI:https://doi.org/10.1113/JP272857
76. **Rennie M, Selby A, Atherton P, Smith K, Kumar V, Glover E, Philips S**. Facts, noise and wishful thinking: muscle protein turnover in aging and human disuse atrophy. *Scand J Med Sci Sports* 20: 5-9, 2010.
DOI:10.1111/j.1600-0838.2009.00967.x
77. **Haddad F, Zaldivar F, Cooper DM, Adams GR**. IL-6-induced skeletal muscle atrophy. *J Appl Physiol* 98: 911-917, 2005.
DOI:10.1152/japplphysiol.01026.2004
78. **De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, Garrone S, Barreca A, Martini A**. Effect of IL-6 on IGF binding protein-3:

a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. *Endocrinology* 142: 4818-4826, 2001.
DOI:10.1210/endo.142.11.8511
79. **Chew J, Tay L, Lim JP, Leung BP, Yeo A, Yew S, Ding YY, Lim WS**. Serum Myostatin and IGF-1 as Gender-Specific Biomarkers of Frailty and Low Muscle Mass in Community-Dwelling Older Adults. *J Nutr Health Aging* 23: 979-986, 2019.
DOI:10.1007/s12603-019-1255-1
80. **Chen F-X, Shen Y, Liu Y, Wang H-F, Liang C-Y, Luo M**. Inflammation-dependent downregulation of miR-532-3p mediates apoptotic signaling in human sarcopenia through targeting BAK1. *Int J Biol Sci* 16: 1481, 2020.
DOI:10.7150/ijbs.41641
81. **Chen FX, Du N, Hu J, Ning F, Mei X, Li Q, Peng L**. Intramuscular accumulation of pentadecanoic acid activates AKT1 to phosphorylate NCOR1 and triggers FOXM1-mediated apoptosis in the pathogenesis of sarcopenia. *Am J Transl Res* 12: 5064-5079, 2020.
DOI:1943-8141/AJTR0117186
82. **Hassan-Smith ZK, Morgan SA, Sherlock M, Hughes B, Taylor AE, Lavery GG, Tomlinson JW, Stewart PM**. Gender-specific differences in skeletal muscle 11β-HSD1 expression across healthy aging. *J Clin Endocrinol Metab* 100: 2673-2681, 2015.
DOI:10.1210/jc.2015-1516
83. **Blodgett J, Theou O, Kirkland S, Andreou P, Rockwood K**. The association between sedentary behaviour, moderate–vigorous physical activity and frailty in NHANES cohorts. *Maturitas* 80: 187-191, 2015.
DOI:10.1016/j.maturitas.2014.11.010
84. **Rice H, Hill K, Fowler R, Watson C, Waterer G, Harrold M**. Reduced Step Count and Clinical Frailty in Hospitalized Adults With Community-Acquired Pneumonia. *Respir Care* 65: 455-463, 2020.
DOI:10.4187/respcare.06992
85. **Theou O, Jakobi JM, Vandervoort AA, Jones GR**. A comparison of physical activity (PA) assessment tools across levels of frailty. *Arch Gerontol Geriatr* 54: e307-314, 2012.
DOI:10.1016/j.archger.2011.12.005
86. **Breen L, Stokes KA, Churchward-Venne TA, Moore DR, Baker SK, Smith K, Atherton PJ, Phillips SM**. Two weeks of reduced activity decreases leg lean mass and induces “anabolic resistance” of myofibrillar protein synthesis in healthy elderly. *J Clin Endocrinol Metab* 98: 2604-2612, 2013.
DOI:https://doi.org/10.1210/jc.2013-1502
87. **Milanović Z, Pantelić S, Trajković N, Sporiš G, Kostić R, James N**. Age-related decrease in physical activity and functional fitness among elderly men and women. *Clin Interv Aging* 8: 549-556, 2013.
DOI:10.2147/cia.S44112
88. **Crossland H, Skirrow S, Puthucheary ZA, Constantin-Teodosiu D, Greenhaff PL**. The impact of immobilisation and inflammation on the regulation of muscle mass and insulin resistance: different routes to similar end-points. *J Physiol* 597: 1259-1270, 2019.
DOI:https://doi.org/10.1113/JP275444

89. **Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ**. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. *JAMA* 297: 1769-1774, 2007.
DOI:10.1001/jama.297.16.1772-b
90. **Deane CS, Willis CRG, Phillips BE, Atherton PJ, Harries LW, Ames RM, Szewczyk NJ, Etheridge T**. Transcriptomic meta-analysis of disuse muscle atrophy vs. resistance exercise-induced hypertrophy in young and older humans. *J Cachexia Sarcopenia Muscle* 12: 629-645, 2021.
DOI:10.1002/jcsm.12706
91. **Ferrando AA, Lane HW, Stuart CA, Davis-Street J, Wolfe RR**. Prolonged bed rest decreases skeletal muscle and whole body protein synthesis. *Am J Physiol Endocrinol Metab* 270: E627-E633, 1996.
DOI:10.1152/ajpendo.1996.270.4.E627
92. **Shur NF, Creedon L, Skirrow S, Atherton PJ, MacDonald IA, Lund J, Greenhaff PL**. Age-related changes in muscle architecture and metabolism in humans: The likely contribution of physical inactivity to age-related functional decline. *Ageing Res Rev* 68: 101344, 2021.
DOI:10.1016/j.arr.2021.101344
93. **Lee JS, Auyeung T-W, Leung J, Kwok T, Woo J**. Transitions in frailty states among community-living older adults and their associated factors. *J Am Med Dir Assoc* 15: 281-286, 2014.
DOI:10.1016/j.jamda.2013.12.002
94. **Piasecki M, Ireland A, Piasecki J, Stashuk D, Swiecicka A, Rutter M, Jones D, McPhee J**. Failure to expand the motor unit size to compensate for declining motor unit numbers distinguishes sarcopenic from non-sarcopenic older men. *J Physiol* 596: 1627-1637, 2018.
DOI:10.1113/JP275520
95. **Nandedkar SD, Sanders DB, Stälberg EV, Andreassen S**. Simulation of concentric needle EMG motor unit action potentials. *Muscle & Nerve: AANEM* 11: 151-159, 1988.
DOI:10.1002/mus.880110211
96. **Rodriguez-Falces J and Place N**. Determinants, analysis and interpretation of the muscle compound action potential (M wave) in humans: implications for the study of muscle fatigue. *Eur J Appl Physiol* 118: 501-521, 2018.
DOI:10.1007/s00421-017-3788-5
97. **Brown WF, Strong MJ and Snow R**. Methods for estimating numbers of motor units in biceps-brachialis muscles and losses of motor units with aging. *Muscle & Nerve: AANEM* 11: 423-432, 1988.
DOI:10.1002/mus.880110503
98. **Larsson L, Degens H, Li M, Salviati L, Lee YI, Thompson W, Kirkland JL, Sandri M**. Sarcopenia: Aging-Related Loss of Muscle Mass and Function. *Physiol Rev* 99: 427-511, 2019.
DOI:https://doi.org/10.1152/physrev.00061.2017
99. **Ansved T and Larsson L**. Quantitative and qualitative morphological properties of the soleus motor nerve and the L5 ventral root in young and old rats: relation to the number of soleus muscle fibres. *J Neurol Sci* 96: 269-282, 1990.
DOI:https://doi.org/10.1016/0022-510X(90)90138-D
100. **Ansved T, Wallner P and Larsson L**. Spatial distribution of motor unit fibres in fast-and slow-twitch rat muscles with special reference to age. *Acta physiologica scandinavica* 143: 345-354, 1991.

DOI:https://doi.org/10.1111/j.1748-1716.1991.tb09242.x
101. **Edström L and Larsson L**. Effects of age on contractile and enzyme-histochemical properties of fast-and slow-twitch single motor units in the rat. *J Physiol* 392: 129-145, 1987.
DOI:https://doi.org/10.1113/jphysiol.1987.sp016773
102. **Power GA, Dalton BH, Behm DG, Doherty TJ, Vandervoort AA, Rice CL**. Motor unit survival in lifelong runners is muscle dependent. *Med Sci Sports Exerc* 44: 1235-1242, 2012.
DOI:10.1249/MSS.0b013e318249953c
103. **Piasecki M, Ireland A, Stashuk D, Hamilton-Wright A, Jones DA, McPhee JS**. Age-related neuromuscular changes affecting human vastus lateralis. *J Physiol* 594: 4525-4536, 2016.
DOI:10.1113/jp271087
104. **R Deschenes M**. Motor unit and neuromuscular junction remodeling with aging. *Curr Aging Sci* 4: 209-220, 2011.
DOI:10.2174/1874609811104030209
105. **Hepple RT and Rice CL**. Innervation and neuromuscular control in ageing skeletal muscle. *J Physiol* 594: 1965-1978, 2016.
DOI:10.1113/JP270561
106. **Sonjak V, Jacob K, Morais JA, Rivera-Zengotita M, Spendiff S, Spake C, Taivassalo T, Chevalier S, Hepple RT**. Fidelity of muscle fibre reinnervation modulates ageing muscle impact in elderly women. *J Physiol* 597: 5009-5023, 2019.
DOI:10.1113/jp278261
107. **Banker BQ, Kelly S and Robbins N**. Neuromuscular transmission and correlative morphology in young and old mice. *J Physiol* 339: 355-377, 1983.
DOI:10.1113/jphysiol.1983.sp014721
108. **Fahim M, Holley J and Robbins N**. Scanning and light microscopic study of age changes at a neuromuscular junction in the mouse. *J Neurocytol* 12: 13-25, 1983.
DOI:10.1007/BF01148085
109. **Tohgi H, Tsukagoshi H and Toyokura Y**. Quantitative changes with age in normal sural nerves. *Acta Neuropathol* 38: 213-220, 1977.
DOI:10.1007/BF00688067
110. **Jacobs J and Love S**. Qualitative and quantitative morphology of human sural nerve at different ages. *Brain* 108: 897-924, 1985.
DOI:10.1093/brain/108.4.897
111. **Swiecicka A, Piasecki M, Stashuk DW, Ireland A, Jones DA, Rutter MK, McPhee JS**. Frailty phenotype and frailty index are associated with distinct neuromuscular electrophysiological characteristics in men. *Exp Physiol* 104: 1154-1161, 2019.
DOI:10.1113/EP087579
112. **Hunter SK, Pereira HM and Keenan KG**. The aging neuromuscular system and motor performance. *J Appl Physiol* 121: 982-995, 2016.
DOI:10.1152/japplphysiol.00475.2016
113. **Swiecicka A, Piasecki M, Stashuk D, Jones D, Wu F, McPhee JS, Rutter MK**. Relationship of Anabolic Hormones With Motor Unit Characteristics in Quadriceps Muscle in Healthy and Frail Aging Men. *J Clin Endocrinol Metab* 105: dgaa100, 2020.
DOI:10.1210/clinem/dgaa100

114. **de Waard MC, van der Pluijm I, Zuiderveen Borgesius N, Comley LH, Haasdijk ED, Rijksen Y, Ridwan Y, Zondag G, Hoeijmakers JH, Elgersma Y**. Age-related motor neuron degeneration in DNA repair-deficient Ercc1 mice. *Acta Neuropathol* 120: 461-475, 2010.
DOI:10.1007/s00401-010-0715-9
115. **Shinpo K, Kikuchi S, Sasaki H, Ogata A, Moriwaka F, Tashiro K**. Selective vulnerability of spinal motor neurons to reactive dicarbonyl compounds, intermediate products of glycation, in vitro: implication of inefficient glutathione system in spinal motor neurons. *Brain Res* 861: 151-159, 2000.
DOI:10.1016/s0006-8993(00)02047-3
116. **Brown M, Hopkins W and Keynes R**. Comparison of effects of denervation and botulinum toxin paralysis on muscle properties in mice. *J Physiol* 327: 29, 1982.
DOI:10.1113/jphysiol.1982.sp014217
117. **Samuel MA, Valdez G, Tapia JC, Lichtman JW, Sanes JR**. Agrin and synaptic laminin are required to maintain adult neuromuscular junctions. 2012.
DOI:10.1371/journal.pone.0046663
118. **Balice-Gordon RJ and Lichtman JW**. Long-term synapse loss induced by focal blockade of postsynaptlc receptors. *Nature* 372: 519-524, 1994.
DOI:10.1038/372519a0
119. **Barik A, Lu Y, Sathyamurthy A, Bowman A, Shen C, Li L, Xiong W-c, Mei L**. LRP4 is critical for neuromuscular junction maintenance. *J Neurosci* 34: 13892-13905, 2014.
DOI:10.1523/JNEUROSCI.1733-14.2014
120. **Byers JS, Huguenard AL, Kuruppu D, Liu NK, Xu XM, Sengelaub DR**. Neuroprotective effects of testosterone on motoneuron and muscle morphology following spinal cord injury. *J Comp Neurol* 520: 2683-2696, 2012.
DOI:10.1002/cne.23066
121. **Kurz EM, Sengelaub DR and Arnold AP**. Androgens regulate the dendritic length of mammalian motoneurons in adulthood. *Science* 232: 395-398, 1986.
DOI:10.1126/science.3961488
122. **Kurz E, Brewer R and Sengelaub D**. Hormonally mediated plasticity of motoneuron morphology in the adult rat spinal cord: a cholera toxin-HRP study. *J Neurobiol* 22: 976-988, 1991.
DOI:10.1002/neu.480220909
123. **Fjell AM and Walhovd KB**. Structural brain changes in aging: courses, causes and cognitive consequences. *Rev Neurosci* 21: 187-221, 2010.
DOI:10.1515/revneuro.2010.21.3.187
124. **Beishon L, Clough RH, Kadicheeni M, Chithiramohan T, Panerai RB, Haunton VJ, Minhas JS, Robinson TG**. Vascular and haemodynamic issues of brain ageing. *Pflugers Arch* 473: 735-751, 2021.
DOI:10.1007/s00424-020-02508-9
125. **Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A**. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. *Neurology* 54: S4-9, 2000.
DOI:https://pubmed.ncbi.nlm.nih.gov/10854354/
126. **Avila-Funes JA, Carcaillon L, Helmer C, Carrière I, Ritchie K, Rouaud O, Tzourio C, Dartigues JF, Amieva H**. Is Frailty a Prodromal Stage of Vascular

Dementia? Results From the Three-City Study. *J Am Geriatr Soc* 60: 1708-1712, 2012.
DOI:10.1111/j.1532-5415.2012.04142.x
127. **Buchman AS, Yu L, Wilson RS, Boyle PA, Schneider JA, Bennett DA, Kritchevsky S**. Brain pathology contributes to simultaneous change in physical frailty and cognition in old age. *J Gerontol A Biol Sci Med Sci* 69: 1536-1544, 2014.
DOI:10.1093/gerona/glu117
128. **Solfrizzi V, Scafato E, Frisardi V, Seripa D, Logroscino G, Maggi S, Imbimbo BP, Galluzzo L, Baldereschi M, Gandin C**. Frailty syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Aging. *Alzheimers Dement* 9: 113-122, 2013.
DOI:10.1016/j.jalz.2011.09.223
129. **Chen WT, Chou KH, Liu LK, Lee PL, Lee WJ, Chen LK, Wang PN, Lin CP**. Reduced cerebellar gray matter is a neural signature of physical frailty. *Hum Brain Mapp* 36: 3666-3676, 2015.
DOI:10.1002/hbm.22870
130. **Chung CP, Chou KH, Chen WT, Liu LK, Lee WJ, Chen LK, Lin CP, Wang PN**. Cerebral microbleeds are associated with physical frailty: a community-based study. *Neurobiol Aging* 44: 143-150, 2016.
DOI:10.1016/j.neurobiolaging.2016.04.025
131. **Del Brutto OH, Mera RM, Cagino K, Fanning KD, Milla-Martinez MF, Nieves JL, Zambrano M, Sedler MJ**. Neuroimaging signatures of frailty: A population-based study in community-dwelling older adults (the A tahualpa P roject). *Geriatr Gerontol Int* 17: 270-276, 2017.
DOI:10.1111/ggi.12708
132. **Grazioplene RG, G. Ryman S, Gray JR, Rustichini A, Jung RE, DeYoung CG**. Subcortical intelligence: Caudate volume predicts IQ in healthy adults. *Hum Brain Mapp* 36: 1407-1416, 2015.
DOI:10.1002/hbm.22710
133. **Pietschnig J, Penke L, Wicherts JM, Zeiler M, Voracek M**. Meta-analysis of associations between human brain volume and intelligence differences: How strong are they and what do they mean? *Neurosci Biobehav Rev* 57: 411-432, 2015.
DOI:10.1016/j.neubiorev.2015.09.017
134. **Fjell AM and Walhovd KB**. Structural brain changes in aging: courses, causes and cognitive consequences. *Rev Neurosci* 21: 187-222, 2010.
DOI:10.1515/revneuro.2010.21.3.187
135. **Fleischman DA, Leurgans S, Arfanakis K, Arvanitakis Z, Barnes LL, Boyle PA, Han SD, Bennett DA**. Gray-matter macrostructure in cognitively healthy older persons: associations with age and cognition. *Brain Structure and Function* 219: 2029-2049, 2014.
DOI:10.1007/s00429-013-0622-7
136. **Yamada M, Takechi H, Mori S, Aoyama T, Arai H**. Global brain atrophy is associated with physical performance and the risk of falls in older adults with cognitive impairment. *Geriatr Gerontol Int* 13: 437-442, 2013.
DOI:10.1111/j.1447-0594.2012.00927.x
137. **Kant IMJ, de Bresser J, van Montfort SJT, Aarts E, Verlaan JJ, Zacharias N, Winterer G, Spies C, Slooter AJC, Hendrikse J**. The association between brain volume, cortical brain infarcts, and physical frailty. *Neurobiol Aging* 70: 247-253, 2018.
DOI:10.1016/j.neurobiolaging.2018.06.032

138. **Tian Q, Williams OA, Landman BA, Resnick SM, Ferrucci L**. Microstructural Neuroimaging of Frailty in Cognitively Normal Older Adults. *Front Med* 7: 546344, 2020.
DOI:10.3389/fmed.2020.546344
139. **Nishita Y, Nakamura A, Kato T, Otsuka R, Iwata K, Tange C, Ando F, Ito K, Shimokata H, Arai H**. Links Between Physical Frailty and Regional Gray Matter Volumes in Older Adults: A Voxel-Based Morphometry Study. *J Am Med Dir Assoc* 20: 1587-1592.e1587, 2019.
DOI:10.1016/j.jamda.2019.09.001
140. **Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RS, Busa E, Morris JC, Dale AM, Fischl B**. Thinning of the cerebral cortex in aging. *Cereb Cortex* 14: 721-730, 2004.
DOI:10.1093/cercor/bhh032
141. **Lemaitre H, Goldman AL, Sambataro F, Verchinski BA, Meyer-Lindenberg A, Weinberger DR, Mattay VS**. Normal age-related brain morphometric changes: nonuniformity across cortical thickness, surface area and gray matter volume? *Neurobiol Aging* 33: 617. e611-617. e619, 2012.
DOI:10.1016/j.neurobiolaging.2010.07.013
142. **Ziegler DA, Piguet O, Salat DH, Prince K, Connally E, Corkin S**. Cognition in healthy aging is related to regional white matter integrity, but not cortical thickness. *Neurobiol Aging* 31: 1912-1926, 2010.
DOI:10.1016/j.neurobiolaging.2008.10.015
143. **Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD**. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. *Cereb Cortex* 19: 497-510, 2009.
DOI:10.1093/cercor/bhn113
144. **Pacheco J, Goh JO, Kraut MA, Ferrucci L, Resnick SM**. Greater cortical thinning in normal older adults predicts later cognitive impairment. *Neurobiol Aging* 36: 903-908, 2015.
DOI:10.1016/j.neurobiolaging.2014.08.031
145. **Lu W-H, de Souto Barreto P, Rolland Y, Rodríguez-Mañas L, Bouyahia A, Fischer C, Mangin J-F, Giudici KV, Vellas B**. Cross-sectional and prospective associations between cerebral cortical thickness and frailty in older adults. *Exp Gerontol* 139: 111018, 2020.
DOI:10.1016/j.exger.2020.111018
146. **Huang C-C, Yang AC, Chou K-H, Liu M-E, Fang S-C, Chen C-C, Tsai S-J, Lin C-P**. Nonlinear pattern of the emergence of white matter hyperintensity in healthy Han Chinese: an adult lifespan study. *Neurobiol Aging* 67: 99-107, 2018.
DOI:10.1016/j.neurobiolaging.2018.03.012
147. **Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, T O'Brien J, Barkhof F, Benavente OR**. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 12: 822-838, 2013.
DOI:10.1016/S1474-4422(13)70124-8
148. **Kynast J, Lampe L, Luck T, Frisch S, Arelin K, Hoffmann K-T, Loeffler M, Riedel-Heller SG, Villringer A, Schroeter ML**. White matter hyperintensities associated with small vessel disease impair social cognition beside attention and memory. *J Cereb Blood Flow Metab* 38: 996-1009, 2018.

DOI:10.1177/0271678X17719380
149. **Srikanth V, Beare R, Blizzard L, Phan T, Stapleton J, Chen J, Callisaya M, Martin K, Reutens D**. Cerebral white matter lesions, gait, and the risk of incident falls: a prospective population-based study. *Stroke* 40: 175-180, 2009.
DOI:10.1161/STROKEAHA.108.524355
150. **Dhamoon MS, Cheung Y-K, Moon Y, DeRosa J, Sacco R, Elkind MS, Wright CB**. Cerebral white matter disease and functional decline in older adults from the Northern Manhattan Study: A longitudinal cohort study. *PLoS Med* 15: e1002529, 2018.
DOI:10.1371/journal.pmed.1002529
151. **Kant IM, Mutsaerts HJ, van Montfort SJ, Jaarsma-Coes MG, Witkamp TD, Winterer G, Spies CD, Hendrikse J, Slooter AJ, de Bresser J**. The association between frailty and MRI features of cerebral small vessel disease. *Sci Rep* 9: 1-9, 2019.
DOI:10.1038/s41598-019-47731-2
152. **Siejka TP, Srikanth VK, Hubbard RE, Moran C, Beare R, Wood A, Phan T, Callisaya ML**. Frailty and Cerebral Small Vessel Disease: A Cross-Sectional Analysis of the Tasmanian Study of Cognition and Gait (TASCOG). *J Gerontol A Biol Sci Med Sci* 73: 255-260, 2018.
DOI:10.1093/gerona/glx145
153. **Siejka TP, Srikanth VK, Hubbard RE, Moran C, Beare R, Wood A, Phan T, Balogun S, Callisaya ML**. White Matter Hyperintensities and the Progression of Frailty—The Tasmanian Study of Cognition and Gait. *J Gerontol A* 75: 1545-1550, 2020.
DOI:10.1093/gerona/glaa024
154. **Jordan N, Gvalda M, Cody R, Galante O, Haywood C, Yates P**. Frailty, MRI, and FDG-PET Measures in an Australian Memory Clinic Cohort. *Front Med* 7: 578243, 2020.
DOI:10.3389/fmed.2020.578243
155. **Moseley M**. Diffusion tensor imaging and aging–a review. *NMR Biomed* 15: 553-560, 2002.
DOI:10.1002/nbm.785
156. **Yassa MA, Muftuler LT and Stark CE**. Ultrahigh-resolution microstructural diffusion tensor imaging reveals perforant path degradation in aged humans in vivo. *Proc Natl Acad Sci U S A* 107: 12687-12691, 2010.
DOI:10.1073/pnas.1002113107
157. **Beaudet G, Tsuchida A, Petit L, Tzourio C, Caspers S, Schreiber J, Pausova Z, Patel Y, Paus T, Schmidt R**. Age-related changes of peak width skeletonized mean diffusivity (PSMD) across the adult lifespan: a multi-cohort study. *Frontiers in psychiatry* 11: 342, 2020.
DOI:10.3389/fpsyt.2020.00342
158. **Avila-Funes JA, Pelletier A, Meillon C, Catheline G, Periot O, Trevin OFI, Gonzalez-Colaco M, Dartigues JF, Peres K, Allard M, Dilharreguy B, Amieva H**. Vascular Cerebral Damage in Frail Older Adults: The AMImage Study. *J Gerontol A Biol Sci Med Sci* 72: 971-977, 2017.
DOI:10.1093/gerona/glw347
159. **Maltais M, de Souto Barreto P, Perus L, Mangin JF, Grigis A, Chupin M, Bouyahia A, Gabelle A, Delrieux J, Rolland Y**. Prospective associations between diffusion tensor imaging parameters and frailty in older adults. *J Am Geriatr Soc* 68: 1050-1055, 2020.

DOI:10.1111/jgs.16343
160. **de Laat KF, Reid AT, Grim DC, Evans AC, Kötter R, van Norden AG, de Leeuw F-E**. Cortical thickness is associated with gait disturbances in cerebral small vessel disease. *Neuroimage* 59: 1478-1484, 2012.
DOI:10.1016/j.neuroimage.2011.08.005
161. **La Fougere C, Zwergal A, Rominger A, Förster S, Fesl G, Dieterich M, Brandt T, Strupp M, Bartenstein P, Jahn K**. Real versus imagined locomotion: a [18F]-FDG PET-fMRI comparison. *Neuroimage* 50: 1589-1598, 2010.
DOI:10.1016/j.neuroimage.2009.12.060
162. **Tian Q, Chastan N, Bair W-N, Resnick SM, Ferrucci L, Studenski SA**. The brain map of gait variability in aging, cognitive impairment and dementia—a systematic review. *Neurosci Biobehav Rev* 74: 149-162, 2017.
DOI:10.1016/j.neubiorev.2017.01.020
163. **Leidhin CN, McMorrow J, Carey D, Newman L, Williamson W, Fagan AJ, Chappell MA, Kenny RA, Meaney JF, Knight SP**. Age-related normative changes in cerebral perfusion: Data from The Irish Longitudinal Study on Ageing (TILDA). *Neuroimage* 229: 117741, 2021.
DOI:10.1016/j.neuroimage.2021.117741
164. **Newman L, Nolan H, Carey D, Reilly RB, Kenny RA**. Age and sex differences in frontal lobe cerebral oxygenation in older adults—normative values using novel, scalable technology: findings from the Irish Longitudinal Study on Ageing (TILDA). *Arch Gerontol Geriatr* 87: 103988, 2020.
DOI:10.1016/j.archger.2019.103988
165. **Binnewijzend MA, Benedictus MR, Kuijer J, van der Flier WM, Teunissen CE, Prins ND, Wattjes MP, van Berckel BN, Scheltens P, Barkhof F**. Cerebral perfusion in the predementia stages of Alzheimer's disease. *Eur Radiol* 26: 506-514, 2016.
DOI:10.1007/s00330-015-3834-9
166. **Yeung MK and Chan AS**. Functional near-infrared spectroscopy reveals decreased resting oxygenation levels and task-related oxygenation changes in mild cognitive impairment and dementia: A systematic review. *J Psychiatr Res* 124: 58-76, 2020.
DOI:10.1016/j.jpsychires.2020.02.017
167. **Khan SA, Chua HW, Hirubalan P, Karthekeyan RB, Kothandan H**. Association between frailty, cerebral oxygenation and adverse post-operative outcomes in elderly patients undergoing non-cardiac surgery: An observational pilot study. *Indian J Anaesth* 60: 102, 2016.
DOI:10.4103/0019-5049.176278
168. **Van Dalen J, Mutsaerts H, Nederveen A, Vrenken H, Steenwijk M, Caan M, Majoie C, van Gool W, Richard E**. White matter hyperintensity volume and cerebral perfusion in older individuals with hypertension using arterial spin-labeling. *Am J Neuroradiol* 37: 1824-1830, 2016.
DOI:10.3174/ajnr.A4828
169. **Akiyama H, Meyer JS, Mortel KF, Terayama Y, Thornby JI, Konno S**. Normal human aging: factors contributing to cerebral atrophy. *J Neurol Sci* 152: 39-49, 1997.
DOI:10.1016/s0022-510x(97)00141-x
170. **Meyer JS, Rauch G, Rauch RA, Haque A**. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. *Neurobiol Aging* 21: 161-169, 2000.

DOI:10.1016/s0197-4580(00)00136-6
171. **Appelman AP, Van der Graaf Y, Vincken KL, Tiehuis AM, Witkamp TD, Mali WP, Geerlings MI, Group SS**. Total cerebral blood flow, white matter lesions and brain atrophy: the SMART-MR study. *J Cereb Blood Flow Metab* 28: 633-639, 2008.
DOI:10.1038/sj.jcbfm.9600563
172. **De la Torre J**. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. *Neurobiol Aging* 21: 331-342, 2000.
DOI:10.1016/s0197-4580(00)00111-1
173. **Flöel A, Ruscheweyh R, Krüger K, Willemer C, Winter B, Völker K, Lohmann H, Zitzmann M, Mooren F, Breitenstein C**. Physical activity and memory functions: are neurotrophins and cerebral gray matter volume the missing link? *Neuroimage* 49: 2756-2763, 2010.
DOI:10.1016/j.neuroimage.2009.10.043
174. **Siddarth P, Burggren AC, Eyre HA, Small GW, Merrill DA**. Sedentary behavior associated with reduced medial temporal lobe thickness in middle-aged and older adults. *PLoS One* 13: e0195549, 2018.
DOI:10.1371/journal.pone.0195549
175. **Arnardottir NY, Koster A, Van Domelen DR, Brychta RJ, Caserotti P, Eiriksdottir G, Sverrisdottir JE, Sigurdsson S, Johannsson E, Chen KY**. Association of change in brain structure to objectively measured physical activity and sedentary behavior in older adults: Age, Gene/Environment Susceptibility-Reykjavik Study. *Behav Brain Res* 296: 118-124, 2016.
DOI:10.1016/j.bbr.2015.09.005
176. **Voss MW, Carr LJ, Clark R, Weng T**. Revenge of the "sit" II: does lifestyle impact neuronal and cognitive health through distinct mechanisms associated with sedentary behavior and physical activity? *Ment Health Phys Act* 7: 9-24, 2014.
DOI:https://doi.org/10.1016/j.mhpa.2014.01.001
177. **Kempuraj D, Thangavel R, Natteru P, Selvakumar G, Saeed D, Zahoor H, Zaheer S, Iyer S, Zaheer A**. Neuroinflammation induces neurodegeneration. *J Neurosurg Spine* 1: 2016.
DOI:https://pubmed.ncbi.nlm.nih.gov/28127589/
178. **Lu T, Pan Y, Kao S-Y, Li C, Kohane I, Chan J, Yankner BA**. Gene regulation and DNA damage in the ageing human brain. *Nature* 429: 883-891, 2004.
DOI:10.1038/nature02661
179. **Chen WW, Zhang X and Huang WJ**. Role of neuroinflammation in neurodegenerative diseases (Review). *Mol Med Rep* 13: 3391-3396, 2016.
DOI:10.3892/mmr.2016.4948
180. **Buchman AS, Schneider JA, Leurgans S, Bennett DA**. Physical frailty in older persons is associated with Alzheimer disease pathology. *Neurology* 71: 499-504, 2008.
DOI:10.1212/01.wnl.0000324864.81179.6a
181. **Sala-Llonch R, Idland A-V, Borza T, Watne LO, Wyller TB, Brækhus A, Zetterberg H, Blennow K, Walhovd KB, Fjell AM**. Inflammation, amyloid, and atrophy in the aging brain: relationships with longitudinal changes in cognition. *J Alzheimer's Dis* 58: 829-840, 2017.
DOI:10.3233/JAD-161146
182. **Falcon C, Monté-Rubio GC, Grau-Rivera O, Suárez-Calvet M, Sánchez-Valle R, Rami L, Bosch B, Haass C, Gispert JD, Molinuevo JL**. CSF glial

biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. *NeuroImage: Clinical* 23: 101801, 2019.
DOI:10.1016/j.nicl.2019.101801
183. **Gallucci M, Piovesan C and Di Battista ME**. Associations between the Frailty Index and Brain Atrophy: The Treviso Dementia (TREDEM) Registry. *J Alzheimers Dis* 62: 1623-1634, 2018.
DOI:10.3233/jad-170938
184. **Walston J, Fedarko N, Yang H, Leng S, Beamer B, Espinoza S, Lipton A, Zheng H, Becker K**. The physical and biological characterization of a frail mouse model. *J Gerontol A Biol Sci Med Sci* 63: 391-398, 2008.
DOI:10.1093/gerona/63.4.391
185. **Wolz R, Julkunen V, Koikkalainen J, Niskanen E, Zhang DP, Rueckert D, Soininen H, Lötjönen J, Initiative AsDN**. Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. *PLoS One* 6: e25446, 2011.
DOI:10.1371/journal.pone.0025446
186. **Bron EE, Smits M, Papma JM, Steketee RM, Meijboom R, De Groot M, van Swieten JC, Niessen WJ, Klein S**. Multiparametric computer-aided differential diagnosis of Alzheimer's disease and frontotemporal dementia using structural and advanced MRI. *Eur Radiol* 27: 3372-3382, 2017.
DOI:10.1007/s00330-016-4691-x
187. **Jousilahti P, Vartiainen E, Tuomilehto J, Puska P**. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. *Circulation* 99: 1165-1172, 1999.
DOI:10.1161/01.cir.99.9.1165
188. **Driver JA, Djoussé L, Logroscino G, Gaziano JM, Kurth T**. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. *BMJ* 337: 2008.
DOI:10.1136/bmj.a2467
189. **Veronese N, Cereda E, Stubbs B, Solmi M, Luchini C, Manzato E, Sergi G, Manu P, Harris T, Fontana L**. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. *Ageing Res Rev* 35: 63-73, 2017.
DOI:10.1016/j.arr.2017.01.003
190. **Lakatta EG and Levy D**. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. *Circulation* 107: 346-354, 2003.
DOI:10.1161/01.cir.0000048893.62841.f7
191. **Alshawabkeh LI, Yee LM, Gardin JM, Gottdiener JS, Odden MC, Bartz TM, Arnold AM, Mukamal KJ, Wallace RB**. Years of able life in older persons—the role of cardiovascular imaging and biomarkers: the Cardiovascular Health Study. *Journal of the American Heart Association* 4: e001745, 2015.
DOI:10.1161/JAHA.114.001745
192. **Leibowitz D, Jacobs JM, Lande-Stessman I, Gilon D, Stessman J**. Cardiac structure and function predicts functional decline in the oldest old. *Eur J Prev Cardiol* 25: 263-269, 2018.
DOI:10.1177/2047487317744365

193. **Newman AB, Gottdiener JS, McBurnie MA, Hirsch CH, Kop WJ, Tracy R, Walston JD, Fried LP**. Associations of subclinical cardiovascular disease with frailty. *J Gerontol A Biol Sci Med Sci* 56: M158-166, 2001.
DOI:10.1093/gerona/56.3.m158
194. **Kusunose K, Okushi Y, Yamada H, Nishio S, Torii Y, Hirata Y, Saijo Y, Ise T, Yamaguchi K, Yagi S**. Prognostic value of frailty and diastolic dysfunction in elderly patients. *Circ J* 82: 2103-2110, 2018.
DOI:10.1253/circj.CJ-18-0017
195. **Leibowitz D, Jacobs JM, Gilon D, Lande-Stessman I, Ein-Mor E, Stessman J**. Cardiac structure and function and frailty in subjects aged 85 and 86 years. *Am J Cardiol* 118: 760-764, 2016.
DOI:10.1016/j.amjcard.2016.06.005
196. **Nadruz Jr W, Kitzman D, Windham BG, Kucharska-Newton A, Butler K, Palta P, Griswold ME, Wagenknecht LE, Heiss G, Solomon SD**. Cardiovascular dysfunction and frailty among older adults in the community: the ARIC study. *J Gerontol A Biol Sci Med Sci* 72: 958-964, 2016.
DOI:10.1093/gerona/glw199
197. **Gharacholou SM, Tashiro T, Cha SS, Scott CG, Takahashi PY, Pellikka PA**. Echocardiographic indices associated with frailty in adults >/=65 years. *Am J Cardiol* 116: 1591-1595, 2015.
DOI:10.1016/j.amjcard.2015.08.023
198. **Sanchis J, Núñez E, Ruiz V, Bonanad C, Fernández J, Cauli O, García-Blas S, Mainar L, Valero E, Rodríguez-Borja E**. Usefulness of clinical data and biomarkers for the identification of frailty after acute coronary syndromes. *Can J Cardiol* 31: 1462-1468, 2015.
DOI:10.1016/j.cjca.2015.07.737
199. **Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ**. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable? *Eur Heart J* 21: 1387-1396, 2000.
DOI:10.1053/euhj.2000.2011
200. **Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ**. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. *Am J Cardiol* 90: 29-34, 2002.
DOI:10.1016/s0002-9149(02)02381-0
201. **Malik SB, Chen N, Parker III RA, Hsu JY**. Transthoracic Echocardiography: Pitfalls and Limitations as Delineated at Cardiac CT and MR Imaging—Erratum. *Radiographics* 37: 1004-1004, 2017.
DOI:10.1148/rg.2017174006
202. **Saeed M, Liu H, Liang C-H, Wilson MW**. Magnetic resonance imaging for characterizing myocardial diseases. *JACC* 33: 1395-1414, 2017.
DOI:10.1007/s10554-017-1127-x
203. **AlGhatrif M, Strait JB, Morrell CH, Canepa M, Wright J, Elango P, Scuteri A, Najjar SS, Ferrucci L, Lakatta EG**. Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore Longitudinal Study of Aging. *Hypertension* 62: 934-941, 2013.
DOI:10.1161/HYPERTENSIONAHA.113.01445

204. **Van den Munckhof I, Scholten R, Cable N, Hopman M, Green D, Thijssen D**. Impact of age and sex on carotid and peripheral arterial wall thickness in humans. *Acta physiologica* 206: 220-228, 2012.
DOI:10.1111/j.1748-1716.2012.02457.x
205. **Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE**. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. *J Am Coll Cardiol* 24: 471-476, 1994.
DOI:10.1016/0735-1097(94)90305-0
206. **Singh N, Prasad S, Singer DR, Mac ALLISTER RJ**. Ageing is associated with impairment of nitric oxide and prostanoid dilator pathways in the human forearm. *Clin Sci* 102: 595-600, 2002.
DOI:https://doi.org/10.1042/cs1020595
207. **Jeon YK, Shin MJ, Saini SK, Custodero C, Aggarwal M, Anton SD, Leeuwenburgh C, Mankowski RT**. Vascular dysfunction as a potential culprit of sarcopenia. *Exp Gerontol* 145: 111220, 2021.
DOI:10.1016/j.exger.2020.111220
208. **Brunner EJ, Shipley MJ, Witte DR, Singh-Manoux A, Britton AR, Tabak AG, McEniery CM, Wilkinson IB, Kivimaki M**. Arterial stiffness, physical function, and functional limitation: the Whitehall II Study. *Hypertension* 57: 1003-1009, 2011.
DOI:10.1161/HYPERTENSIONAHA.110.168864
209. **Orkaby AR, Lunetta KL, Sun FJ, Driver JA, Benjamin EJ, Hamburg NM, Mitchell GF, Vasan RS, Murabito JM**. Cross-sectional association of frailty and arterial stiffness in community-dwelling older adults: the Framingham heart study. *J Gerontol A* 74: 373-379, 2019.
DOI:10.1093/gerona/gly134
210. **Amarasekera AT, Chang D, Schwarz P, Tan TC**. Does vascular endothelial dysfunction play a role in physical frailty and sarcopenia? A systematic review. *Age and Ageing* 2020.
DOI:10.1093/ageing/afaa237
211. **Alonso-Bouzón C, Carcaillon L, García-García FJ, Amor-Andrés MS, El Assar M, Rodríguez-Mañas L**. Association between endothelial dysfunction and frailty: the Toledo Study for Healthy Aging. *Age (Dordr)* 36: 495-505, 2014.
DOI:10.1007/s11357-013-9576-1
212. **Santillo E, Migale M and Balestrini F**. Frailty and flow-mediated dilation: A pilot study in hospitalized elderly. *J current res sci med* 2: 92, 2016.
DOI:10.4103/2455-3069.198368
213. **Mansur HN, Lovisi JCM, Colugnati FAB, Raposo NRB, da Silva Fernandes NM, Bastos MG**. Association of frailty with endothelial dysfunction and its possible impact on negative outcomes in Brazilian predialysis patients with chronic kidney disease. *BMC Nephrol* 16: 1-9, 2015.
DOI:10.1186/s12882-015-0150-1
214. **Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, De Ferranti S, Després J-P, Fullerton HJ, Howard VJ**. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation* 131: e29-e322, 2015.
DOI:10.1161/CIR.0000000000000152
215. **Lakatta EG and Levy D**. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a “set up” for vascular disease. *Circulation* 107: 139-146, 2003.

DOI:10.1161/01.cir.0000048892.83521.58
216. **Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A**. Aging and endothelial function in normotensive subjects and patients with essential hypertension. *Circulation* 91: 1981-1987, 1995.
DOI:10.1161/01.cir.91.7.1981
217. **Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B**. The heart in hypertension. *New England Journal of Medicine* 327: 998-1008, 1992.
DOI:10.1056/NEJM199210013271406
218. **Dumurgier J, Elbaz A, Dufouil C, Tavernier B, Tzourio C**. Hypertension and lower walking speed in the elderly: the Three-City study. *J Hypertens* 28: 1506, 2010.
DOI:10.1097/HJH.0b013e328338bbec
219. **Balzi D, Lauretani F, Barchielli A, Ferrucci L, Bandinelli S, Buiatti E, Milaneschi Y, Guralnik JM**. Risk factors for disability in older persons over 3-year follow-up. *Age and Ageing* 39: 92-98, 2010.
DOI:10.1093/ageing/afp209
220. **Cherubini A, Lowenthal DT, Paran E, Mecocci P, Williams LS, Senin U**. Hypertension and cognitive function in the elderly. *Dis Mon* 56: 106-147, 2010.
DOI:10.1016/j.disamonth.2009.12.007
221. **Vetrano DL, Palmer KM, Galluzzo L, Giampaoli S, Marengoni A, Bernabei R, Onder G**. Hypertension and frailty: a systematic review and meta-analysis. *BMJ Open* 8: e024406, 2018.
DOI:10.1136/bmjopen-2018-024406
222. **Odden MC, Peralta CA, Berlowitz DR, Johnson KC, Whittle J, Kitzman DW, Beddhu S, Nord JW, Papademetriou V, Williamson JD**. Effect of intensive blood pressure control on gait speed and mobility limitation in adults 75 years or older: a randomized clinical trial. *JAMA internal medicine* 177: 500-507, 2017.
DOI:10.1001/jamainternmed.2016.9104
223. **Di Bari M, Pahor M, Franse LV, Shorr RI, Wan JY, Ferrucci L, Somes GW, Applegate WB**. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. *Am J Epidemiol* 153: 72-78, 2001.
DOI:10.1093/aje/153.1.72
224. **Masiha S, Sundström J and Lind L**. Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women. *J Hum Hypertens* 27: 13-17, 2013.
DOI:10.1038/jhh.2011.113
225. **Hartupee J, Szalai GD, Wang W, Ma X, Diwan A, Mann DL**. Impaired protein quality control during left ventricular remodeling in mice with cardiac restricted overexpression of tumor necrosis factor. *Circ Heart Fail* 10: e004252, 2017.
DOI:10.1161/CIRCHEARTFAILURE.117.004252
226. **Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, Mann DL**. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. *Circulation* 104: 826-831, 2001.
DOI:10.1161/hc3401.093154
227. **Schafnitzel A, Lorbeer R, Bayerl C, Patscheider H, Auweter SD, Meisinger C, Heier M, Ertl-Wagner B, Reiser M, Peters A**. Association of smoking

and physical inactivity with MRI derived changes in cardiac function and structure in cardiovascular healthy subjects. *Sci Rep* 9: 1-10, 2019.
DOI:10.1038/s41598-019-54956-8
228. **Dorfman TA, Levine BD, Tillery T, Peshock RM, Hastings JL, Schneider SM, Macias BR, Biolo G, Hargens AR**. Cardiac atrophy in women following bed rest. *J Appl Physiol* 103: 8-16, 2007.
DOI:10.1152/japplphysiol.01162.2006
229. **Bederman IR, Lai N, Shuster J, Henderson L, Ewart S, Cabrera ME**. Chronic hindlimb suspension unloading markedly decreases turnover rates of skeletal and cardiac muscle proteins and adipose tissue triglycerides. *J Appl Physiol* 119: 16-26, 2015.
DOI:10.1152/japplphysiol.00004.2014
230. **Park W, Park H-Y, Lim K, Park J**. The role of habitual physical activity on arterial stiffness in elderly individuals: a systematic review and meta-analysis. *J exerc nutrition biochem* 21: 16, 2017.
DOI:10.20463/jenb.2017.0041
231. **Gnasso A, Carallo C, Irace C, De Franceschi MS, Mattioli PL, Motti C, Cortese C**. Association between wall shear stress and flow-mediated vasodilation in healthy men. *Atherosclerosis* 156: 171-176, 2001.
DOI:10.1016/S0021-9150(00)00617-1
232. **Cheng C, van Haperen R, de Waard M, van Damme LC, Tempel D, Hanemaaijer L, van Cappellen GW, Bos J, Slager CJ, Duncker DJ**. Shear stress affects the intracellular distribution of eNOS: direct demonstration by a novel in vivo technique. *Blood* 106: 3691-3698, 2005.
DOI:10.1182/blood-2005-06-2326
233. **Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR**. Nitric oxide regulates local arterial distensibility in vivo. *Circulation* 105: 213-217, 2002.
DOI:10.1161/hc0202.101970
234. **Pereira BI and Akbar AN**. Convergence of Innate and Adaptive Immunity during Human Aging. *Front Immunol* 7: 445, 2016.
DOI:10.3389/fimmu.2016.00445
235. **Hazeldine J, Lord JM and Hampson P**. Immunesenescence and inflammaging: a contributory factor in the poor outcome of the geriatric trauma patient. *Ageing Res Rev* 24: 349-357, 2015.
DOI:10.1016/j.arr.2015.10.003
236. **Franceschi C and Campisi J**. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J Gerontol A Biol Sci Med Sci* 69 Suppl 1: S4-9, 2014.
DOI:10.1093/gerona/glu057
237. **Desdín-Micó G, Soto-Heredero G, Aranda JF, Oller J, Carrasco E, Gabandé-Rodríguez E, Blanco EM, Alfranca A, Cussó L, Desco M, Ibañez B, Gortazar AR, Fernández-Marcos P, Navarro MN, Hernaez B, Alcamí A, Baixauli F, Mittelbrunn M**. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. *Science* 368: 1371-1376, 2020.
DOI:10.1126/science.aax0860
238. **Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti ME, Zareian N, Accardi G**. Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. *Front Immunol* 10: 2247, 2019.

DOI:10.3389/fimmu.2019.02247
239. **Álvarez-Rodríguez L, López-Hoyos M, Muñoz-Cacho P, Martínez-Taboada VM**. Aging is associated with circulating cytokine dysregulation. *Cell Immunol* 273: 124-132, 2012.
DOI:10.1016/j.cellimm.2012.01.001
240. **Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S**. Inflammaging and 'Garb-aging'. *Trends Endocrinol Metab* 28: 199-212, 2017.
DOI:10.1016/j.tem.2016.09.005
241. **Di Mitri D, Azevedo RI, Henson SM, Libri V, Riddell NE, Macaulay R, Kipling D, Soares MV, Battistini L, Akbar AN**. Reversible senescence in human CD4+ CD45RA+ CD27− memory T cells. *J Immunol* 187: 2093-2100, 2011.
DOI:10.4049/jimmunol.1100978
242. **Callender LA, Carroll EC, Beal RW, Chambers ES, Nourshargh S, Akbar AN, Henson SM**. Human CD 8+ EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK. *Aging Cell* 17: e12675, 2018.
DOI:10.1111/acel.12675
243. **Schmitt V, Rink L and Uciechowski P**. The Th17/Treg balance is disturbed during aging. *Exp Gerontol* 48: 1379-1386, 2013.
DOI:10.1016/j.exger.2013.09.003
244. **Mogilenko DA, Shpynov O, Andhey PS, Arthur L, Swain A, Esaulova E, Brioschi S, Shchukina I, Kerndl M, Bambouskova M, Yao Z, Laha A, Zaitsev K, Burdess S, Gillfilan S, Stewart SA, Colonna M, Artyomov MN**. Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK(+) CD8(+) T Cells as Conserved Hallmark of Inflammaging. *Immunity* 54: 99-115.e112, 2021.
DOI:10.1016/j.immuni.2020.11.005
245. **Duggal NA, Upton J, Phillips AC, Sapey E, Lord JM**. An age-related numerical and functional deficit in CD19(+) CD24(hi) CD38(hi) B cells is associated with an increase in systemic autoimmunity. *Aging Cell* 12: 873-881, 2013.
DOI:10.1111/acel.12114
246. **Pereira BI, Devine OP, Vukmanovic-Stejic M, Chambers ES, Subramanian P, Patel N, Virasami A, Sebire NJ, Kinsler V, Valdovinos A, LeSaux CJ, Passos JF, Antoniou A, Rustin MHA, Campisi J, Akbar AN**. Senescent cells evade immune clearance via HLA-E-mediated NK and CD8(+) T cell inhibition. *Nat Commun* 10: 2387, 2019.
DOI:10.1038/s41467-019-10335-5
247. **Hazeldine J, Hampson P and Lord JM**. Reduced release and binding of perforin at the immunological synapse underlies the age-related decline in natural killer cell cytotoxicity. *Aging Cell* 11: 751-759, 2012.
DOI:10.1111/j.1474-9726.2012.00839.x
248. **Ng TP, Camous X, Nyunt MSZ, Vasudev A, Tan CTY, Feng L, Fulop T, Yap KB, Larbi A**. Markers of T-cell senescence and physical frailty: insights from Singapore Longitudinal Ageing Studies. *NPJ Aging Mech Dis* 1: 15005, 2015.
DOI:10.1038/npjamd.2015.5
249. **Zhang H, Hao M, Hu Z, Li Y, Jiang X, Wang J, Jin L, Liu Z, Wang X, Sun X**. Association of immunity markers with the risk of incident frailty: the Rugao longitudinal aging study. *Immun Ageing* 19: 1, 2022.
DOI:10.1186/s12979-021-00257-6
250. **Granic A, Martin-Ruiz C, Dodds RM, Robinson L, Spyridopoulos I, Kirkwood TB, von Zglinicki T, Sayer AA**. Immunosenescence profiles are not

associated with muscle strength, physical performance and sarcopenia risk in very old adults: The Newcastle 85+ Study. *Mech Ageing Dev* 190: 111321, 2020. DOI:10.1016/j.mad.2020.111321

251. **Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G**. Inflamm-aging: an evolutionary perspective on immunosenescence. *Ann N Y Acad Sci* 908: 244-254, 2000. DOI:10.1111/j.1749-6632.2000.tb06651.x

252. **Bartlett DB, Firth CM, Phillips AC, Moss P, Baylis D, Syddall H, Sayer AA, Cooper C, Lord JM**. The age-related increase in low-grade systemic inflammation (Inflammaging) is not driven by cytomegalovirus infection. *Aging Cell* 11: 912-915, 2012. DOI:10.1111/j.1474-9726.2012.00849.x

253. **Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M**. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. *Mech Ageing Dev* 128: 92-105, 2007. DOI:10.1016/j.mad.2006.11.016

254. **Morrisette-Thomas V, Cohen AA, Fülöp T, Riesco É, Legault V, Li Q, Milot E, Dusseault-Bélanger F, Ferrucci L**. Inflamm-aging does not simply reflect increases in pro-inflammatory markers. *Mech Ageing Dev* 139: 49-57, 2014. DOI:10.1016/j.mad.2014.06.005

255. **Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E**. From discoveries in ageing research to therapeutics for healthy ageing. *Nature* 571: 183-192, 2019. DOI:10.1038/s41586-019-1365-2

256. **Singh T and Newman AB**. Inflammatory markers in population studies of aging. *Ageing Res Rev* 10: 319-329, 2011. DOI:10.1016/j.arr.2010.11.002

257. **Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, Sergi G, Isik AT, Manzato E, Maggi S**. Inflammation and frailty in the elderly: a systematic review and meta-analysis. *Ageing Res Rev* 31: 1-8, 2016. DOI:10.1016/j.arr.2016.08.006

258. **Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB**. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. *Cancer Epidemiol* 14: 2413-2418, 2005. DOI:10.1158/1055-9965.EPI-05-0316

259. **Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL**. Inflammation and Alzheimer's disease. *Neurobiol Aging* 21: 383-421, 2000. DOI:10.1016/s0197-4580(00)00124-x

260. **Franceschi C, Monti D, Sansoni P, Cossarizza A**. The immunology of exceptional individuals: the lesson of centenarians. *Immunol Today* 16: 12-16, 1995. DOI:10.1016/0167-5699(95)80064-6

261. **Arranz L, Lord JM and De la Fuente M**. Preserved ex vivo inflammatory status and cytokine responses in naturally long-lived mice. *Age* 32: 451-466, 2010. DOI:10.1007/s11357-010-9151-y

262. **Duggal NA, Niemiro G, Harridge SD, Simpson RJ, Lord JM**. Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity? *Nat Rev Immunol* 19: 563-572, 2019. DOI:10.1038/s41577-019-0177-9

263. **Ko F, Yu Q, Xue Q-L, Yao W, Brayton C, Yang H, Fedarko N, Walston J**. Inflammation and mortality in a frail mouse model. *Age* 34: 705-715, 2012. DOI:10.1007/s11357-011-9269-6

264. **Mourkioti F, Kratsios P, Luedde T, Song Y-H, Delafontaine P, Adami R, Parente V, Bottinelli R, Pasparakis M, Rosenthal N**. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. *The Journal of clinical investigation* 116: 2945-2954, 2006. DOI:10.1172/JCI28721

265. **Vatic M, von Haehling S and Ebner N**. Inflammatory biomarkers of frailty. *Exp Gerontol* 133: 110858, 2020. DOI:10.1016/j.exger.2020.110858

266. **Ferrucci L and Fabbri E**. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nature Reviews Cardiology* 15: 505-522, 2018. DOI:10.1038/s41569-018-0064-2

267. **Wilson D, Jackson T, Sapey E, Lord JM**. Frailty and sarcopenia: The potential role of an aged immune system. *Ageing Res Rev* 36: 1-10, 2017. DOI:10.1016/j.arr.2017.01.006

268. **Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, Harris TB**. Relationship of interleukin-6 and tumor necrosis factor-α with muscle mass and muscle strength in elderly men and women: the Health ABC Study. *J Gerontol A Biol Sci Med Sci* 57: M326-M332, 2002. DOI:10.1093/gerona/57.5.m326

269. **Peterson MJ, Thompson DK, Pieper CF, Morey MC, Kraus VB, Kraus WE, Sullivan P, Fillenbaum G, Cohen HJ**. A novel analytic technique to measure associations between circulating biomarkers and physical performance across the adult life span. *J Gerontol A Biol Sci Med Sci* 71: 196-202, 2016. DOI:10.1093/gerona/glv007

270. **Levinger I, Howlett KF, Peake J, Garnham A, Hare DL, Jerums G, Selig S, Goodman C**. Akt, AS160, metabolic risk factors and aerobic fitness in middle-aged women. *Exerc Immunol Rev* 16: 98-104, 2010. DOI:DU:30033425

271. **Cesari M, Kritchevsky SB, Nicklas B, Kanaya AM, Patrignani P, Tacconelli S, Tranah GJ, Tognoni G, Harris TB, Incalzi RA**. Oxidative damage, platelet activation, and inflammation to predict mobility disability and mortality in older persons: results from the health aging and body composition study. *J Gerontol A Biol Sci Med Sci* 67: 671-676, 2012. DOI:10.1093/gerona/glr246

272. **Gale CR, Baylis D, Cooper C, Sayer AA**. Inflammatory markers and incident frailty in men and women: the English Longitudinal Study of Ageing. *Age* 35: 2493-2501, 2013. DOI:10.1007/s11357-013-9528-9

273. **Fried LP, Xue Q-L, Cappola AR, Ferrucci L, Chaves P, Varadhan R, Guralnik JM, Leng SX, Semba RD, Walston JD**. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. *J Gerontol A Biol Sci Med Sci* 64: 1049-1057, 2009. DOI:10.1093/gerona/glp076

274. **Marcos-Pérez D, Sánchez-Flores M, Proietti S, Bonassi S, Costa S, Teixeira JP, Fernández-Tajes J, Pásaro E, Laffon B, Valdiglesias V**. Association of inflammatory mediators with frailty status in older adults: results from a systematic review and meta-analysis. *GeroScience* 42: 1-23, 2020.

DOI:10.1007/s11357-020-00247-4
275. **Landino K, Tanaka T, Fantoni G, Candia J, Bandinelli S, Ferrucci L**. Characterization of the plasma proteomic profile of frailty phenotype. *Geroscience* 43: 1029-1037, 2021.
DOI:10.1007/s11357-020-00288-9
276. **Lin C-C, Wu F-Y, Liao L-N, Li C-I, Lin C-H, Yang C-W, Meng N-H, Chang C-K, Lin W-Y, Liu C-S**. Association of CRP gene polymorphisms with serum CRP level and handgrip strength in community-dwelling elders in Taiwan: Taichung Community Health Study for Elders (TCHS-E). *Exp Gerontol* 57: 141-148, 2014.
DOI:10.1016/j.exger.2014.05.012
277. **Almeida OP, Norman PE, van Bockxmeer FM, Hankey GJ, Flicker L**. CRP 1846G> A polymorphism increases risk of frailty. *Maturitas* 71: 261-266, 2012.
DOI:10.1016/j.maturitas.2011.11.022
278. **Taekema DG, Westendorp RG, Frölich M, Gussekloo J**. High innate production capacity of tumor necrosis factor-α and decline of handgrip strength in old age. *Mech Ageing Dev* 128: 517-521, 2007.
DOI:10.1016/j.mad.2007.07.001
279. **Sanders JL, Ding V, Arnold AM, Kaplan RC, Cappola AR, Kizer JR, Boudreau RM, Cushman M, Newman AB**. Do changes in circulating biomarkers track with each other and with functional changes in older adults? *J Gerontol A Biol Sci Med Sci* 69: 174-181, 2014.
DOI:10.1093/gerona/glt088
280. **Westbury L, Fuggle N, Syddall HE, Duggal N, Shaw S, Maslin K, Dennison E, Lord J, Cooper C**. Relationships between markers of inflammation and muscle mass, strength and function: findings from the Hertfordshire Cohort Study. *Calcif Tissue Int* 102: 287-295, 2018.
DOI:10.1007/s00223-017-0354-4
281. **Samson LD, Buisman AM, Ferreira JA, Picavet HSJ, Verschuren WM, Boots AM, Engelfriet P**. Inflammatory marker trajectories associated with frailty and ageing in a 20-year longitudinal study. *Clinical & translational immunology* 11: e1374, 2022.
DOI:10.1002/cti2.1374
282. **Welstead M, Muniz-Terrera G, Russ TC, Corley J, Taylor AM, Gale CR, Luciano M**. Inflammation as a risk factor for the development of frailty in the Lothian Birth Cohort 1936. *Exp Gerontol* 139: 111055, 2020.
DOI:10.1016/j.exger.2020.111055
283. **Alturki M, Beyer I, Mets T, Bautmans I**. Impact of drugs with anti-inflammatory effects on skeletal muscle and inflammation: a systematic literature review. *Exp Gerontol* 114: 33-49, 2018.
DOI:10.1016/j.exger.2018.10.011
284. **Huang Z, Zhong L, Zhu J, Xu H, Ma W, Zhang L, Shen Y, Law BY-K, Ding F, Gu X**. Inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy. *Ann Transl Med* 8: 1681, 2020.
DOI:10.21037/atm-20-7269
285. **Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, Inman CL, Ogrodnik MB, Hachfeld CM, Fraser DG**. Senolytics improve physical function and increase lifespan in old age. *Nat Med* 24: 1246-1256, 2018.
DOI:10.1038/s41591-018-0092-9
286. **Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Prata L, Masternak MM, Kritchevsky SB, Musi N**. Senolytics in idiopathic

pulmonary fibrosis: results from a first-in-human, open-label, pilot study. *EBioMedicine* 40: 554-563, 2019.
DOI:10.1016/j.ebiom.2018.12.052
287. **Schoenfeld BJ**. Non-steroidal anti-inflammatory drugs may blunt more than pain. *Acta Physiol (Oxf)* 222: 2018.
DOI:10.1111/apha.12990
288. **Schoenfeld BJ**. The use of nonsteroidal anti-inflammatory drugs for exercise-induced muscle damage: implications for skeletal muscle development. *Sports Med* 42: 1017-1028, 2012.
DOI:10.1007/bf03262309
289. **Jenny NS, Tracy RP, Ogg MS, Luong LA, Kuller LH, Arnold AM, Sharrett AR, Humphries SE**. In the elderly, interleukin-6 plasma levels and the− 174G> C polymorphism are associated with the development of cardiovascular disease. *Arterioscler Thromb Vasc Biol* 22: 2066-2071, 2002.
DOI:10.1161/01.Atv.0000040224.49362.60
290. **Sanada F, Taniyama Y, Muratsu J, Otsu R, Shimizu H, Rakugi H, Morishita R**. Source of chronic inflammation in aging. *Front Cardiovasc Med* 5: 12, 2018.
DOI:10.3389/fcvm.2018.00012
291. **López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G**. The hallmarks of aging. *Cell* 153: 1194-1217, 2013.
DOI:10.1016/j.cell.2013.05.039
292. **Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, Saltness RA, Jeganathan KB, Verzosa GC, Pezeshki A**. Naturally occurring p16 Ink4a-positive cells shorten healthy lifespan. *Nature* 530: 184-189, 2016.
DOI:10.1038/nature16932
293. **Kirkland JL and Tchkonia T**. Senolytic drugs: From discovery to translation. *J Intern Med* 288: 518-536, 2020.
DOI:10.1111/joim.13141
294. **Freund A, Orjalo AV, Desprez P-Y, Campisi J**. Inflammatory networks during cellular senescence: causes and consequences. *Trends Mol Med* 16: 238-246, 2010.
DOI:10.1016/j.molmed.2010.03.003
295. **Santoro A, Ostan R, Candela M, Biagi E, Brigidi P, Capri M, Franceschi C**. Gut microbiota changes in the extreme decades of human life: a focus on centenarians. *Cell Mol Life Sci* 75: 129-148, 2018.
DOI:10.1007/s00018-017-2674-y
296. **Wilson QN, Wells M, Davis AT, Sherrill C, Tsilimigras MC, Jones RB, Fodor AA, Kavanagh K**. Greater microbial translocation and vulnerability to metabolic disease in healthy aged female monkeys. *Sci Rep* 8: 1-10, 2018.
DOI:10.1038/s41598-018-29473-9
297. **Conway J and Duggal NA**. Ageing of the gut microbiome: potential influences on immune senescence and inflammageing. *Ageing Res Rev* 68: 101323, 2021.
DOI:10.1016/j.arr.2021.101323
298. **DeJong EN, Surette MG and Bowdish DM**. The gut microbiota and unhealthy aging: disentangling cause from consequence. *Cell Host Microbe* 28: 180-189, 2020.
DOI:10.1016/j.chom.2020.07.013

299. **Thevaranjan N, Puchta A, Schulz C, Naidoo A, Szamosi J, Verschoor CP, Loukov D, Schenck LP, Jury J, Foley KP**. Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction. *Cell Host Microbe* 21: 455-466. e454, 2017.
DOI:10.1016/j.chom.2017.03.002
300. **Bartlett DB and Duggal NA**. Moderate physical activity associated with a higher naïve/memory T-cell ratio in healthy old individuals: potential role of IL15. *Age Ageing* 49: 368-373, 2020.
DOI:10.1093/ageing/afaa035
301. **Reuben DB, Judd-Hamilton L, Harris TB, Seeman TE**. The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur studies of successful aging. *J Am Geriatr Soc* 51: 1125-1130, 2003.
DOI:10.1046/j.1532-5415.2003.51380.x
302. **Bautmans I, Salimans L, Njemini R, Beyer I, Lieten S, Liberman K**. The effects of exercise interventions on the inflammatory profile of older adults: A systematic review of the recent literature. *Exp Gerontol* 146: 111236, 2021.
DOI:10.1016/j.exger.2021.111236
303. **Stout MB, Tchkonia T and Kirkland JL**. The aging adipose organ: lipid redistribution, inflammation, and cellular senescence. In: *Adipose Tissue and Adipokines in Health and Disease*: Springer, 2014, p. 69-80.
304. **Kimura M, Suzuki S, Moriya A, Nogami K, Uchida R, Saito Y, Saito H**. The Effects of Continuous and Withdrawal Voluntary Wheel Running Exercise on the Expression of Senescence-Related Genes in the Visceral Adipose Tissue of Young Mice. *Int J Mol Sci* 22: 264, 2021.
DOI:10.3390/ijms22010264
305. **Pedersen BK and Fischer CP**. Beneficial health effects of exercise–the role of IL-6 as a myokine. *Trends Pharmacol Sci* 28: 152-156, 2007.
DOI:10.1016/j.tips.2007.02.002
306. **Steensberg A, Fischer CP, Keller C, Møller K, Pedersen BK**. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. *Am J Physiol Endocrinol Metab* 285: E433-E437, 2003.
DOI:10.1152/ajpendo.00074.2003
307. **Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theurich S, Hausen AC, Schmitz J, Brönneke HS**. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. *Nat Immunol* 15: 423-430, 2014.
DOI:10.1038/ni.2865
308. **Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, Simonsick EM, Tylavsky FA, Visser M, Newman AB**. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. *J Gerontol A Biol Sci Med Sci* 61: 1059-1064, 2006.
DOI:10.1093/gerona/61.10.1059
309. **Machann J, Thamer C, Schnoedt B, Stefan N, Stumvoll M, Haring H-U, Claussen C, Schick F, Fritsche A**. Age and gender related effects on adipose tissue compartments of subjects with increased risk for type 2 diabetes: a whole body MRI/MRS study. *Magn Reson Mater Phys, Biol Med* 18: 128-137, 2005.
DOI:10.1007/s10334-005-0104-x

310. **Fuke Y, Okabe S, Kajiwara N, Suastika K, Budhiarta A, Maehata S, Taniguchi H**. Increase of visceral fat area in Indonesians and Japanese with normal BMI. *Diabetes Res Clin Pract* 77: S224-S227, 2007.
DOI:10.1016/j.diabres.2007.01.062
311. **Schwenzer NF, Martirosian P, Machann J, Schraml C, Steidle G, Claussen CD, Schick F**. Aging effects on human calf muscle properties assessed by MRI at 3 Tesla. *Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine* 29: 1346-1354, 2009.
DOI:10.1002/jmri.21789
312. **Hughes VA, Roubenoff R, Wood M, Frontera WR, Evans WJ, Fiatarone Singh MA**. Anthropometric assessment of 10-y changes in body composition in the elderly. *Am J Clin Nutr* 80: 475-482, 2004.
DOI:10.1093/ajcn/80.2.475
313. **Van Pelt RE, Jankowski CM, Gozansky WS, Wolfe P, Schwartz RS, Kohrt WM**. Sex differences in the association of thigh fat and metabolic risk in older adults. *Obesity* 19: 422-428, 2011.
DOI:10.1038/oby.2010.140
314. **Monteverde M, Noronha K, Palloni A, Novak B**. Obesity and excess mortality among the elderly in the United States and Mexico. *Demography* 47: 79-96, 2010.
DOI:10.1353/dem.0.0085
315. **Freedman D, Ron E, Ballard-Barbash R, Doody M, Linet M**. Body mass index and all-cause mortality in a nationwide US cohort. *International journal of obesity* 30: 822-829, 2006.
DOI:10.1038/sj.ijo.0803193
316. **Chapman IM**. Obesity paradox during aging. *Body composition and aging* 37: 20-36, 2010.
DOI:10.1159/000319992
317. **Wang L, Liu W, He X, Chen Y, Lu J, Liu K, Cao K, Yin P**. Association of overweight and obesity with patient mortality after acute myocardial infarction: a meta-analysis of prospective studies. *International journal of obesity* 40: 220-228, 2016.
DOI:10.1038/ijo.2015.176
318. **Greenlee H, Unger JM, LeBlanc M, Ramsey S, Hershman DL**. Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials. *Cancer Epidemiol* 26: 21-29, 2017.
DOI:10.1158/1055-9965.EPI-15-1336
319. **Boutin E, Natella P-A, Schott A-M, Bastuji-Garin S, David J-P, Paillaud E, Rolland Y, Canouï-Poitrine F**. Interrelations between body mass index, frailty, and clinical adverse events in older community-dwelling women: The EPIDOS cohort study. *Clin Nutr* 37: 1638-1644, 2018.
DOI:10.1016/j.clnu.2017.07.023
320. **Schaap LA, Koster A and Visser M**. Adiposity, muscle mass, and muscle strength in relation to functional decline in older persons. *Epidemiol Rev* 35: 51-65, 2013.
DOI:10.1093/epirev/mxs006
321. **Cawthon PM, Fox KM, Gandra SR, Delmonico MJ, Chiou CF, Anthony MS, Caserotti P, Kritchevsky SB, Newman AB, Goodpaster BH**. Clustering of strength, physical function, muscle, and adiposity characteristics and risk of disability in older adults. *J Am Geriatr Soc* 59: 781-787, 2011.

DOI:10.1111/j.1532-5415.2011.03389.x
322. **Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, Masaki K, Murray A, Newman AB**. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. *J Am Geriatr Soc* 53: 1321-1330, 2005.
DOI:10.1111/j.1532-5415.2005.53405.x
323. **Landré B, Czernichow S, Goldberg M, Zins M, Ankri J, Herr M**. Association Between Life-Course Obesity and Frailty in Older Adults: Findings in the GAZEL Cohort. *Obesity* 28: 388-396, 2020.
DOI:10.1002/oby.22682
324. **Blaum CS, Xue QL, Michelon E, Semba RD, Fried LP**. The association between obesity and the frailty syndrome in older women: the Women's Health and Aging Studies. *J Am Geriatr Soc* 53: 927-934, 2005.
DOI:10.1111/j.1532-5415.2005.53300.x
325. **Sewo Sampaio PY, Sampaio RAC, Coelho Júnior HJ, Teixeira LFM, Tessutti VD, Uchida MC, Arai H**. Differences in lifestyle, physical performance and quality of life between frail and robust Brazilian community-dwelling elderly women. *Geriatr Gerontol Int* 16: 829-835, 2016.
DOI:10.1111/ggi.12562
326. **Bowden Davies KA, Sprung VS, Norman JA, Thompson A, Mitchell KL, Halford JC, Harrold JA, Wilding JP, Kemp GJ, Cuthbertson DJ**. Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes. *Diabetologia* 61: 1282-1294, 2018.
DOI:10.1007/s00125-018-4603-5
327. **Olsen RH, Krogh-Madsen R, Thomsen C, Booth FW, Pedersen BK**. Metabolic responses to reduced daily steps in healthy nonexercising men. *JAMA* 299: 1261-1263, 2008.
DOI:10.1001/jama.299.11.1259
328. **del Pozo-Cruz B, Mañas A, Martín-García M, Marín-Puyalto J, García-García FJ, Rodriguez-Mañas L, Guadalupe-Grau A, Ara I**. Frailty is associated with objectively assessed sedentary behaviour patterns in older adults: Evidence from the Toledo Study for Healthy Aging (TSHA). *PLoS One* 12: e0183911, 2017.
DOI:10.1371/journal.pone.0183911
329. **Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Befroy D, Zemany L, Kahn BB**. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. *Proc Natl Acad Sci U S A* 104: 12587-12594, 2007.
DOI:10.1073/pnas.0705408104
330. **Rector RS and Thyfault JP**. Does physical inactivity cause nonalcoholic fatty liver disease? *Journal of applied physiology* 111: 1828-1835, 2011.
DOI:10.1152/japplphysiol.00384.2011
331. **Blanc Sp, Normand S, Pachiaudi C, Fortrat J-O, Laville M, Gharib C**. Fuel homeostasis during physical inactivity induced by bed rest. *J Clin Endocrinol Metab* 85: 2223-2233, 2000.
DOI:10.1210/jcem.85.6.6617
332. **Manini TM, Clark BC, Nalls MA, Goodpaster BH, Ploutz-Snyder LL, Harris TB**. Reduced physical activity increases intermuscular adipose tissue in healthy young adults. *Am J Clin Nutr* 85: 377-384, 2007.
DOI:10.1093/ajcn/85.2.377

333. **Gemmink A, Goodpaster BH, Schrauwen P, Hesselink MK**. Intramyocellular lipid droplets and insulin sensitivity, the human perspective. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids* 1862: 1242-1249, 2017.
DOI:10.1016/j.bbalip.2017.07.010
334. **Hannukainen JC, Nuutila P, Ronald B, Kaprio J, Kujala UM, Janatuinen T, Heinonen OJ, Kapanen J, Viljanen T, Haaparanta M**. Increased physical activity decreases hepatic free fatty acid uptake: a study in human monozygotic twins. *J Physiol* 578: 347-358, 2007.
DOI:10.1113/jphysiol.2006.121368
335. **Iozzo P, Takala T, Oikonen V, Bergman Jr, Grönroos T, Ferrannini E, Nuutila P, Knuuti J**. Effect of training status on regional disposal of circulating free fatty acids in the liver and skeletal muscle during physiological hyperinsulinemia. *Diabetes Care* 27: 2172-2177, 2004.
DOI:10.2337/diacare.27.9.2172
336. **Leng SX, Yang H and Walston JD**. Decreased cell proliferation and altered cytokine production in frail older adults. *Aging Clin Exp Res* 16: 249-252, 2004.
DOI:10.1007/BF03327392
337. **Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, Gottdiener J, Fried LP**. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. *Arch Intern Med* 162: 2333-2341, 2002.
DOI:10.1001/archinte.162.20.2333
338. **Cesari M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BW, Lenchik L, Palla SL, Ambrosius WT, Tracy RP, Pahor M**. Sarcopenia, obesity, and inflammation—results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study–. *Am J Clin Nutr* 82: 428-434, 2005.
DOI:10.1093/ajcn.82.2.428
339. **Mohamed-Ali V, Goodrick S, Rawesh A, Katz D, Miles J, Yudkin J, Klein S, Coppack S**. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. *J Clin Endocrinol Metab* 82: 4196-4200, 1997.
DOI:10.1210/jc.82.12.4196
340. **Murton AJ, Marimuthu K, Mallinson JE, Selby AL, Smith K, Rennie MJ, Greenhaff PL**. Obesity appears to be associated with altered muscle protein synthetic and breakdown responses to increased nutrient delivery in older men, but not reduced muscle mass or contractile function. *Diabetes* 64: 3160-3171, 2015.
DOI:10.2337/db15-0021
341. **Cohen AA, Milot E, Yong J, Seplaki CL, Fülöp T, Bandeen-Roche K, Fried LP**. A novel statistical approach shows evidence for multi-system physiological dysregulation during aging. *Mech Ageing Dev* 134: 110-117, 2013.
DOI:10.1016/j.mad.2013.01.004
342. **Weinert BT and Timiras PS**. Invited review: Theories of aging. *J Appl Physiol* 95: 1706-1716, 2003.
DOI:10.1152/japplphysiol.00288.2003
343. **Samper-Ternent R, Reyes-Ortiz C, Ottenbacher KJ, Cano CA**. Frailty and sarcopenia in Bogotá: results from the SABE Bogotá Study. *Aging Clin Exp Res* 29: 265-272, 2017.
DOI:10.1007/s40520-016-0561-2

344. **Amaral LA, Díaz-Guilera A, Moreira AA, Goldberger AL, Lipsitz LA**. Emergence of complex dynamics in a simple model of signaling networks. *Proc Natl Acad Sci U S A* 101: 15551-15555, 2004.
DOI:10.1073/pnas.0404843101
345. **Yates FE**. Complexity of a human being: changes with age. *Neurobiol Aging* 23: 17, 2002.
DOI:10.1016/S0197-4580(01)00261-5
346. **Li Q, Wang S, Milot E, Bergeron P, Ferrucci L, Fried LP, Cohen AA**. Homeostatic dysregulation proceeds in parallel in multiple physiological systems. *Aging Cell* 14: 1103-1112, 2015.
DOI:10.1111/acel.12402
347. **Ghachem A, Fried LP, Legault V, Bandeen-Roche K, Presse N, Gaudreau P, Cohen AA**. Evidence from two cohorts for the frailty syndrome as an emergent state of parallel dysregulation in multiple physiological systems. *Biogerontology* 22: 63-79, 2020.
DOI:10.1007/s10522-020-09903-w
348. **Theou O, Cann L, Blodgett J, Wallace LM, Brothers TD, Rockwood K**. Modifications to the frailty phenotype criteria: Systematic review of the current literature and investigation of 262 frailty phenotypes in the Survey of Health, Ageing, and Retirement in Europe. *Ageing Res Rev* 21: 78-94, 2015.
DOI:10.1016/j.arr.2015.04.001
349. **Gordon E, Peel N, Samanta M, Theou O, Howlett S, Hubbard R**. Sex differences in frailty: a systematic review and meta-analysis. *Exp Gerontol* 89: 30-40, 2017.
DOI:10.1016/j.exger.2016.12.021
350. **Varadhan R, Seplaki C, Xue QL, Bandeen-Roche K, Fried LP**. Stimulus-response paradigm for characterizing the loss of resilience in homeostatic regulation associated with frailty. *Mech Ageing Dev* 129: 666-670, 2008.
DOI:10.1016/j.mad.2008.09.013
351. **Fried LP, Hadley EC, Walston JD, Newman AB, Guralnik JM, Studenski S, Harris TB, Ershler WB, Ferrucci L**. From bedside to bench: research agenda for frailty. *Science of aging knowledge environment: SAGE KE* 2005: pe24-pe24, 2005.
DOI:10.1126/sageke.2005.31.pe24
352. **Fried LP, Cohen AA, Xue Q-L, Walston J, Bandeen-Roche K, Varadhan R**. The physical frailty syndrome as a transition from homeostatic symphony to cacophony. *Nat Aging* 1: 36-46, 2021.
DOI:43587-020-00017-z
353. **Heinonen I, Kalliokoski KK, Hannukainen JC, Duncker DJ, Nuutila P, Knuuti J**. Organ-specific physiological responses to acute physical exercise and long-term training in humans. *Physiology* 2014.
DOI:10.1152/physiol.00067.2013
354. **Greenhaff P, Hultman E and Harris R**. Carbohydrate metabolism. In: *Principles of exercise biochemistry*: Karger Publishers, 1993, p. 89-136.
355. **Das AM, Steuerwald U and Illsinger S**. Inborn errors of energy metabolism associated with myopathies. *J Biomed Biotechnol* 2010: 340849, 2010.
DOI:10.1155/2010/340849
356. **Radda GK**. The use of NMR spectroscopy for the understanding of disease. *Science* 233: 640-645, 1986.
DOI:10.1126/science.3726553

357. **Formenti F, Constantin-Teodosiu D, Emmanuel Y, Cheeseman J, Dorrington KL, Edwards LM, Humphreys SM, Lappin TR, McMullin MF, McNamara CJ**. Regulation of human metabolism by hypoxia-inducible factor. *Proc Natl Acad Sci U S A* 107: 12722-12727, 2010.
DOI:10.1073/pnas.1002339107
358. **Steiner MC, Evans R, Deacon SJ, Singh SJ, Patel P, Fox J, Greenhaff PL, Morgan MD**. Adenine nucleotide loss in the skeletal muscles during exercise in chronic obstructive pulmonary disease. *Thorax* 60: 932-936, 2005.
DOI:10.1136/thx.2004.038802
359. **Greenhaff P, Bodin K, Soderlund K, Hultman E**. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. *Am J Physiol Endocrinol Metab* 266: E725-E730, 1994.
DOI:10.1152/ajpendo.1994.266.5.E725
360. **Hesselink MK, Greenhaff PL, Constantin-Teodosiu D, Hultman E, Saris WH, Nieuwlaat R, Schaart G, Kornips E, Schrauwen P**. Increased uncoupling protein 3 content does not affect mitochondrial function in human skeletal muscle in vivo. *J Clin Invest* 111: 479-486, 2003.
DOI:10.1172/jci16653
361. **Andreux PA, van Diemen MP, Heezen MR, Auwerx J, Rinsch C, Groeneveld GJ, Singh A**. Mitochondrial function is impaired in the skeletal muscle of pre-frail elderly. *Sci Rep* 8: 1-12, 2018.
DOI:10.1038/s41598-018-26944-x
362. **Picard M, Godin R, Sinnreich M, Baril J, Bourbeau J, Perrault H, Taivassalo T, Burelle Y**. The mitochondrial phenotype of peripheral muscle in chronic obstructive pulmonary disease: disuse or dysfunction? *Am J Respir Crit Care Med* 178: 1040-1047, 2008.
DOI:10.1164/rccm.200807-1005OC
363. **Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsøe R, Dela F**. Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. *Diabetologia* 50: 790-796, 2007.
DOI:10.1007/s00125-007-0594-3
364. **St-Jean-Pelletier F, Pion CH, Leduc-Gaudet JP, Sgarioto N, Zovilé I, Barbat-Artigas S, Reynaud O, Alkaterji F, Lemieux FC, Grenon A**. The impact of ageing, physical activity, and pre-frailty on skeletal muscle phenotype, mitochondrial content, and intramyocellular lipids in men. *J Cachexia Sarcopenia Muscle* 8: 213-228, 2017.
DOI:10.1002/jcsm.12139
365. **Sonjak V, Jacob KJ, Spendiff S, Vuda M, Perez A, Miguez K, Minozzo FC, Spake C, Morais JA, Hepple RT**. Reduced mitochondrial content, elevated reactive oxygen species, and modulation by denervation in skeletal muscle of prefrail or frail elderly women. *J Gerontol A* 74: 1887-1895, 2019.
DOI:10.1093/gerona/glz066
366. **Ashar FN, Moes A, Moore AZ, Grove ML, Chaves PH, Coresh J, Newman AB, Matteini AM, Bandeen-Roche K, Boerwinkle E**. Association of mitochondrial DNA levels with frailty and all-cause mortality. *J Mol Med* 93: 177-186, 2015.
DOI:10.1007/s00109-014-1233-3
367. **Moore AZ, Biggs ML, Matteini A, O'Connor A, McGuire S, Beamer BA, Fallin MD, Fried LP, Walston J, Chakravarti A**. Polymorphisms in the mitochondrial DNA control region and frailty in older adults. *PLoS One* 5: e11069, 2010.

DOI:10.1371/journal.pone.0011069
368. **Drummond MJ, Addison O, Brunker L, Hopkins PN, McClain DA, LaStayo PC, Marcus RL**. Downregulation of E3 ubiquitin ligases and mitophagy-related genes in skeletal muscle of physically inactive, frail older women: a cross-sectional comparison. *J Gerontol A Biol Sci Med Sci* 69: 1040-1048, 2014.
DOI:10.1093/gerona/glu004
369. **Davidson MB**. The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. *Metabolism* 28: 688-705, 1979.
DOI:10.1016/0026-0495(79)90024-6
370. **Metter EJ, Windham BG, Maggio M, Simonsick EM, Ling SM, Egan JM, Ferrucci L**. Glucose and insulin measurements from the oral glucose tolerance test and mortality prediction. *Diabetes Care* 31: 1026-1030, 2008.
DOI:10.2337/dc07-2102
371. **Kalyani RR, Varadhan R, Weiss CO, Fried LP, Cappola AR**. Frailty status and altered glucose-insulin dynamics. *J Gerontol A Biol Sci Med Sci* 67: 1300-1306, 2012.
DOI:10.1093/gerona/glr141
372. **Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, Gottdiener J, Fried LP**. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. *Arch Intern Med* 162: 2333-2341, 2002.
DOI:10.1001/archinte.162.20.2333
373. **Goulet ED, Khursigara Z, Gougeon R, Morais JA**. Postprandial insulin sensitivity and thermogenesis in frail elderly women. *Appl Physiol Nutr Metab* 35: 526-533, 2010.
DOI:10.1139/H10-041
374. **Rothman MD, Leo-Summers L and Gill TM**. Prognostic significance of potential frailty criteria. *J Am Geriatr Soc* 56: 2211-2216, 2008.
DOI:10.1111/j.1532-5415.2008.02008.x
375. **Woudstra T and Thomson AB**. Nutrient absorption and intestinal adaptation with ageing. *Best Pract Res Clin Gastroenterol* 16: 1-15, 2002.
DOI:10.1053/bega.2001.0262
376. **Fink RI, Kolterman OG, Griffin J, Olefsky JM**. Mechanisms of insulin resistance in aging. *J Clin Invest* 71: 1523-1535, 1983.
DOI:10.1172/jci110908
377. **Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD, Fried LP**. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. *Arch Intern Med* 167: 635-641, 2007.
DOI:10.1001/archinte.167.7.635
378. **Goulet ED, Hassaine A, Dionne IJ, Gaudreau P, Khalil A, Fulop T, Shatenstein B, Tessier D, Morais JA**. Frailty in the elderly is associated with insulin resistance of glucose metabolism in the postabsorptive state only in the presence of increased abdominal fat. *Exp Gerontol* 44: 740-744, 2009.
DOI:10.1016/j.exger.2009.08.008
379. **Peng P-S, Kao T-W, Chang P-K, Chen W-L, Peng P-J, Wu L-W**. Association between HOMA-IR and frailty among US middle-aged and elderly population. *Sci Rep* 9: 1-8, 2019.
DOI:10.1038/s41598-019-40902-1

380. **Sorkin JD, Muller DC, Fleg JL, Andres R**. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. *Diabetes Care* 28: 2626-2632, 2005.
DOI:10.2337/diacare.28.11.2626
381. **Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, Kuller LH, Kronmal RA, Resnick HE, Psaty BM**. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. *Arch Intern Med* 162: 209-216, 2002.
DOI:10.1001/archinte.162.2.209
382. **Alves S, Teixeira L, Ribeiro O, Paúl C**. Examining frailty phenotype dimensions in the oldest old. *Front Psychol* 11: 434, 2020.
DOI:10.3389/fpsyg.2020.00434
383. **Baylis D, Bartlett DB, Syddall HE, Ntani G, Gale CR, Cooper C, Lord JM, Sayer AA**. Immune-endocrine biomarkers as predictors of frailty and mortality: a 10-year longitudinal study in community-dwelling older people. *Age* 35: 963-971, 2013.
DOI:10.1007/s11357-012-9396-8
384. **Santos-Eggimann B, Cuénoud P, Spagnoli J, Junod J**. Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries. *J Gerontol A* 64: 675-681, 2009.
DOI:10.1093/gerona/glp012
385. **Aguirre LE and Villareal DT**. Physical exercise as therapy for frailty. *Frailty: Pathophysiology, phenotype and patient care* 83: 83-92, 2015.
DOI:10.1159/000382065
386. **Cadore EL, Rodríguez-Mañas L, Sinclair A, Izquierdo M**. Effects of different exercise interventions on risk of falls, gait ability, and balance in physically frail older adults: a systematic review. *Rejuvenation Res* 16: 105-114, 2013.
DOI:10.1089/rej.2012.1397
387. **Campbell E, Petermann-Rocha F, Welsh P, Celis-Morales C, Pell JP, Ho FK, Gray SR**. The effect of exercise on quality of life and activities of daily life in frail older adults: A systematic review of randomised control trials. *Exp Gerontol* 147: 111287, 2021.
DOI:10.1016/j.exger.2021.111287
388. **Chou C-H, Hwang C-L and Wu Y-T**. Effect of exercise on physical function, daily living activities, and quality of life in the frail older adults: a meta-analysis. *Arch Phys Med Rehabil* 93: 237-244, 2012.
DOI:10.1016/j.apmr.2011.08.042
389. **Macdonald SH-F, Travers J, Shé ÉN, Bailey J, Romero-Ortuno R, Keyes M, O'Shea D, Cooney MT**. Primary care interventions to address physical frailty among community-dwelling adults aged 60 years or older: A meta-analysis. *PLoS One* 15: e0228821, 2020.
DOI:10.1371/journal.pone.0228821
390. **Travers J, Romero-Ortuno R, Bailey J, Cooney M-T**. Delaying and reversing frailty: a systematic review of primary care interventions. *Br J Gen Pract* 69: e61-e69, 2019.
DOI:10.3399/bjgp18X700241
391. **Theou O, Stathokostas L, Roland KP, Jakobi JM, Patterson C, Vandervoort AA, Jones GR**. The effectiveness of exercise interventions for the management of frailty: a systematic review. *J Aging Res* 2011: 569194, 2011.
DOI:10.4061/2011/569194

392. **Cameron ID, Fairhall N, Langron C, Lockwood K, Monaghan N, Aggar C, Sherrington C, Lord SR, Kurrle SE**. A multifactorial interdisciplinary intervention reduces frailty in older people: randomized trial. *BMC Med* 11: 1-10, 2013.
DOI:10.1186/1741-7015-11-65
393. **Kim H, Suzuki T, Kim M, Kojima N, Ota N, Shimotoyodome A, Hase T, Hosoi E, Yoshida H**. Effects of exercise and milk fat globule membrane (MFGM) supplementation on body composition, physical function, and hematological parameters in community-dwelling frail Japanese women: a randomized double blind, placebo-controlled, follow-up trial. *PLoS One* 10: e0116256, 2015.
DOI:10.1371/journal.pone.0116256
394. **Tarazona-Santabalbina FJ, Gómez-Cabrera MC, Pérez-Ros P, Martínez-Arnau FM, Cabo H, Tsaparas K, Salvador-Pascual A, Rodriguez-Mañas L, Viña J**. A multicomponent exercise intervention that reverses frailty and improves cognition, emotion, and social networking in the community-dwelling frail elderly: a randomized clinical trial. *J Am Med Dir Assoc* 17: 426-433, 2016.
DOI:10.1016/j.jamda.2016.01.019
395. **Cesari M, Vellas B, Hsu F-C, Newman AB, Doss H, King AC, Manini TM, Church T, Gill TM, Miller ME**. A physical activity intervention to treat the frailty syndrome in older persons—results from the LIFE-P study. *J Gerontol A Biol Sci Med Sci* 70: 216-222, 2015.
DOI:10.1093/gerona/glu099
396. **Labott BK, Bucht H, Morat M, Morat T, Donath L**. Effects of exercise training on handgrip strength in older adults: a meta-analytical review. *Gerontology* 65: 686-698, 2019.
DOI:10.1159/000501203
397. **Vaughan S, Wallis M, Polit D, Steele M, Shum D, Morris N**. The effects of multimodal exercise on cognitive and physical functioning and brain-derived neurotrophic factor in older women: a randomised controlled trial. *Age Ageing* 43: 623-629, 2014.
DOI:10.1093/ageing/afu010
398. **Hennebry A, Oldham J, Shavlakadze T, Grounds MD, Sheard P, Fiorotto ML, Falconer S, Smith HK, Berry C, Jeanplong F**. IGF1 stimulates greater muscle hypertrophy in the absence of myostatin in male mice. *J Endocrinol* 234: 187-200, 2017.
DOI:10.1530/JOE-17-0032
399. **Sherrington C, Canning C, Dean C, Allen N, Blackman K**. Weightbearing Exercise for Better Balance (WEBB)-A challenging, safe, evidencebased physiotherapy program for older people. *Verfügbar unter: http://www webb org au/attachments/File/WEBB_draft_19 pdf [2006 2013]* 2008.

400. **Fairhall N, Sherrington C, Kurrle SE, Lord SR, Lockwood K, Cameron ID**. Effect of a multifactorial interdisciplinary intervention on mobility-related disability in frail older people: randomised controlled trial. *BMC Med* 10: 1-13, 2012.
DOI:10.1186/1741-7015-10-120
401. **Pahor M, Blair SN, Espeland M, Fielding R, Gill TM, Guralnik JM, Hadley EC, King AC, Kritchevsky SB, Maraldi C, Miller ME, Newman AB, Rejeski WJ, Romashkan S, Studenski S**. Effects of a physical activity intervention on measures of physical performance: Results of the lifestyle interventions and independence for Elders Pilot (LIFE-P) study. *J Gerontol A Biol Sci Med Sci* 61: 1157-1165, 2006.
DOI:10.1093/gerona/61.11.1157

402. **Chen R, Wu Q, Wang D, Li Z, Liu H, Liu G, Cui Y, Song L**. Effects of elastic band exercise on the frailty states in pre-frail elderly people. *Physiother Theory Pract* 36: 1000-1008, 2019.
DOI:10.1080/09593985.2018.1548673
403. **Serra-Prat M, Sist X, Domenich R, Jurado L, Saiz A, Roces A, Palomera E, Tarradelles M, Papiol M**. Effectiveness of an intervention to prevent frailty in pre-frail community-dwelling older people consulting in primary care: a randomised controlled trial. *Age Ageing* 46: 401-407, 2017.
DOI:10.1093/ageing/afw242
404. **Ng TP, Feng L, Nyunt MS, Feng L, Niti M, Tan BY, Chan G, Khoo SA, Chan SM, Yap P, Yap KB**. Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial. *Am J Med* 128: 1225-1236.e1221, 2015.
DOI:10.1016/j.amjmed.2015.06.017
405. **Chan D-CD, Tsou H-H, Yang R-S, Tsauo J-Y, Chen C-Y, Hsiung CA, Kuo KN**. A pilot randomized controlled trial to improve geriatric frailty. *BMC Geriatr* 12: 1-12, 2012.
DOI:10.1186/1471-2318-12-58
406. **Seino S, Nishi M, Murayama H, Narita M, Yokoyama Y, Nofuji Y, Taniguchi Y, Amano H, Kitamura A, Shinkai S**. Effects of a multifactorial intervention comprising resistance exercise, nutritional and psychosocial programs on frailty and functional health in community-dwelling older adults: a randomized, controlled, cross-over trial. *Geriatr Gerontol Int* 17: 2034-2045, 2017.
DOI:10.1111/ggi.13016
407. **Shinkai S, Watanabe N, Yoshida H, Fujiwara Y, Amano H, Lee S, Nishi M, Tsuchiya Y**. Research on screening for frailty: development of" the Kaigo-Yobo Checklist". *[Nihon koshu eisei zasshi] Japanese journal of public health* 57: 345-354, 2010.
DOI:https://pubmed.ncbi.nlm.nih.gov/20666121/
408. **Shinkai S, Watanabe N, Yoshida H, Fujiwara Y, Nishi M, Fukaya T, Lee S, Kim MJ, Ogawa K, Murayama H**. Validity of the" Kaigo-Yobo Check-List" as a frailty index. *[Nihon koshu eisei zasshi] Japanese journal of public health* 60: 262-274, 2013.
DOI:https://pubmed.ncbi.nlm.nih.gov/23942023/
409. **Nagai K, Miyamato T, Okamae A, Tamaki A, Fujioka H, Wada Y, Uchiyama Y, Shinmura K, Domen K**. Physical activity combined with resistance training reduces symptoms of frailty in older adults: A randomized controlled trial. *Arch Gerontol Geriatr* 76: 41-47, 2018.
DOI:10.1016/j.archger.2018.02.005
410. **Chan DC, Tsou HH, Chang CB, Yang RS, Tsauo JY, Chen CY, Hsiao CF, Hsu YT, Chen CH, Chang SF**. Integrated care for geriatric frailty and sarcopenia: a randomized control trial. *J Cachexia Sarcopenia Muscle* 8: 78-88, 2017.
DOI:10.1002/jcsm.12132
411. **Luger E, Dorner TE, Haider S, Kapan A, Lackinger C, Schindler K**. Effects of a home-based and volunteer-administered physical training, nutritional, and social support program on malnutrition and frailty in older persons: a randomized controlled trial. *J Am Med Dir Assoc* 17: 671. e679-671. e616, 2016.
DOI:10.1016/j.jamda.2016.04.018

412. **Oh G, Lee H, Park CM, Jung HW, Lee E, Jang IY, Guralnik JM, Kim DH**. Long-term effect of a 24-week multicomponent intervention on physical performance and frailty in community-dwelling older adults. *Age Ageing* 2021.
DOI:10.1093/ageing/afab149
413. **Leoni R, Oliveira I, Pontes-Neto O, Santos A, Leite J**. Cerebral blood flow and vasoreactivity in aging: an arterial spin labeling study. *Braz J Med Biol Res* 50: e5670, 2017.
DOI:10.1590/1414-431X20175670
414. **Bastos-Leite A, Kuijer J, Rombouts S, Sanz-Arigita E, Van Straaten E, Gouw A, van der Flier W, Scheltens P, Barkhof F**. Cerebral blood flow by using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities. *Am J Neuroradiol* 29: 1296-1301, 2008.
DOI:10.3174/ajnr.A1091
415. **Wang J, Maxwell CA and Yu F**. Biological Processes and Biomarkers Related to Frailty in Older Adults: A State-of-the-Science Literature Review. *Biol Res Nurs* 21: 80-106, 2019.
DOI:10.1177/1099800418798047
416. **Buchman AS, Yu L, Wilson RS, Schneider JA, Bennett DA**. Association of brain pathology with the progression of frailty in older adults. *Neurology* 80: 2055-2061, 2013.
DOI:10.1212/WNL.0b013e318294b462
417. **Maltais M, de Souto Barreto P, Moon SY, Rolland Y, Vellas B**. Prospective association of white matter hyperintensity volume and frailty in older adults. *Exp Gerontol* 118: 51-54, 2019.
DOI:10.1016/j.exger.2019.01.007
418. **Jung HW, Kim SW, Lim JY, Kim KW, Jang HC, Kim CH, Kim KI**. Frailty status can predict further lean body mass decline in older adults. *J Am Geriatr Soc* 62: 2110-2117, 2014.
DOI:10.1111/jgs.13107
419. **Marengoni A, Zucchelli A, Vetrano DL, Aloisi G, Brandi V, Ciutan M, Panait CL, Bernabei R, Onder G, Palmer K**. Heart failure, frailty, and pre-frailty: A systematic review and meta-analysis of observational studies. *Int J Cardiol* 316: 161-171, 2020.
DOI:10.1016/j.ijcard.2020.04.043
420. **Palmer K, Vetrano DL, Padua L, Romano V, Rivoiro C, Scelfo B, Marengoni A, Bernabei R, Onder G**. Frailty syndromes in persons with cerebrovascular disease: a systematic review and meta-analysis. *Front Neurol* 10: 1255, 2019.
DOI:10.3389/fneur.2019.01255
421. **Palmer K, Villani ER, Vetrano DL, Cherubini A, Cruz-Jentoft AJ, Curtin D, Denkinger M, Gutiérrez-Valencia M, Guðmundsson A, Knol W, Mak DV, O'Mahony D, Pazan F, Petrovic M, Rajkumar C, Topinkova E, Trevisan C, van der Cammen TJM, van Marum RJ, Wehling M, Ziere G, Bernabei R, Onder G**. Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis. *Eur Geriatr Med* 10: 9-36, 2019.
DOI:10.1007/s41999-018-0124-5
422. **Palmer K, Vetrano DL, Marengoni A, Tummolo AM, Villani ER, Acampora N, Bernabei R, Onder G**. The Relationship between Anaemia and Frailty: A Systematic Review and Meta-Analysis of Observational Studies. *J Nutr Health Aging* 22: 965-974, 2018.

DOI:10.1007/s12603-018-1049-x
423. **Vetrano DL, Palmer K, Marengoni A, Marzetti E, Lattanzio F, Roller-Wirnsberger R, Lopez Samaniego L, Rodríguez-Mañas L, Bernabei R, Onder G**. Frailty and Multimorbidity: A Systematic Review and Meta-analysis. *J Gerontol A Biol Sci Med Sci* 74: 659-666, 2019.
DOI:10.1093/gerona/gly110
424. **Davies B, García F, Ara I, Artalejo FR, Rodriguez-Mañas L, Walter S**. Relationship Between Sarcopenia and Frailty in the Toledo Study of Healthy Aging: A Population Based Cross-Sectional Study. *J Am Med Dir Assoc* 19: 282-286, 2018.
DOI:10.1016/j.jamda.2017.09.014
425. **Avila-Funes JA, Amieva H, Barberger-Gateau P, Le Goff M, Raoux N, Ritchie K, Carrière I, Tavernier B, Tzourio C, Gutiérrez-Robledo LM, Dartigues JF**. Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. *J Am Geriatr Soc* 57: 453-461, 2009.
DOI:10.1111/j.1532-5415.2008.02136.x
426. **Armstrong JJ, Stolee P, Hirdes JP, Poss JW**. Examining three frailty conceptualizations in their ability to predict negative outcomes for home-care clients. *Age Ageing* 39: 755-758, 2010.
DOI:10.1093/ageing/afq121









Brain

Increased:
- WMH volume

Decreased:
- Grey matter volume
- Whole brain volume
- Microstructural integrity
- Cortical thickness

Cardiac

Increased:
- LV mass
- LAVI

Decreased:
- LV systolic function
- LV diastolic function

Immune system

Increased:
- Inflammation
- Senescent T cells
- Neutrophil:lymphocyte ratio
- Memory:naïve T cell ratio

Decreased:
- Regulatory cell function (IL10)
- Thymic output

Adiposity

Increased:
- BMI?

Decreased:
- Visceral adiposity?

U-shaped relationship? (low and high adiposity associated with frailty)

Skeletal muscle

Increased:
- IMAT

Decreased:
- SkM volume
- SkM CSA
- Lean mass
- MU size/number

Vasculature

Increased:
- Arterial stiffness

Decreased:
- Endothelial function







DTI - Microstructural integrity

- Diffusion tensor imaging (DTI) measures the diffusion of water through axonal fibres. The degree and directionality of diffusion is indicative of the microstructural integrity of brain tissue (e.g. myelination, fibre density, axonal diameter).

Microstructural integrity deterioration



MRI - Brain volumes and cortical thickness

- Structural MRI scanning detects signal from water protons to create 3D images of the brain. This allows for the calculation of whole brain volume, grey and white matter volume, and cortical thickness.

Reduced brain volume and cortical thickness



MRI - White matter hyperintensities

- Alternate structural MRI scan sequences null signals from brain fluids to enable the assessment of WMH (a type of lesion) presence and volume. WMHs are markers of brain structure deterioration associated with cognitive impairment and physical function decline.

Increased WMH volume







Clinical manifestations of frailty

Frailty is associated with…

Demographics

- Female gender
- A lower level of education
- A lower socioeconomic background

Conditions

- Polypharmacy
- Sarcopenia
- Multimorbidity

Frailty = higher risk of adverse outcomes e.g. hospitalisation, falls, disability

What is the physiological phenotype of frailty?



- Multi-organ syndrome?
- Does cumulative physiological dysregulation underpin the development of whole-body functional decline?

Potential drivers of frailty development



Chronic inflammation

- Many studies report the pre-frail to frail transition is associated with greater inflammation

Chronic physical inactivity

- Promotes deconditioning, insulin resistance, muscle anabolic resistance and a pro-inflammatory profile
- Reduces neuromuscular function
- Increases adiposity and senescent cell load

Interventions to prevent and reduce frailty



Exercise

- Interventions should ideally be intense, supervised and maintained for frailty prevention to persist

- Multimodal approaches may be more effective than individual component approaches